-DOCSTART-	O

Title	O
:	O
Music	B-I
therapy	I-I
in	O
moderate	O
and	O
severe	O
dementia	O
of	O
Alzheimer	O
'	O
s	O
type	O
:	O
a	O
case	O
-	O
control	O
study	O
.	O

METHODS	O
:	O
This	O
case	O
-	O
control	O
study	O
was	O
carried	O
out	O
by	O
qualified	O
music	O
therapists	O
in	O
two	O
nursing	O
homes	O
and	O
two	O
psychogeriatric	O
wards	O
.	O

The	O
participants	O
were	O
38	B-P
patients	I-P
with	I-P
moderate	I-P
or	I-P
severe	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
(	I-P
AD	I-P
)	I-P
assigned	O
randomly	O
to	O
a	B-I
music	I-I
therapy	I-I
group	O
and	O
a	O
control	O
group	O
.	O

-DOCSTART-	O

Title	O
:	O
Keep	O
music	O
live	O
:	O
music	B-I
and	O
the	O
alleviation	O
of	O
apathy	O
in	O
dementia	B-P
subjects	I-P
.	O

METHODS	O
:	O
Thirty	B-P
-	I-P
two	I-P
subjects	I-P
meeting	I-P
ICD	I-P
-	I-P
10	I-P
diagnostic	I-P
criteria	I-P
for	I-P
moderate	I-P
to	I-P
severe	I-P
dementia	I-P
and	I-P
fulfilling	I-P
diagnostic	I-P
criteria	I-P
for	I-P
apathy	I-P
were	O
exposed	O
to	O
live	B-I
interactive	I-I
music	I-I
,	O
passive	B-I
pre	I-I
-	I-I
recorded	I-I
music	I-I
or	O
silence	B-I
for	O
30	O
minutes	O
.	O

Each	O
subject	O
was	O
randomized	O
to	O
30	O
-	O
minute	O
music	O
or	O
silent	O
periods	O
and	O
was	O
video	O
recorded	O
and	O
the	O
muted	O
recording	O
analyzed	O
every	O
3	O
minutes	O
using	O
dementia	B-O
care	I-O
mapping	I-O
to	O
assess	O
the	B-O
quality	I-O
of	I-O
engagement	I-O
to	I-O
the	I-O
blinded	I-O
music	I-O
intervention	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Memantine	B-I
treatment	I-I
in	O
mild	O
to	O
moderate	O
Alzheimer	O
disease	O
:	O
a	O
24	O
-	O
week	O
randomized	O
,	O
controlled	O
trial	O
.	O

METHODS	O
:	O
This	O
was	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
clinical	O
trial	O
conducted	O
at	O
42	O
U	O
.	O
S	O
.	O
sites	O
.	O

Participants	O
were	O
403	B-P
outpatients	I-P
with	I-P
mild	I-P
to	I-P
moderate	I-P
AD	I-P
and	I-P
Mini	I-P
-	I-P
Mental	I-P
State	I-P
Examination	I-P
scores	I-P
of	I-P
10	I-P
-	I-P
22	I-P
randomized	O
to	O
memantine	B-I
(	O
20	O
mg	O
/	O
day	O
;	O
N=201	O
)	O
or	O
placebo	B-C
(	O
N=202	O
)	O
for	O
24	O
weeks	O
.	O

Primary	O
outcomes	O
were	O
change	O
from	O
baseline	O
at	O
24	O
weeks	O
on	O
the	B-O
Alzheimer	I-O
'	I-O
s	I-O
Disease	I-O
Assessment	I-O
Scale	I-O
-	I-O
Cognitive	I-O
Subscale	I-O
(	I-O
ADAS	I-O
-	I-O
cog	I-O
)	I-O
,	O
a	O
measure	O
of	O
cognition	B-O
,	O
and	O
on	O
the	B-O
Clinician	I-O
'	I-O
s	I-O
Interview	I-O
-	I-O
Based	I-O
Impression	I-O
of	I-O
Change	I-O
Plus	I-O
Caregiver	I-O
Input	I-O
(	I-O
CIBIC	I-O
-	I-O
Plus	I-O
)	I-O
,	O
a	O
global	O
measure	O
.	O

Secondary	O
outcomes	O
included	O
change	O
on	O
the	B-O
Neuropsychiatric	I-O
Inventory	I-O
(	I-O
NPI	I-O
)	I-O
and	O
the	B-O
Alzheimer	I-O
'	I-O
s	I-O
Disease	I-O
Cooperative	I-O
Study	I-O
Activities	I-O
of	I-O
Daily	I-O
Living	I-O
Inventory	I-O
(	I-O
ADCS	I-O
-	I-O
ADL	I-O
(	I-O
23	I-O
)	I-O
)	I-O
,	O
measures	O
of	O
behavior	B-O
and	O
function	B-O
,	O
respectively	O
.	O

-DOCSTART-	O

Title	O
:	O
Safety	O
and	O
efficacy	O
of	O
donepezil	B-I
in	O
African	B-P
Americans	I-P
with	I-P
mild	I-P
-	I-P
to	I-P
-	I-P
moderate	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
.	O

METHODS	O
:	O
Efficacy	O
was	O
assessed	O
via	O
the	B-O
Mini	I-O
-	I-O
Mental	I-O
State	I-O
Examination	I-O
(	I-O
MMSE	I-O
)	I-O
,	O
Clinician	B-O
'	I-O
s	I-O
Interview	I-O
-	I-O
Based	I-O
Impression	I-O
of	I-O
Change	I-O
-	I-O
Plus	I-O
interview	I-O
with	I-O
the	I-O
patient	I-O
and	I-O
caregiver	I-O
(	I-O
CIBIC	I-O
-	I-O
Plus	I-O
)	I-O
and	O
Fuld	B-O
Object	I-O
Memory	I-O
Evaluation	I-O
(	I-O
FOME	I-O
)	I-O
,	O
a	O
measure	O
that	O
has	O
been	O
validated	O
for	O
use	O
with	O
elderly	O
African	O
Americans	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
Phase	O
II	O
study	O
targeting	O
amyloid	O
-	O
beta	O
with	O
3	B-I
APS	I-I
in	O
mild	O
-	O
to	O
-	O
moderate	O
Alzheimer	O
disease	O
.	O

METHODS	O
:	O
We	O
assessed	O
the	O
safety	O
,	O
tolerability	O
,	O
and	O
pharmacokinetic	O
/	O
pharmacodynamic	O
effect	O
of	O
3	B-I
APS	I-I
in	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
Phase	O
II	O
study	O
in	O
which	O
58	B-P
subjects	I-P
with	I-P
mild	I-P
-	I-P
to	I-P
-	I-P
moderate	I-P
AD	I-P
were	O
randomly	O
assigned	O
to	O
receive	O
placebo	B-C
or	O
3	B-I
APS	I-I
50	O
,	O
100	O
,	O
or	O
150	O
mg	O
BID	O
for	O
3	O
months	O
.	O

At	O
the	O
end	O
of	O
the	O
double	O
-	O
blind	O
phase	O
,	O
42	O
of	O
these	O
subjects	O
entered	O
an	O
open	O
-	O
label	O
phase	O
in	O
which	O
they	O
received	O
3	B-I
APS	I-I
150	O
mg	O
BID	O
for	O
17	O
months	O
.	O

Assessments	O
included	O
plasma	B-O
and	O
CSF	B-O
3	I-O
APS	I-O
concentrations	I-O
,	O
CSF	B-O
levels	I-O
of	I-O
Abeta	I-O
(	I-O
Abeta	I-O
(	I-O
40	I-O
)	I-O
and	I-O
Abeta	I-O
(	I-O
42	I-O
)	I-O
)	I-O
,	O
and	O
total	B-O
tau	I-O
,	O
as	O
well	O
as	O
cognitive	B-O
(	O
Alzheimer	B-O
'	I-O
s	I-O
Disease	I-O
Assessment	I-O
Scale	I-O
-	I-O
cognitive	I-O
subscale	I-O
,	O
Mini	B-O
-	I-O
Mental	I-O
State	I-O
Examination	I-O
)	O
and	O
clinical	B-O
(	O
Clinical	B-O
Dementia	I-O
Rating	I-O
scale	I-O
-	I-O
Sum	I-O
of	I-O
Boxes	I-O
)	O
measures	O
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
statins	B-I
on	O
Alzheimer	O
'	O
s	O
disease	O
biomarkers	O
in	O
cerebrospinal	O
fluid	O
.	O

METHODS	O
:	O
We	O
measured	O
levels	B-O
of	I-O
cerebrospinal	I-O
fluid	I-O
(	I-O
CSF	I-O
)	I-O
AD	I-O
biomarkers	I-O
following	O
14	O
weeks	O
of	O
treatment	O
with	O
simvastatin	B-I
(	O
a	B-I
CNS	I-I
permeant	I-I
statin	I-I
;	O
n=10	O
)	O
at	O
40	O
mg	O
/	O
day	O
or	O
pravastatin	B-I
(	O
a	B-I
CNS	I-I
impermeant	I-I
statin	I-I
;	O
n=13	O
)	O
at	O
80	O
mg	O
/	O
day	O
in	O
hypercholesterolemic	B-P
subjects	I-P
without	I-P
dementia	I-P
.	O

-DOCSTART-	O

Title	O
:	O
Exercise	B-I
program	I-I
for	O
nursing	B-P
home	I-P
residents	I-P
with	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
:	O
a	O
1	O
-	O
year	O
randomized	O
,	O
controlled	O
trial	O
.	O

METHODS	O
:	O
Randomized	O
,	O
controlled	O
trial	O
.	O

Five	O
nursing	O
homes	O
.	O

One	B-P
hundred	I-P
thirty	I-P
-	I-P
four	I-P
ambulatory	I-P
patients	I-P
with	I-P
mild	I-P
to	I-P
severe	I-P
AD	I-P
.	O

Collective	B-I
exercise	I-I
program	I-I
(	O
1	B-I
hour	I-I
,	I-I
twice	I-I
weekly	I-I
of	I-I
walk	I-I
,	O
strength	B-I
,	O
balance	B-I
,	O
and	O
flexibility	B-I
training	I-I
)	O
or	O
routine	B-C
medical	I-C
care	I-C
for	O
12	O
months	O
.	O

ADLs	B-O
were	O
assessed	O
using	O
the	B-O
Katz	I-O
Index	I-O
of	I-O
ADLs	I-O
.	O

Physical	B-O
performance	I-O
was	O
evaluated	O
using	O
6	B-O
-	I-O
meter	I-O
walking	I-O
speed	I-O
,	O
the	B-O
get	I-O
-	I-O
up	I-O
-	I-O
and	I-O
-	I-O
go	I-O
test	I-O
,	O
and	O
the	B-O
one	I-O
-	I-O
leg	I-O
-	I-O
balance	I-O
test	I-O
.	O

Behavioral	B-O
disturbance	I-O
,	O
depression	B-O
,	O
and	O
nutritional	B-O
status	I-O
were	O
evaluated	O
using	O
the	B-O
Neuropsychiatric	I-O
Inventory	I-O
,	O
the	B-O
Montgomery	I-O
and	I-O
Asberg	I-O
Depression	I-O
Rating	I-O
Scale	I-O
,	O
and	O
the	B-O
Mini	I-O
-	I-O
Nutritional	I-O
Assessment	I-O
.	O

For	O
each	O
outcome	O
measure	O
,	O
the	O
mean	O
change	O
from	O
baseline	O
to	O
12	O
months	O
was	O
calculated	O
using	O
intention	O
-	O
to	O
-	O
treat	O
analysis	O
.	O

-DOCSTART-	O

Title	O
:	O
Open	O
label	O
,	O
multicenter	O
,	O
28	O
-	O
week	O
extension	O
study	O
of	O
the	O
safety	O
and	O
tolerability	O
of	O
memantine	B-I
in	O
patients	B-P
with	I-P
mild	I-P
to	I-P
moderate	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
.	O

METHODS	O
:	O
This	O
28	O
-	O
week	O
study	O
enrolled	O
314	B-P
patients	I-P
with	I-P
mild	I-P
to	I-P
moderate	I-P
AD	I-P
who	I-P
had	I-P
completed	I-P
a	I-P
24	I-P
-	I-P
week	I-P
,	I-P
double	I-P
-	I-P
blind	I-P
,	I-P
placebo	I-P
-	I-P
controlled	I-P
lead	I-P
-	I-P
in	I-P
clinical	I-P
trial	I-P
of	I-P
memantine	I-P
in	I-P
AD	I-P
.	O

Following	O
an	O
8	O
-	O
week	O
double	O
-	O
blind	O
dose	O
titration	O
phase	O
(	O
used	O
to	O
assess	O
the	O
tolerability	O
of	O
different	O
dosing	O
regimens	O
)	O
,	O
subjects	O
were	O
assigned	O
to	O
continuous	B-I
open	I-I
label	I-I
memantine	I-I
(	O
10	O
mg	O
,	O
bi	O
.	O
d	O
.	O
)	O
treatment	O
for	O
20	O
weeks	O
.	O

Safety	O
outcome	O
measures	O
included	O
treatment	B-O
-	I-O
emergent	I-O
adverse	I-O
events	I-O
(	I-O
AEs	I-O
)	I-O
,	O
deaths	B-O
,	O
vital	B-O
signs	I-O
,	O
electrocardiograms	B-O
,	O
and	O
laboratory	B-O
parameters	I-O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
six	O
-	O
month	O
double	O
-	O
blind	O
,	O
randomized	O
,	O
placebo	O
-	O
controlled	O
study	O
of	O
a	B-I
transdermal	I-I
patch	I-I
in	O
Alzheimer	O
'	O
s	O
disease	O
-	O
-	O
rivastigmine	B-I
patch	I-I
versus	O
capsule	B-I
.	O

METHODS	O
:	O
In	O
this	O
24	O
-	O
week	O
,	O
multicenter	O
,	O
double	O
-	O
blind	O
,	O
double	O
-	O
dummy	O
,	O
placebo	O
-	O
and	O
active	O
-	O
controlled	O
trial	O
,	O
patients	B-P
with	I-P
probable	I-P
AD	I-P
were	O
randomized	O
to	O
one	O
of	O
four	O
treatment	O
groups	O
:	O
12	B-I
mg	I-I
/	I-I
day	I-I
rivastigmine	I-I
capsules	I-I
;	O
10	B-I
cm2	I-I
(	I-I
9	I-I
.	I-I
5	I-I
mg	I-I
/	I-I
24	I-I
h	I-I
)	I-I
rivastigmine	I-I
patch	I-I
;	O
20	B-I
cm	I-I
(	I-I
2	I-I
)	I-I
(	I-I
17	I-I
.	I-I
4	I-I
mg	I-I
/	I-I
24	I-I
h	I-I
)	I-I
rivastigmine	I-I
patch	I-I
;	O
or	O
placebo	B-C
.	O

Primary	O
efficacy	O
measures	O
were	O
the	B-O
Alzheimer	I-O
'	I-O
s	I-O
Disease	I-O
Assessment	I-O
Scale	I-O
-	I-O
Cognitive	I-O
subscale	I-O
(	I-O
ADAS	I-O
-	I-O
Cog	I-O
)	I-O
and	O
Alzheimer	B-O
'	I-O
s	I-O
Disease	I-O
Cooperative	I-O
Study	I-O
-	I-O
-	I-O
Clinical	I-O
Global	I-O
Impression	I-O
of	I-O
Change	I-O
(	I-O
ADCS	I-O
-	I-O
CGIC	I-O
)	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Antiaggressive	O
effect	O
of	O
cyproterone	B-I
versus	O
haloperidol	B-I
in	O
Alzheimer	O
'	O
s	O
disease	O
:	O
a	O
randomized	O
double	O
-	O
blind	O
pilot	O
study	O
.	O

METHODS	O
:	O
The	O
subjects	O
were	O
27	B-P
elderly	I-P
patients	I-P
referred	I-P
to	I-P
the	I-P
University	I-P
Hospital	I-P
of	I-P
Guadalajara	I-P
Psychogeriatric	I-P
Clinic	I-P
diagnosed	I-P
with	I-P
AD	I-P
and	I-P
associated	I-P
aggressive	I-P
behavior	I-P
(	I-P
mean	I-P
Staff	I-P
Observation	I-P
Aggression	I-P
Scale	I-P
[	I-P
SOAS	I-P
]	I-P
score	I-P
>	I-P
or=2	I-P
)	I-P
.	O

Each	O
patient	O
underwent	O
a	O
15	O
-	O
day	O
washout	O
for	O
psychotropics	O
and	O
then	O
was	O
randomly	O
assigned	O
to	O
receive	O
stable	O
doses	O
of	O
either	O
cyproterone	B-I
(	O
100	O
mg	O
/	O
day	O
)	O
or	O
haloperidol	B-I
(	O
2	O
mg	O
/	O
day	O
)	O
for	O
90	O
days	O
.	O

The	O
primary	O
outcome	O
measure	O
was	O
the	B-O
SOAS	I-O
score	I-O
.	O

This	O
trial	O
was	O
conducted	O
between	O
October	O
27	O
,	O
1993	O
,	O
and	O
March	O
24	O
,	O
1998	O
.	O

-DOCSTART-	O

Title	O
:	O
Key	O
lessons	O
learned	O
from	O
short	O
-	O
term	O
treatment	O
trials	O
of	O
cholinesterase	B-I
inhibitors	I-I
for	O
amnestic	O
MCI	O
.	O

METHODS	O
:	O
The	O
study	O
was	O
a	O
24	O
-	O
week	O
placebo	O
-	O
controlled	O
trial	O
designed	O
to	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
donepezil	B-I
HCl	I-I
(	I-I
donepezil	I-I
)	I-I
in	O
the	O
treatment	O
of	O
cognitive	O
impairment	O
in	O
subjects	B-P
with	I-P
MCI	I-P
.	O

Primary	O
outcome	O
measures	O
were	O
the	B-O
NYU	I-O
Paragraphs	I-O
Test	I-O
and	O
the	B-O
ADCS	I-O
Clinicians	I-O
Global	I-O
-	I-O
Impression	I-O
of	I-O
Change	I-O
in	O
the	O
intent	O
-	O
to	O
-	O
treat	O
last	O
-	O
observation	O
-	O
carried	O
-	O
forward	O
group	O
.	O

-DOCSTART-	O

Title	O
:	O
Intranasal	B-I
insulin	I-I
improves	O
cognition	O
and	O
modulates	O
beta	O
-	O
amyloid	O
in	O
early	O
AD	O
.	O

METHODS	O
:	O
Twenty	B-P
-	I-P
five	I-P
participants	I-P
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
placebo	B-I
(	O
n	O
=	O
12	O
)	O
or	O
20	B-I
IU	I-I
BID	I-I
intranasal	I-I
insulin	I-I
treatment	I-I
(	O
n	O
=	O
13	O
)	O
using	O
an	O
electronic	O
atomizer	O
,	O
and	O
24	O
participants	O
completed	O
the	O
study	O
.	O

Participants	O
,	O
caregivers	O
,	O
and	O
all	O
clinical	O
evaluators	O
were	O
blinded	O
to	O
treatment	O
assignment	O
.	O

Cognitive	O
measures	O
and	O
blood	O
were	O
obtained	O
at	O
baseline	O
and	O
after	O
21	O
days	O
of	O
treatment	O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
views	O
of	O
Alzheimer	B-P
disease	I-P
patients	I-P
and	I-P
their	I-P
study	I-P
partners	I-P
on	O
proxy	O
consent	O
for	O
clinical	O
trial	O
enrollment	O
.	O

METHODS	O
:	O
Cross	O
-	O
sectional	O
interview	O
.	O

At	O
the	O
13	O
study	O
sites	O
of	O
a	O
randomized	O
and	O
placebo	O
controlled	O
study	O
of	O
simvastatin	B-I
for	O
the	O
treatment	O
of	O
AD	O
.	O

Patients	B-P
with	I-P
mild	I-P
-	I-P
to	I-P
-	I-P
moderate	I-P
AD	I-P
and	I-P
their	I-P
study	I-P
partners	I-P
enrolled	O
in	O
an	O
Alzheimer	O
'	O
s	O
Disease	O
Cooperative	O
Study	O
trial	O
of	O
simvastatin	B-I
.	O

Interviews	O
to	O
assess	O
how	B-O
participants	I-O
made	I-O
the	I-O
decision	I-O
to	I-O
enroll	I-O
in	I-O
a	I-O
randomized	I-O
controlled	I-O
trial	I-O
and	O
their	B-O
attitudes	I-O
on	I-O
proxy	I-O
consent	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Safety	O
and	O
efficacy	O
of	O
galantamine	B-I
in	O
subjects	B-P
with	I-P
mild	I-P
cognitive	I-P
impairment	I-P
.	O

METHODS	O
:	O
In	O
two	O
studies	O
,	O
2	B-P
,	I-P
048	I-P
subjects	I-P
,	I-P
990	I-P
in	I-P
Study	I-P
1	I-P
and	I-P
1	I-P
,	I-P
058	I-P
in	I-P
Study	I-P
2	I-P
,	I-P
with	I-P
a	I-P
Clinical	I-P
Dementia	I-P
Rating	I-P
(	I-P
CDR	I-P
)	I-P
=	I-P
0	I-P
.	I-P
5	I-P
,	I-P
CDR	I-P
memory	I-P
score	I-P
>	I-P
or	I-P
=0	I-P
.	I-P
5	I-P
,	I-P
without	I-P
dementia	I-P
were	O
randomized	O
to	O
double	B-I
-	I-I
blind	I-I
galantamine	I-I
(	O
16	O
-	O
24	O
mg	O
/	O
day	O
)	O
or	O
placebo	B-C
for	O
24	O
months	O
.	O

Primary	O
efficacy	O
endpoint	O
at	O
month	O
24	O
was	O
number	B-O
(	I-O
%	I-O
)	I-O
of	I-O
subjects	I-O
who	I-O
converted	I-O
from	I-O
MCI	I-O
to	I-O
dementia	I-O
(	I-O
CDR	I-O
>	I-O
or	I-O
=	I-O
1	I-O
.	I-O
0	I-O
)	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Cognitive	O
effects	O
of	O
treating	B-I
obstructive	I-I
sleep	I-I
apnea	I-I
in	O
Alzheimer	O
'	O
s	O
disease	O
:	O
a	O
randomized	O
controlled	O
study	O
.	O

METHODS	O
:	O
Randomized	O
double	O
-	O
blind	O
placebo	O
-	O
controlled	O
trial	O
.	O

Participants	O
were	O
randomized	O
to	O
therapeutic	B-I
CPAP	I-I
for	O
6	O
weeks	O
or	O
placebo	B-C
CPAP	I-C
for	O
3	O
weeks	O
followed	O
by	O
therapeutic	B-I
CPAP	I-I
for	O
3	O
weeks	O
.	O

General	O
clinical	O
research	O
center	O
.	O

Fifty	B-P
-	I-P
two	I-P
men	I-P
and	I-P
women	I-P
with	I-P
mild	I-P
to	I-P
moderate	I-P
AD	I-P
and	I-P
OSA	I-P
.	O

CPAP	B-I
.	O

A	B-O
complete	I-O
neuropsychological	I-O
test	I-O
battery	I-O
was	O
administered	O
before	O
treatment	O
and	O
at	O
3	O
and	O
at	O
6	O
weeks	O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
Correlation	O
analysis	O
on	O
changes	O
between	O
cognitive	O
ability	O
and	O
brain	O
fMRI	O
after	O
acupoint	B-I
thread	I-I
embedding	I-I
in	O
Alzheimer	B-P
'	I-P
s	I-P
disease	I-P
patients	I-P
]	O
.	O

METHODS	O
:	O
Twenty	B-P
-	I-P
six	I-P
patients	I-P
with	I-P
mild	I-P
to	I-P
moderate	I-P
AD	I-P
were	O
assigned	O
to	O
the	O
tested	O
group	O
and	O
the	O
control	O
group	O
in	O
pairing	O
,	O
13	O
in	O
each	O
group	O
.	O

ATE	B-I
was	O
performed	O
in	O
patients	O
of	O
the	O
tested	O
group	O
at	O
Shenmen	O
(	O
HT7	O
)	O
,	O
Fenglong	O
(	O
ST40	O
)	O
,	O
Taixi	O
(	O
KI3	O
)	O
and	O
Zusanli	O
(	O
ST36	O
)	O
acupoints	O
,	O
once	O
every	O
month	O
for	O
6	O
times	O
in	O
total	O
;	O
but	O
for	O
patients	O
of	O
the	O
control	O
group	O
only	O
sham	O
operation	O
was	O
done	O
at	O
the	O
same	O
acupoints	O
.	O

The	O
correlation	O
between	O
cognitive	B-O
ability	I-O
and	O
fMRI	B-O
were	O
assessed	O
by	O
comparing	O
the	B-O
scores	I-O
of	I-O
Mini	I-O
-	I-O
Mental	I-O
State	I-O
Examination	I-O
(	I-O
MMSE	I-O
)	I-O
and	O
Alzhemer	B-O
'	I-O
s	I-O
Disease	I-O
Assessment	I-O
Scale	I-O
-	I-O
Cognitive	I-O
section	I-O
(	I-O
ADAS	I-O
-	I-O
Cog	I-O
)	I-O
,	O
monitored	O
at	O
two	O
time	O
points	O
,	O
namely	O
,	O
in	O
one	O
week	O
before	O
starting	O
treatment	O
and	O
1	O
week	O
after	O
terminating	O
6	O
-	O
month	O
treatment	O
.	O

Furthermore	O
,	O
fMRI	B-O
was	O
detected	O
to	O
obtain	O
the	O
data	O
of	O
the	B-O
cerebral	I-O
blood	I-O
oxygen	I-O
content	I-O
before	O
treatment	O
and	O
6	O
months	O
after	O
completing	O
the	O
6	O
-	O
month	O
therapeutic	O
course	O
.	O

Correlation	O
analysis	O
was	O
conducted	O
on	O
the	O
obtained	O
data	O
using	O
software	O
SPM	O
.	O

-DOCSTART-	O

Title	O
:	O
Melatonin	B-I
fails	O
to	O
improve	O
sleep	O
or	O
agitation	O
in	O
double	O
-	O
blind	O
randomized	O
placebo	O
-	O
controlled	O
trial	O
of	O
institutionalized	B-P
patients	I-P
with	I-P
Alzheimer	I-P
disease	I-P
.	O

METHODS	O
:	O
Randomized	O
,	O
placebo	O
-	O
controlled	O
study	O
.	O

Nursing	O
homes	O
in	O
San	O
Diego	O
,	O
CA	O
,	O
metropolitan	O
area	O
.	O

Subjects	O
were	O
patients	B-P
with	I-P
probable	I-P
Alzheimer	I-P
disease	I-P
.	O

Melatonin	B-I
(	O
8	O
.	O
5	O
mg	O
immediate	O
release	O
and	O
1	O
.	O
5	O
mg	O
sustained	O
release	O
)	O
(	O
N	O
=	O
24	O
)	O
or	O
placebo	B-C
(	O
N	O
=	O
17	O
)	O
administered	O
at	O
10	O
:	O
00	O
P	O
.	O
M	O
.	O
for	O
10	O
consecutive	O
nights	O
.	O

The	O
protocol	O
consisted	O
of	O
baseline	O
(	O
3	O
days	O
)	O
,	O
treatment	O
(	O
10	O
days	O
)	O
,	O
and	O
posttreatment	O
(	O
5	O
days	O
)	O
phases	O
.	O

Sleep	B-O
was	O
measured	O
continuously	O
using	O
actigraphy	B-O
.	O

Agitation	B-O
was	O
rated	O
using	O
both	O
the	B-O
Agitated	I-O
Behavior	I-O
Rating	I-O
Scale	I-O
and	O
the	B-O
Cohen	I-O
-	I-O
Mansfield	I-O
Agitation	I-O
Inventory	I-O
.	O

Treatment	O
effects	O
were	O
examined	O
both	O
across	O
the	O
24	O
-	O
hr	O
day	O
and	O
separately	O
by	O
nursing	O
shift	O
.	O

-DOCSTART-	O

Title	O
:	O
Donepezil	B-I
treatment	I-I
of	O
patients	B-P
with	I-P
MCI	I-P
:	O
a	O
48	O
-	O
week	O
randomized	O
,	O
placebo	O
-	O
controlled	O
trial	O
.	O

METHODS	O
:	O
In	O
this	O
multicenter	O
,	O
randomized	O
,	O
placebo	O
-	O
controlled	O
trial	O
,	O
subjects	B-P
with	I-P
MCI	I-P
entered	O
a	O
3	O
-	O
week	O
placebo	O
run	O
-	O
in	O
period	O
followed	O
by	O
48	B-I
weeks	I-I
of	I-I
double	I-I
-	I-I
blind	I-I
donepezil	I-I
(	O
5	O
mg	O
/	O
day	O
for	O
6	O
weeks	O
,	O
then	O
10	O
mg	O
/	O
day	O
for	O
42	O
weeks	O
)	O
or	O
placebo	B-C
treatment	I-C
.	O

Primary	O
efficacy	O
variables	O
included	O
change	O
from	O
baseline	O
in	O
the	B-O
modified	I-O
Alzheimer	I-O
Disease	I-O
Assessment	I-O
Scale	I-O
-	I-O
cognitive	I-O
subscale	I-O
(	I-O
ADAS	I-O
-	I-O
Cog	I-O
)	I-O
and	O
Clinical	B-O
Dementia	I-O
Rating	I-O
Scale	I-O
-	I-O
sum	I-O
of	I-O
boxes	I-O
(	I-O
CDR	I-O
-	I-O
SB	I-O
)	I-O
after	O
48	O
weeks	O
of	O
treatment	O
(	O
modified	O
intention	O
-	O
to	O
-	O
treat	O
analysis	O
)	O
.	O

Secondary	O
efficacy	O
measures	O
evaluated	O
cognition	B-O
,	O
behavior	B-O
,	O
and	O
function	B-O
.	O

-DOCSTART-	O

Title	O
:	O
Different	B-I
cholinesterase	I-I
inhibitor	I-I
effects	O
on	O
CSF	O
cholinesterases	O
in	O
Alzheimer	B-P
patients	I-P
.	O

-DOCSTART-	O

Title	O
:	O
Effects	O
of	O
cranial	B-I
electrical	I-I
stimulation	I-I
on	O
sleep	O
disturbances	O
,	O
depressive	O
symptoms	O
,	O
and	O
caregiving	O
appraisal	O
in	O
spousal	B-P
caregivers	I-P
of	I-P
persons	I-P
with	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
.	O

METHODS	O
:	O
Thirty	B-P
-	I-P
eight	I-P
participants	I-P
were	O
randomly	O
assigned	O
to	O
receive	O
active	B-I
CES	I-I
or	O
sham	B-C
CES	I-C
for	O
4	O
weeks	O
.	O

-DOCSTART-	O

Title	O
:	O
Donepezil	B-I
delays	O
progression	O
to	O
AD	O
in	O
MCI	B-P
subjects	I-P
with	I-P
depressive	I-P
symptoms	I-P
.	O

METHODS	O
:	O
The	O
study	O
sample	O
was	O
composed	O
of	O
756	B-P
participants	I-P
with	I-P
aMCI	I-P
from	I-P
the	I-P
3	I-P
-	I-P
year	I-P
,	I-P
double	I-P
-	I-P
blind	I-P
,	I-P
placebo	I-P
-	I-P
controlled	I-P
Alzheimer	I-P
'	I-P
s	I-P
Disease	I-P
Cooperative	I-P
Study	I-P
drug	I-P
trial	I-P
of	I-P
donepezil	I-P
and	I-P
vitamin	I-P
E	I-P
.	O

Beck	B-O
Depression	I-O
Inventory	I-O
(	I-O
BDI	I-O
)	I-O
was	O
used	O
to	O
assess	O
depressive	B-O
symptoms	I-O
at	O
baseline	O
and	O
participants	O
were	O
followed	O
either	O
to	O
the	O
end	O
of	O
study	O
or	O
to	O
the	O
primary	O
endpoint	O
of	O
progression	O
to	O
probable	O
or	O
possible	O
AD	O
.	O

-DOCSTART-	O

Title	O
:	O
Lithium	B-I
trial	O
in	O
Alzheimer	O
'	O
s	O
disease	O
:	O
a	O
randomized	O
,	O
single	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
multicenter	O
10	O
-	O
week	O
study	O
.	O

METHODS	O
:	O
A	B-P
total	I-P
of	I-P
71	I-P
patients	I-P
with	I-P
mild	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
(	I-P
Mini	I-P
-	I-P
Mental	I-P
State	I-P
Examination	I-P
score	I-P
>	I-P
or	I-P
=	I-P
21	I-P
and	I-P
<	I-P
or	I-P
=	I-P
26	I-P
)	I-P
were	O
successfully	O
randomly	O
assigned	O
to	O
placebo	B-C
(	O
N	O
=	O
38	O
)	O
or	O
lithium	B-I
treatment	I-I
(	O
N	O
=	O
33	O
)	O
at	O
6	O
academic	O
expert	O
memory	O
clinics	O
.	O

The	O
10	O
-	O
week	O
treatment	O
included	O
a	O
6	O
-	O
week	O
titration	O
phase	O
to	O
reach	O
the	O
target	O
serum	O
level	O
of	O
lithium	B-I
(	O
0	O
.	O
5	O
-	O
0	O
.	O

8	O
mmol	O
/	O
L	O
)	O
.	O

The	O
primary	O
outcome	O
measures	O
were	O
cerebrospinal	B-O
fluid	I-O
(	I-O
CSF	I-O
)	I-O
levels	I-O
of	I-O
phosphorylated	I-O
tau	I-O
(	I-O
p	I-O
-	I-O
tau	I-O
)	I-O
and	O
GSK	B-O
-	I-O
3	I-O
activity	I-O
in	I-O
lymphocytes	I-O
.	O

Secondary	O
outcome	O
measures	O
were	O
CSF	B-O
concentration	I-O
of	I-O
total	I-O
tau	I-O
and	O
beta	B-O
-	I-O
amyloid	I-O
(	I-O
1	I-O
-	I-O
42	I-O
)	I-O
(	I-O
Abeta	I-O
(	I-O
1	I-O
-	I-O
42	I-O
)	I-O
)	I-O
,	O
plasma	B-O
levels	I-O
of	I-O
Abeta	I-O
(	I-O
1	I-O
-	I-O
42	I-O
)	I-O
,	O
Alzheimer	B-O
'	I-O
s	I-O
Disease	I-O
Assessment	I-O
Scale	I-O
(	I-O
ADAS	I-O
)	I-O
-	I-O
Cognitive	I-O
summary	I-O
scores	I-O
,	O
MMSE	B-O
,	O
and	O
Neuropsychiatric	B-O
Inventory	I-O
(	I-O
NPI	I-O
)	I-O
.	O

Patients	O
were	O
enrolled	O
in	O
the	O
study	O
from	O
November	O
2004	O
to	O
July	O
2005	O
.	O

-DOCSTART-	O

Title	O
:	O
Atomoxetine	B-I
augmentation	O
of	O
cholinesterase	B-I
inhibitor	I-I
therapy	I-I
in	O
patients	B-P
with	I-P
Alzheimer	I-P
disease	I-P
:	O
6	O
-	O
month	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
parallel	O
-	O
trial	O
study	O
.	O

METHODS	O
:	O
A	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
(	O
PLA	O
)	O
-	O
controlled	O
,	O
parallel	O
-	O
groups	O
study	O
,	O
starting	O
with	O
a	O
5	O
-	O
33	O
-	O
day	O
screening	O
and	O
evaluation	O
period	O
,	O
followed	O
by	O
a	O
6	O
-	O
month	O
treatment	O
period	O
.	O

Eight	O
independent	O
or	O
academic	O
outpatient	O
clinics	O
in	O
the	O
United	O
States	O
.	O

Male	B-P
or	I-P
female	I-P
patients	I-P
,	I-P
aged	I-P
55	I-P
years	I-P
and	I-P
older	I-P
,	I-P
with	I-P
mild	I-P
-	I-P
to	I-P
-	I-P
moderate	I-P
Alzheimer	I-P
disease	I-P
(	I-P
Mini	I-P
-	I-P
Mental	I-P
State	I-P
Examination	I-P
score	I-P
between	I-P
10	I-P
and	I-P
26	I-P
)	I-P
at	I-P
baseline	I-P
.	O

ATX	B-I
(	O
25	O
-	O
80	O
mg	O
/	O
day	O
)	O
or	O
PLA	B-I
for	O
up	O
to	O
6	O
months	O
,	O
added	O
to	O
ongoing	B-I
cholinesterase	I-I
-	I-I
inhibitor	I-I
therapy	I-I
.	O

Alzheimer	B-O
Disease	I-O
Assessment	I-O
Scale	I-O
-	I-O
Cognitive	I-O
Portion	I-O
(	I-O
ADAS	I-O
-	I-O
Cog	I-O
,	O
primary	O
measure	O
)	O
,	O
Clinician	B-O
'	I-O
s	I-O
Interview	I-O
-	I-O
Based	I-O
Impression	I-O
of	I-O
Change	I-O
score	I-O
at	O
end	O
point	O
,	O
Neuropsychiatric	B-O
Inventory	I-O
,	O
and	O
Alzheimer	B-O
'	I-O
s	I-O
Disease	I-O
Cooperative	I-O
Study	I-O
Inventory	I-O
-	I-O
Activities	I-O
of	I-O
Daily	I-O
Living	I-O
Inventory	I-O
total	I-O
score	I-O
,	O
safety	B-O
measures	I-O
(	O
secondary	O
measures	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Effectiveness	O
of	O
donepezil	B-I
in	O
reducing	O
clinical	O
worsening	O
in	O
patients	B-P
with	I-P
mild	I-P
-	I-P
to	I-P
-	I-P
moderate	I-P
alzheimer	I-P
'	I-P
s	I-P
disease	I-P
.	O

METHODS	O
:	O
Data	O
from	O
906	B-P
patients	I-P
(	I-P
388	I-P
receiving	I-P
placebo	I-P
;	I-P
518	I-P
receiving	I-P
donepezil	I-P
)	I-P
with	I-P
mild	I-P
-	I-P
to	I-P
-	I-P
moderate	I-P
AD	I-P
[	I-P
Mini	I-P
-	I-P
Mental	I-P
State	I-P
Examination	I-P
(	I-P
MMSE	I-P
)	I-P
score	I-P
10	I-P
-	I-P
27	I-P
]	I-P
were	O
pooled	O
from	O
3	O
randomized	O
,	O
double	O
-	O
blind	O
placebo	O
-	O
controlled	O
studies	O
.	O

Clinical	O
worsening	O
was	O
defined	O
as	O
decline	O
in	O
(	O
1	O
)	O
cognition	B-O
(	O
MMSE	B-O
)	O
,	O
(	O
2	O
)	O
cognition	B-O
and	O
global	B-O
ratings	I-O
(	O
Clinician	B-O
'	I-O
s	I-O
Interview	I-O
-	I-O
Based	I-O
Impression	I-O
of	I-O
Change	I-O
plus	I-O
Caregiver	I-O
Input	I-O
/	O
Gottfries	B-O
-	I-O
Brne	I-O
-	I-O
Steen	I-O
scale	I-O
)	O
or	O
(	O
3	O
)	O
cognition	B-O
,	O
global	B-O
ratings	I-O
and	O
function	B-O
(	O
various	B-O
functional	I-O
measures	I-O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
25	O
-	O
week	O
,	O
open	O
-	O
label	O
trial	O
investigating	O
rivastigmine	B-I
transdermal	I-I
patches	I-I
with	O
concomitant	B-I
memantine	I-I
in	O
mild	O
-	O
to	O
-	O
moderate	O
Alzheimer	O
'	O
s	O
disease	O
:	O
a	O
post	O
hoc	O
analysis	O
.	O

METHODS	O
:	O
Post	O
hoc	O
analysis	O
of	O
a	O
25	O
-	O
week	O
,	O
randomized	O
,	O
prospective	O
,	O
open	O
-	O
label	O
,	O
parallel	O
-	O
group	O
study	O
.	O

Patients	O
receiving	O
donepezil	O
were	O
switched	O
to	O
rivastigmine	O
patches	O
(	O
4	O
.	O
6	O
mg	O
/	O
24	O
h	O
)	O
immediately	O
or	O
following	O
a	O
7	O
-	O
day	O
withdrawal	O
for	O
4	O
weeks	O
(	O
core	O
phase	O
)	O
,	O
before	O
titrating	O
up	O
to	O
9	O
.	O
5	O
mg	O
/	O
24	O
h	O
for	O
a	O
further	O
20	O
-	O
week	O
extension	O
phase	O
.	O

Prior	O
memantine	O
therapy	O
was	O
continued	O
throughout	O
.	O

Tolerability	B-O
(	O
adverse	B-O
events	I-O
[	I-O
AEs	I-O
]	I-O
,	O
serious	B-O
AEs	I-O
[	I-O
SAEs	I-O
]	I-O
and	O
discontinuations	B-O
)	O
and	O
efficacy	B-O
(	O
cognition	B-O
,	O
global	B-O
functioning	I-O
and	O
activities	B-O
of	I-O
daily	I-O
living	I-O
[	I-O
ADLs	I-O
]	I-O
)	O
were	O
assessed	O
for	O
the	O
rivastigmine	B-I
transdermal	I-I
patch	I-I
,	O
with	O
or	O
without	O
concomitant	B-I
memantine	I-I
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
tarenflurbil	B-I
on	O
cognitive	O
decline	O
and	O
activities	O
of	O
daily	O
living	O
in	O
patients	B-P
with	I-P
mild	I-P
Alzheimer	I-P
disease	I-P
:	O
a	O
randomized	O
controlled	O
trial	O
.	O

METHODS	O
:	O
A	O
multicenter	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
trial	O
enrolling	O
patients	B-P
with	I-P
mild	I-P
AD	I-P
was	O
conducted	O
at	O
133	O
trial	O
sites	O
in	O
the	O
United	O
States	O
between	O
February	O
21	O
,	O
2005	O
,	O
and	O
April	O
30	O
,	O
2008	O
.	O

Concomitant	O
treatment	O
with	O
cholinesterase	O
inhibitors	O
or	O
memantine	O
was	O
permitted	O
.	O

Tarenflurbil	B-I
,	O
800	O
mg	O
,	O
or	O
placebo	B-C
,	O
administered	O
twice	O
a	O
day	O
.	O

Co	O
-	O
primary	O
efficacy	O
end	O
points	O
were	O
the	O
change	O
from	O
baseline	O
to	O
month	O
18	O
in	O
total	O
score	O
on	O
the	B-O
subscale	I-O
of	I-O
the	I-O
Alzheimer	I-O
Disease	I-O
Assessment	I-O
Scale	I-O
-	I-O
Cognitive	I-O
Subscale	I-O
(	I-O
ADAS	I-O
-	I-O
Cog	I-O
,	I-O
80	I-O
-	I-O
point	I-O
version	I-O
)	I-O
and	O
Alzheimer	B-O
Disease	I-O
Cooperative	I-O
Studies	I-O
-	I-O
activities	I-O
of	I-O
daily	I-O
living	I-O
(	I-O
ADCS	I-O
-	I-O
ADL	I-O
)	I-O
scale	I-O
.	O

Additional	O
prespecified	O
slope	O
analyses	O
explored	O
the	O
possibility	O
of	O
disease	O
modification	O
.	O

-DOCSTART-	O

Title	O
:	O
Double	O
-	O
blind	O
,	O
controlled	O
phase	O
II	O
study	O
of	O
a	B-I
5	I-I
-	I-I
HT6	I-I
receptor	I-I
antagonist	I-I
,	O
SB	B-I
-	I-I
742457	I-I
,	O
in	O
Alzheimer	O
'	O
s	O
disease	O
.	O

METHODS	O
:	O
Participating	B-P
subjects	I-P
had	I-P
a	I-P
Mini	I-P
-	I-P
Mental	I-P
State	I-P
Examination	I-P
(	I-P
MMSE	I-P
)	I-P
score	I-P
of	I-P
12	I-P
to	I-P
26	I-P
after	I-P
a	I-P
4	I-P
-	I-P
week	I-P
,	I-P
single	I-P
-	I-P
blind	I-P
,	I-P
placebo	I-P
run	I-P
-	I-P
in	I-P
phase	I-P
,	O
and	O
were	O
randomized	O
(	O
2:1:1	O
:	O
2	O
)	O
to	O
receive	O
placebo	B-C
,	O
SB	B-I
-	I-I
742457	I-I
5	O
mg	O
,	O
15	O
mg	O
,	O
or	O
35	O
mg	O
once	O
daily	O
for	O
24	O
weeks	O
.	O

Coprimary	O
efficacy	O
endpoints	O
were	O
the	B-O
Clinician	I-O
'	I-O
s	I-O
Interview	I-O
-	I-O
Based	I-O
Impression	I-O
of	I-O
Change	I-O
with	I-O
caregiver	I-O
input	I-O
(	I-O
CIBIC	I-O
+	I-O
)	I-O
score	I-O
and	O
change	O
from	O
baseline	O
in	O
Alzheimer	B-O
'	I-O
s	I-O
Disease	I-O
Assessment	I-O
Scale	I-O
-	I-O
Cognitive	I-O
subscale	I-O
(	I-O
ADAS	I-O
-	I-O
Cog	I-O
)	I-O
score	I-O
at	O
Week	O
24	O
,	O
in	O
the	O
intent	O
-	O
to	O
-	O
treat	O
(	O
ITT	O
)	O
population	O
.	O

A	O
model	O
-	O
based	O
design	O
provided	O
90	O
%	O
power	O
to	O
detect	O
a	O
linear	O
trend	O
in	O
treatment	O
response	O
across	O
increasing	O
doses	O
and	O
>	O
or	O
=90	O
%	O
power	O
to	O
compare	O
SB	B-I
-	I-I
742457	I-I
35	O
mg	O
with	O
placebo	B-C
.	O

-DOCSTART-	O

Title	O
:	O
Effects	O
of	O
aerobic	B-I
exercise	I-I
on	O
mild	O
cognitive	O
impairment	O
:	O
a	O
controlled	O
trial	O
.	O

METHODS	O
:	O
Six	O
-	O
month	O
,	O
randomized	O
,	O
controlled	O
,	O
clinical	O
trial	O
.	O

Veterans	O
Affairs	O
Puget	O
Sound	O
Health	O
Care	O
System	O
clinical	O
research	O
unit	O
.	O

Thirty	B-P
-	I-P
three	I-P
adults	I-P
(	I-P
17	I-P
women	I-P
)	I-P
with	I-P
amnestic	I-P
mild	I-P
cognitive	I-P
impairment	I-P
ranging	I-P
in	I-P
age	I-P
from	I-P
55	I-P
to	I-P
85	I-P
years	I-P
(	I-P
mean	I-P
age	I-P
,	I-P
70	I-P
years	I-P
)	I-P
.	O

Intervention	O
Participants	O
were	O
randomized	O
either	O
to	O
a	B-I
high	I-I
-	I-I
intensity	I-I
aerobic	I-I
exercise	I-I
or	O
stretching	B-C
control	I-C
group	O
.	O

The	B-I
aerobic	I-I
group	O
exercised	O
under	O
the	O
supervision	O
of	O
a	O
fitness	O
trainer	O
at	O
75	O
%	O
to	O
85	O
%	O
of	O
heart	O
rate	O
reserve	O
for	O
45	O
to	O
60	O
min	O
/	O
d	O
,	O
4	O
d	O
/	O
wk	O
for	O
6	O
months	O
.	O

The	O
control	O
group	O
carried	O
out	O
supervised	B-C
stretching	I-C
activities	I-C
according	O
to	O
the	O
same	O
schedule	O
but	O
maintained	O
their	O
heart	O
rate	O
at	O
or	O
below	O
50	O
%	O
of	O
their	O
heart	O
rate	O
reserve	O
.	O

Before	O
and	O
after	O
the	O
study	O
,	O
glucometabolic	B-O
and	O
treadmill	B-O
tests	I-O
were	O
performed	O
and	O
fat	B-O
distribution	I-O
was	O
assessed	O
using	O
dual	B-O
-	I-O
energy	I-O
x	I-O
-	I-O
ray	I-O
absorptiometry	I-O
.	O

At	O
baseline	O
,	O
month	O
3	O
,	O
and	O
month	O
6	O
,	O
blood	O
was	O
collected	O
for	O
assay	B-O
and	O
cognitive	B-O
tests	I-O
were	O
administered	O
.	O

Performance	O
measures	O
on	O
Symbol	B-O
-	I-O
Digit	I-O
Modalities	I-O
,	O
Verbal	B-O
Fluency	I-O
,	O
Stroop	B-O
,	O
Trails	B-O
B	I-O
,	O
Task	B-O
Switching	I-O
,	O
Story	B-O
Recall	I-O
,	O
and	O
List	B-O
Learning	I-O
.	O

Fasting	B-O
plasma	I-O
levels	I-O
of	I-O
insulin	I-O
,	O
cortisol	B-O
,	O
brain	B-O
-	I-O
derived	I-O
neurotrophic	I-O
factor	I-O
,	O
insulinlike	B-O
growth	I-O
factor	I-O
-	I-O
I	I-O
,	O
and	O
beta	B-O
-	I-O
amyloids	I-O
40	I-O
and	O
42	B-O
.	O

-DOCSTART-	O

Title	O
:	O
11	O
C	O
-	O
PiB	O
PET	O
assessment	O
of	O
change	O
in	O
fibrillar	O
amyloid	O
-	O
beta	O
load	O
in	O
patients	B-P
with	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
treated	O
with	O
bapineuzumab	B-I
:	O
a	O
phase	O
2	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
ascending	O
-	O
dose	O
study	O
.	O

METHODS	O
:	O
Patients	B-P
with	I-P
mild	I-P
-	I-P
to	I-P
-	I-P
moderate	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
were	O
randomly	O
assigned	O
to	O
receive	O
intravenous	B-I
bapineuzumab	I-I
or	O
placebo	B-C
in	O
a	O
ratio	O
of	O
seven	O
to	O
three	O
in	O
three	O
ascending	O
dose	O
groups	O
(	O
0	O
.	O
5	O
,	O
1	O
.	O
0	O
,	O
or	O
2	O
.	O
0	O
mg	O
/	O
kg	O
)	O
.	O

Each	O
dose	O
group	O
was	O
enrolled	O
after	O
safety	O
review	O
of	O
the	O
previous	O
group	O
.	O

Randomisation	O
was	O
by	O
interactive	O
voice	O
response	O
system	O
;	O
masking	O
was	O
achieved	O
with	O
numbered	O
kit	O
allocation	O
.	O

Patients	O
,	O
investigators	O
,	O
study	O
site	O
personnel	O
,	O
sponsor	O
staff	O
,	O
and	O
carers	O
were	O
masked	O
to	O
treatment	O
.	O

Patients	O
received	O
up	O
to	O
six	O
infusions	O
,	O
13	O
weeks	O
apart	O
,	O
and	O
had	O
(	O
11	O
)	O
C	O
-	O
PiB	O
PET	O
scans	O
at	O
baseline	O
and	O
at	O
weeks	O
20	O
,	O
45	O
,	O
and	O
78	O
.	O

The	O
primary	O
outcome	O
was	O
the	O
difference	O
between	O
the	B-I
pooled	I-I
bapineuzumab	I-I
group	O
and	O
the	B-C
pooled	I-C
placebo	I-C
group	O
in	O
mean	O
change	O
from	O
screening	O
to	O
week	O
78	O
in	O
(	B-O
11	I-O
)	I-O
C	I-O
-	I-O
PiB	I-O
cortical	I-O
to	I-O
cerebellar	I-O
retention	I-O
ratio	I-O
averaged	I-O
across	I-O
six	I-O
cortical	I-O
regions	I-O
of	I-O
interest	I-O
.	O

Analysis	O
was	O
by	O
modified	O
intention	O
to	O
treat	O
.	O

This	O
study	O
is	O
registered	O
with	O
EudraCT	O
,	O
number	O
2004-004120-12	O
;	O
ISRCTN17517446	O
.	O

-DOCSTART-	O

Title	O
:	O
Spine	B-I
Surgery	I-I
under	O
general	B-I
anesthesia	I-I
may	O
not	O
increase	O
the	O
risk	O
of	O
Alzheimer	O
'	O
s	O
disease	O
.	O

METHODS	O
:	O
We	O
searched	O
the	O
Clinical	O
Data	O
Repository	O
of	O
the	O
University	O
of	O
Virginia	O
for	O
patients	B-P
receiving	I-P
spine	I-P
surgery	I-P
from	I-P
January	I-P
1	I-P
,	I-P
1992	I-P
to	I-P
March	I-P
1	I-P
,	I-P
2004	I-P
.	O

Patients	B-P
with	I-P
newly	I-P
-	I-P
diagnosed	I-P
AD	I-P
after	I-P
the	I-P
surgery	I-P
but	I-P
before	I-P
March	I-P
1	I-P
,	I-P
2009	I-P
(	I-P
a	I-P
minimal	I-P
5	I-P
-	I-P
year	I-P
follow	I-P
-	I-P
up	I-P
time	I-P
after	I-P
the	I-P
surgery	I-P
)	I-P
were	O
identified	O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
Human	B-I
Albumin	I-I
Grifols	I-I
5	O
%	O
in	O
plasmapheresis	O
:	O
a	O
new	O
therapy	O
involving	O
beta	O
-	O
amyloid	O
mobilisation	O
in	O
Alzheimer	O
'	O
s	O
disease	O
]	O
.	O

-DOCSTART-	O

Title	O
:	O
Effectiveness	O
and	O
tolerability	O
of	O
high	B-I
-	I-I
dose	I-I
(	I-I
23	I-I
mg	I-I
/	I-I
d	I-I
)	I-I
versus	O
standard	B-I
-	I-I
dose	I-I
(	I-I
10	I-I
mg	I-I
/	I-I
d	I-I
)	I-I
donepezil	I-I
in	O
moderate	O
to	O
severe	O
Alzheimer	O
'	O
s	O
disease	O
:	O
A	O
24	O
-	O
week	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
study	O
.	O

METHODS	O
:	O
This	O
randomized	O
,	O
double	O
-	O
blind	O
study	O
was	O
conducted	O
at	O
219	O
sites	O
in	O
Asia	O
,	O
Europe	O
,	O
Australia	O
,	O
North	O
America	O
,	O
South	O
Africa	O
,	O
and	O
South	O
America	O
from	O
June	O
6	O
,	O
2007	O
,	O
to	O
March	O
27	O
,	O
2009	O
.	O

Patients	B-P
aged	I-P
45	I-P
to	I-P
90	I-P
years	I-P
with	I-P
probable	I-P
AD	I-P
,	I-P
Mini	I-P
-	I-P
Mental	I-P
State	I-P
Examination	I-P
score	I-P
0	I-P
to	I-P
20	I-P
(	I-P
moderate	I-P
to	I-P
severe	I-P
impairment	I-P
)	I-P
,	I-P
and	I-P
who	I-P
were	I-P
receiving	I-P
donepezil	I-P
10	I-P
mg	I-P
once	I-P
daily	I-P
for	I-P
>	I-P
or	I-P
=12	I-P
weeks	I-P
before	I-P
the	I-P
start	I-P
of	I-P
the	I-P
study	I-P
were	O
eligible	O
.	O

Patients	O
(	O
n	O
=	O
1467	O
)	O
were	O
randomly	O
assigned	O
to	O
receive	O
high	B-I
-	I-I
dose	I-I
donepezil	I-I
(	O
23	O
mg	O
once	O
daily	O
)	O
or	O
standard	B-I
-	I-I
dose	I-I
donepezil	I-I
(	O
10	O
mg	O
once	O
daily	O
)	O
for	O
24	O
weeks	O
.	O

Coprimary	O
effectiveness	O
measures	O
were	O
changes	O
in	O
cognition	B-O
and	O
global	B-O
functioning	I-O
,	O
as	O
assessed	O
using	O
least	O
squares	O
mean	O
changes	O
from	O
baseline	O
(	O
LSM	O
[	O
SE	O
]	O
A	O
)	O
scores	O
(	O
last	O
observation	O
carried	O
forward	O
)	O
on	O
the	B-O
Severe	I-O
Impairment	I-O
Battery	I-O
(	I-O
SIB	I-O
;	I-O
cognition	I-O
)	I-O
and	O
the	B-O
Clinician	I-O
'	I-O
s	I-O
Interview	I-O
-	I-O
Based	I-O
Impression	I-O
of	I-O
Change	I-O
Plus	I-O
Caregiver	I-O
Input	I-O
scale	I-O
(	I-O
CIBIC	I-O
+	I-O
;	I-O
global	I-O
function	I-O
rating	I-O
)	I-O
overall	O
change	O
score	O
(	O
mean	O
[	O
SD	O
]	O
)	O
at	O
week	O
24	O
.	O

Treatment	B-O
-	I-O
emergent	I-O
adverse	I-O
events	I-O
(	I-O
TEAEs	I-O
)	I-O
were	O
assessed	O
using	O
spontaneous	B-O
patient	I-O
/	I-O
caregiver	I-O
reporting	I-O
and	O
open	B-O
-	I-O
ended	I-O
questioning	I-O
;	O
clinical	B-O
laboratory	I-O
testing	I-O
(	O
hematology	B-O
,	O
biochemistry	B-O
,	O
and	O
urinalysis	B-O
panels	I-O
analyzed	O
by	O
a	O
central	O
laboratory	O
)	O
;	O
12	B-O
-	I-O
lead	I-O
ECG	I-O
;	O
and	O
physical	B-O
and	O
neurologic	B-O
examinations	I-O
,	O
including	O
vital	B-O
sign	I-O
measurements	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Assessing	O
the	O
cost	O
-	O
effectiveness	O
of	O
the	B-I
rivastigmine	I-I
transdermal	I-I
patch	I-I
for	O
Alzheimer	O
'	O
s	O
disease	O
in	O
the	O
UK	O
using	O
MMSE	O
-	O
and	O
ADL	O
-	O
based	O
models	O
.	O

METHODS	O
:	O
Incremental	B-O
costs	I-O
and	O
Quality	B-O
Adjusted	I-O
Life	I-O
Years	I-O
(	I-O
QALYs	I-O
)	I-O
associated	O
with	O
rivastigmine	B-I
patch	I-I
and	O
capsule	B-I
treatment	I-I
versus	O
best	B-C
supportive	I-C
care	I-C
(	I-C
BSC	I-C
)	I-C
were	O
calculated	O
using	O
two	O
economic	O
models	O
,	O
one	O
based	O
solely	O
on	O
Mini	B-O
-	I-O
Mental	I-O
State	I-O
Examination	I-O
(	I-O
MMSE	I-O
)	I-O
scores	I-O
,	O
and	O
one	O
also	O
incorporating	O
activities	B-O
of	I-O
daily	I-O
living	I-O
(	I-O
ADL	I-O
)	I-O
scores	I-O
.	O

The	O
clinical	O
pathway	O
was	O
populated	O
with	O
data	O
from	O
a	O
clinical	O
trial	O
of	O
rivastigmine	B-I
patch	I-I
(	O
9	O
.	O
5	O
mg	O
/	O
24	O
h	O
)	O
and	O
capsules	B-I
(	O
12	O
mg	O
/	O
day	O
)	O
versus	O
placebo	B-C
.	O

Costs	O
were	O
based	O
on	O
the	O
UK	O
health	O
and	O
social	O
care	O
costs	O
and	O
basic	O
UK	O
National	O
Health	O
Service	O
(	O
NHS	O
)	O
prices	O
.	O

Disease	O
progression	O
was	O
modelled	O
beyond	O
the	O
trial	O
period	O
over	O
5	O
years	O
using	O
published	O
equations	O
to	O
predict	O
natural	O
decline	O
in	O
AD	O
patients	O
.	O

Base	O
case	O
costing	O
variables	O
included	O
drugs	O
,	O
clinical	O
monitoring	O
,	O
and	O
institutionalization	O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
effects	O
on	O
cognitive	O
functions	O
of	O
a	B-I
movement	I-I
-	I-I
based	I-I
intervention	I-I
in	O
patients	B-P
with	I-P
Alzheimer	I-P
'	I-P
s	I-P
type	I-P
dementia	I-P
:	O
a	O
pilot	O
study	O
.	O

METHODS	O
:	O
The	O
sample	O
consisted	O
of	O
27	B-P
patients	I-P
fulfilling	I-P
the	I-P
AD	I-P
ICD	I-P
-	I-P
10	I-P
diagnostic	I-P
criteria	I-P
.	O

The	O
patient	O
sample	O
was	O
randomly	O
divided	O
into	O
two	O
groups	O
:	O
The	B-I
Exercise	I-I
Group	O
received	O
6	B-I
weeks	I-I
movement	I-I
training	I-I
and	O
comprised	O
15	O
participants	O
with	O
a	O
mean	O
age	O
of	O
70	O
.	O
5	O
years	O
(	O
SD	O
:	O
8	O
)	O
.	O

Control	O
Group	O
participated	O
in	O
a	B-C
standard	I-C
care	I-C
group	O
,	O
which	O
served	O
as	O
a	O
control	O
intervention	O
,	O
and	O
consisted	O
of	O
12	O
patients	O
with	O
an	O
average	O
age	O
of	O
75	O
.	O
7	O
years	O
(	O
SD	O
:	O
6	O
.	O
90	O
)	O
.	O

Cognitive	B-O
functions	I-O
were	O
assessed	O
using	O
six	B-O
computerised	I-O
tests	I-O
from	I-O
the	I-O
CANTAB	I-O
,	O
pre	O
and	O
post	O
training	O
.	O

Data	O
were	O
analysed	O
using	O
t	O
-	O
tests	O
.	O

The	O
false	O
discovery	O
rate	O
(	O
FDR	O
)	O
for	O
multiple	O
comparisons	O
as	O
well	O
as	O
Cohen	O
'	O
s	O
d	O
effect	O
size	O
was	O
used	O
to	O
assess	O
the	O
significant	O
effects	O
.	O

-DOCSTART-	O

Title	O
:	O
EHT0202	B-I
in	O
Alzheimer	O
'	O
s	O
disease	O
:	O
a	O
3	O
-	O
month	O
,	O
randomized	O
,	O
placebo	O
-	O
controlled	O
,	O
double	O
-	O
blind	O
study	O
.	O

METHODS	O
:	O
This	O
pilot	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
parallel	O
group	O
,	O
multicentre	O
,	O
Phase	O
IIA	O
study	O
was	O
conducted	O
in	O
159	B-P
randomized	I-P
patients	I-P
suffering	I-P
from	I-P
mild	I-P
to	I-P
moderate	I-P
Alzheimer	I-P
'	I-P
s	I-P
Disease	I-P
.	O

EHT0202	B-I
(	O
40	O
or	O
80	O
mg	O
bid	O
)	O
or	O
placebo	B-C
was	O
administered	O
as	O
adjunctive	O
therapy	O
to	O
one	B-I
acetylcholinesterase	I-I
inhibitor	I-I
over	O
a	O
3	O
-	O
month	O
period	O
.	O

This	O
study	O
was	O
designed	O
to	O
assess	O
the	O
clinical	B-O
safety	I-O
and	O
tolerability	B-O
of	O
EHT0202	B-I
as	O
a	O
primary	O
objective	O
,	O
with	O
secondary	O
endpoints	O
(	O
cognitive	B-O
function	I-O
,	O
daily	B-O
living	I-O
activities	I-O
,	O
behaviour	B-O
,	O
caregiver	B-O
burden	I-O
and	O
global	B-O
functioning	I-O
)	O
included	O
to	O
explore	O
clinical	O
efficacy	O
of	O
EHT0202	B-I
versus	O
placebo	B-C
.	O

-DOCSTART-	O

Title	O
:	O
Dose	O
effects	O
associated	O
with	O
rivastigmine	B-I
transdermal	I-I
patch	I-I
in	O
patients	B-P
with	I-P
mild	I-P
-	I-P
to	I-P
-	I-P
moderate	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
.	O

METHODS	O
:	O
This	O
was	O
a	O
retrospective	O
analysis	O
of	O
a	O
large	O
,	O
international	O
,	O
24	O
-	O
week	O
,	O
randomised	O
,	O
placebo	O
-	O
and	O
active	O
-	O
controlled	O
trial	O
(	O
IDEAL	O
,	O
CENA713D2320	O
)	O
of	O
rivastigmine	B-I
in	O
patients	B-P
with	I-P
mild	I-P
-	I-P
to	I-P
-	I-P
moderate	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
(	I-P
AD	I-P
)	I-P
.	O

Patients	O
received	O
the	B-I
9	I-I
.	I-I
5	I-I
mg	I-I
/	I-I
24	I-I
h	I-I
rivastigmine	I-I
patch	I-I
,	O
the	B-I
17	I-I
.	I-I
4	I-I
mg	I-I
/	I-I
24	I-I
h	I-I
rivastigmine	I-I
patch	I-I
,	O
12	B-I
mg	I-I
/	I-I
day	I-I
rivastigmine	I-I
capsules	I-I
or	O
placebo	B-C
.	O

Changes	O
from	O
baseline	O
at	O
week	O
24	O
on	O
the	B-O
AD	I-O
Assessment	I-O
Scale	I-O
-	I-O
cognitive	I-O
subscale	I-O
(	I-O
ADAS	I-O
-	I-O
cog	I-O
)	I-O
,	O
AD	B-O
Cooperative	I-O
Study	I-O
-	I-O
Clinical	I-O
Global	I-O
Impression	I-O
of	I-O
Change	I-O
(	I-O
ADCS	I-O
-	I-O
CGIC	I-O
)	I-O
and	O
the	B-O
AD	I-O
Cooperative	I-O
Study	I-O
-	I-O
Activities	I-O
of	I-O
Daily	I-O
Living	I-O
(	I-O
ADCS	I-O
-	I-O
ADL	I-O
)	I-O
scale	I-O
were	O
calculated	O
based	O
on	O
the	O
patient	O
'	O
s	O
mode	O
and	O
last	O
prescribed	O
patch	O
dose	O
.	O

The	O
analysis	O
included	O
the	O
4	O
.	O
6	O
mg	O
/	O
24	O
h	O
and	O
13	O
.	O
3	O
mg	O
/	O
24	O
h	O
patch	O
doses	O
,	O
for	O
which	O
efficacy	O
data	O
have	O
not	O
previously	O
been	O
reported	O
.	O

-DOCSTART-	O

Title	O
:	O
Escitalopram	B-I
versus	O
risperidone	B-I
for	O
the	O
treatment	O
of	O
behavioral	O
and	O
psychotic	O
symptoms	O
associated	O
with	O
Alzheimer	O
'	O
s	O
disease	O
:	O
a	O
randomized	O
double	O
-	O
blind	O
pilot	O
study	O
.	O

METHODS	O
:	O
Inpatients	B-P
with	I-P
AD	I-P
,	I-P
who	I-P
had	I-P
been	I-P
hospitalized	I-P
because	I-P
of	I-P
behavioral	I-P
symptoms	I-P
,	O
were	O
recruited	O
to	O
a	O
six	O
-	O
week	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
controlled	O
trial	O
.	O

Participants	O
(	O
n	O
=	O
40	O
)	O
were	O
randomized	O
to	O
once	B-I
daily	I-I
risperidone	I-I
1	O
mg	O
or	O
escitalopram	B-I
10	O
mg	O
.	O

-DOCSTART-	O

Title	O
:	O
Tolerability	O
and	O
efficacy	O
of	O
memantine	B-I
add	I-I
-	I-I
on	I-I
therapy	I-I
to	O
rivastigmine	B-I
transdermal	I-I
patches	I-I
in	O
mild	O
to	O
moderate	O
Alzheimer	O
'	O
s	O
disease	O
:	O
a	O
multicenter	O
,	O
randomized	O
,	O
open	O
-	O
label	O
,	O
parallel	O
-	O
group	O
study	O
.	O

METHODS	O
:	O
In	O
this	O
multicenter	O
,	O
randomized	O
,	O
open	O
-	O
label	O
study	O
,	O
patients	O
entered	O
an	O
8	O
-	O
week	O
run	O
-	O
in	O
period	O
(	O
a	O
5	O
cm	O
2	O
rivastigmine	O
patch	O
for	O
4	O
weeks	O
,	O
then	O
a	O
10	O
cm	O
(	O
2	O
)	O
patch	O
for	O
4	O
weeks	O
)	O
followed	O
by	O
16	B-I
weeks	I-I
of	I-I
memantine	I-I
plus	O
rivastigmine	B-I
patch	I-I
or	O
rivastigmine	B-I
patch	I-I
monotherapy	I-I
.	O

The	O
primary	O
outcome	O
measure	O
was	O
the	B-O
retention	I-O
rate	I-O
at	O
the	O
end	O
of	O
the	O
trial	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
trial	O
of	O
simvastatin	B-I
to	O
treat	O
Alzheimer	O
disease	O
.	O

METHODS	O
:	O
This	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
trial	O
of	O
simvastatin	B-I
was	O
conducted	O
in	O
individuals	B-P
with	I-P
mild	I-P
to	I-P
moderate	I-P
AD	I-P
and	I-P
normal	I-P
lipid	I-P
levels	I-P
.	O

Participants	O
were	O
randomly	O
assigned	O
to	O
receive	O
simvastatin	B-I
,	O
20	O
mg	O
/	O
day	O
,	O
for	O
6	O
weeks	O
then	O
40	O
mg	O
per	O
day	O
for	O
the	O
remainder	O
of	O
18	O
months	O
or	O
identical	B-C
placebo	I-C
.	O

The	O
primary	O
outcome	O
was	O
the	O
rate	O
of	O
change	O
in	O
the	B-O
Alzheimer	I-O
'	I-O
s	I-O
Disease	I-O
Assessment	I-O
Scale	I-O
-	I-O
cognitive	I-O
portion	I-O
(	I-O
ADAS	I-O
-	I-O
Cog	I-O
)	I-O
.	O

Secondary	O
outcomes	O
measured	O
clinical	B-O
global	I-O
change	I-O
,	O
cognition	B-O
,	O
function	B-O
,	O
and	O
behavior	B-O
.	O

METHODS	O
:	O
This	O
study	O
provides	O
Class	O
I	O
evidence	O
that	O
simvastatin	O
40	O
mg	O
/	O
day	O
does	O
not	O
slow	O
decline	O
on	O
the	O
ADAS	O
-	O
Cog	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
6	O
-	O
month	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
pilot	O
discontinuation	O
trial	O
following	O
response	O
to	O
haloperidol	B-I
treatment	I-I
of	O
psychosis	O
and	O
agitation	O
in	O
Alzheimer	O
'	O
s	O
disease	O
.	O

METHODS	O
:	O
In	O
outpatients	B-P
with	I-P
AD	I-P
with	I-P
symptoms	I-P
of	I-P
psychosis	I-P
or	I-P
agitation	I-P
,	I-P
responders	I-P
to	I-P
20	I-P
weeks	I-P
of	I-P
haloperidol	I-P
(	I-P
0	I-P
.	I-P
5	I-P
-	I-P
5	I-P
mg	I-P
daily	I-P
)	I-P
were	O
randomized	O
to	O
a	O
24	O
-	O
week	O
,	O
double	O
-	O
blind	O
pilot	O
trial	O
of	O
discontinuation	O
on	O
placebo	B-C
versus	O
continuation	B-I
haloperidol	I-I
.	O

Phase	O
A	O
response	O
criteria	O
were	O
minimum	O
50	O
%	O
reduction	O
in	O
three	B-O
target	I-O
symptoms	I-O
,	O
and	O
improvement	O
on	O
the	B-O
Clinical	I-O
Global	I-O
Impression	I-O
-	I-O
Change	I-O
(	I-O
CGI	I-O
-	I-O
C	I-O
)	I-O
score	I-O
for	O
psychosis	B-O
/	O
agitation	B-O
.	O

Phase	O
B	O
relapse	O
criteria	O
required	O
50	O
%	O
worsening	O
in	O
target	B-O
symptoms	I-O
and	O
on	O
the	B-O
CGI	I-O
-	I-O
C	I-O
.	O

?	O
=	O
0	O
.	O
1	O
was	O
the	O
significance	O
criterion	O
in	O
this	O
pilot	O
study	O
.	O

-DOCSTART-	O

Title	O
:	O
Effects	O
of	O
telmisartan	B-I
on	O
cognition	O
and	O
regional	O
cerebral	O
blood	O
flow	O
in	O
hypertensive	B-P
patients	I-P
with	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
.	O

METHODS	O
:	O
A	B-P
total	I-P
of	I-P
20	I-P
patients	I-P
with	I-P
probable	I-P
AD	I-P
and	I-P
essential	I-P
hypertension	I-P
were	O
randomly	O
assigned	O
to	O
the	B-I
telmisartan	I-I
group	O
(	O
n	O
=	O
10	O
,	O
40	O
-	O
80	O
mg	O
daily	O
)	O
or	O
the	B-I
amlodipine	I-I
group	O
(	O
n	O
=	O
10	O
,	O
5	O
-	O
10	O
mg	O
daily	O
)	O
for	O
6	O
months	O
.	O

-DOCSTART-	O

Title	O
:	O
Health	B-I
and	I-I
nutrition	I-I
promotion	I-I
program	I-I
for	O
patients	B-P
with	I-P
dementia	I-P
(	O
NutriAlz	O
)	O
:	O
cluster	O
randomized	O
trial	O
.	O

METHODS	O
:	O
Cluster	O
randomized	O
multi	O
-	O
centre	O
study	O
with	O
one	O
-	O
year	O
follow	O
-	O
up	O
.	O

11	O
Alzheimer	O
outpatients	O
and	O
day	O
care	O
centres	O
(	O
Barcelona	O
,	O
Spain	O
)	O
.	O

Nine	B-P
hundred	I-P
and	I-P
forty	I-P
six	I-P
home	I-P
-	I-P
living	I-P
Alzheimer	I-P
patients	I-P
with	I-P
identified	I-P
caregiver	I-P
were	O
consecutively	O
recruited	O
(	O
intervention	O
group	O
:	O
6	O
centres	O
,	O
448	O
patients	O
vs	O
control	O
group	O
:	O
5	O
centres	O
,	O
498	O
patients	O
)	O
.	O

The	O
intervention	O
was	O
a	B-I
teaching	I-I
and	I-I
training	I-I
intervention	I-I
on	I-I
health	I-I
and	I-I
nutrition	I-I
program	I-I
,	O
NutriAlz	O
,	O
directed	O
both	O
to	O
physician	O
and	O
main	O
caregiver	O
,	O
as	O
well	O
as	O
persons	O
affected	O
by	O
Alzheimer	O
'	O
s	O
disease	O
or	O
other	O
dementias	O
,	O
including	O
a	O
standardised	O
protocol	O
for	O
feeding	O
and	O
nutrition	O
.	O

The	O
main	O
outcome	O
measure	O
was	O
the	O
reduction	O
in	O
the	B-O
loss	I-O
of	I-O
autonomy	I-O
(	O
Activities	B-O
of	I-O
daily	I-O
living	I-O
(	I-O
ADL	I-O
/	I-O
IADL	I-O
)	I-O
scales	I-O
)	O
assessed	O
at	O
6	O
and	O
12	O
months	O
.	O

Secondary	O
outcomes	O
measures	O
were	O
Improvement	O
in	O
nutritional	B-O
status	I-O
(	O
Mini	B-O
Nutritional	I-O
Assessment	I-O
(	I-O
MNA	I-O
)	I-O
,	O
BMI	B-O
,	O
and	O
weight	B-O
changes	I-O
)	O
,	O
and	O
caregiver	B-O
burden	I-O
(	O
Zarit	B-O
scale	I-O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Efficacy	O
and	O
safety	O
of	O
donepezil	B-I
23	O
mg	O
versus	O
donepezil	B-I
10	O
mg	O
for	O
moderate	O
-	O
to	O
-	O
severe	O
Alzheimer	O
'	O
s	O
disease	O
:	O
a	O
subgroup	O
analysis	O
in	O
patients	O
already	O
taking	O
or	O
not	O
taking	O
concomitant	O
memantine	O
.	O

METHODS	O
:	O
Prespecified	O
analysis	O
of	O
data	O
from	O
a	O
24	O
-	O
week	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
trial	O
.	O

Patients	O
were	O
randomized	O
to	O
donepezil	B-I
doses	O
(	O
23	O
vs	O
.	O
10	O
mg	O
/	O
day	O
)	O
and	O
stratified	O
by	O
concomitant	O
memantine	O
use	O
(	O
yes	O
or	O
no	O
)	O
.	O

Efficacy	O
and	O
safety	O
were	O
assessed	O
for	O
each	O
donepezil	B-I
dose	O
in	O
subgroups	O
taking	O
or	O
not	O
taking	O
concomitant	O
memantine	O
.	O

-DOCSTART-	O

Title	O
:	O
Nutritional	B-I
treatment	I-I
of	O
aged	B-P
individuals	I-P
with	I-P
Alzheimer	I-P
disease	I-P
living	I-P
at	I-P
home	I-P
with	I-P
their	I-P
spouses	I-P
:	O
study	O
protocol	O
for	O
a	O
randomized	O
controlled	O
trial	O
.	O

METHODS	O
:	O
AD	B-P
patients	I-P
and	I-P
their	I-P
spouses	I-P
(	I-P
aged	I-P
>	I-P
65	I-P
years	I-P
)	I-P
living	I-P
at	I-P
home	I-P
(	I-P
n	I-P
=	I-P
202	I-P
,	I-P
102	I-P
AD	I-P
patients	I-P
)	I-P
were	O
recruited	O
using	O
central	O
AD	O
registers	O
in	O
Finland	O
.	O

The	O
couples	O
were	O
randomized	O
into	O
intervention	O
and	O
control	O
groups	O
.	O

A	O
trained	O
nutritionist	O
visited	O
intervention	O
couples	O
4	O
-	O
8	O
times	O
at	O
their	O
homes	O
and	O
the	O
couples	O
received	O
tailored	B-I
nutritional	I-I
care	I-I
.	O

When	O
necessary	O
,	O
the	O
couples	O
were	O
given	O
protein	O
and	O
nutrient	O
-	O
enriched	O
complementary	O
drinks	O
.	O

All	O
intervention	O
couples	O
were	O
advised	O
to	O
take	O
vitamin	B-I
D	I-I
20	O
?g	O
/	O
day	O
.	O

The	O
intervention	O
lasted	O
for	O
one	O
year	O
.	O

The	O
couples	O
of	O
the	O
control	O
group	O
received	O
a	B-C
written	I-C
guide	I-C
on	O
nutrition	O
of	O
older	O
people	O
.	O

Participants	O
in	O
the	O
intervention	O
group	O
were	O
assessed	O
every	O
three	O
months	O
.	O

The	O
primary	O
outcome	O
measure	O
is	O
weight	B-O
change	I-O
.	O

Secondary	O
measures	O
are	O
the	B-O
intake	I-O
of	I-O
energy	I-O
,	O
protein	B-O
,	O
and	O
other	B-O
nutrients	I-O
,	O
nutritional	B-O
status	I-O
,	O
cognition	B-O
,	O
caregiver	B-O
'	I-O
s	I-O
burden	I-O
,	O
depression	B-O
,	O
health	B-O
related	I-O
quality	I-O
of	I-O
life	I-O
and	O
grip	B-O
strength	I-O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
combination	O
of	O
galantamine	B-I
and	O
memantine	B-I
modifies	O
cognitive	O
function	O
in	O
subjects	B-P
with	I-P
amnestic	I-P
MCI	I-P
.	O

METHODS	O
:	O
For	O
a	O
2	O
-	O
year	O
,	O
double	O
-	O
blinded	O
,	O
placebo	O
-	O
controlled	O
study	O
MCI	B-P
patients	I-P
,	I-P
presenting	I-P
with	I-P
an	I-P
amnestic	I-P
syndrome	I-P
but	I-P
not	I-P
necessarily	I-P
based	I-P
on	I-P
presumed	I-P
prodromal	I-P
AD	I-P
were	O
randomized	O
.	O

Patients	O
received	O
(	O
a	O
)	O
a	O
combination	O
of	O
16	B-I
mg	I-I
galantamine	I-I
plus	O
20	B-I
mg	I-I
memantine	I-I
,	O
or	O
(	O
b	O
)	O
16	B-I
mg	I-I
galantamine	I-I
alone	O
or	O
(	O
c	O
)	O
placebo	B-C
.	O

The	O
primary	O
objective	O
was	O
to	O
explore	O
the	O
differential	O
impact	O
of	O
these	O
interventions	O
on	O
the	B-O
progression	I-O
to	I-O
dementia	I-O
and	O
on	O
cognitive	B-O
changes	I-O
as	O
measured	O
by	O
the	B-O
ADAScog	I-O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
trial	O
of	O
modafinil	B-I
for	O
the	O
treatment	O
of	O
apathy	O
in	O
individuals	B-P
with	I-P
mild	I-P
-	I-P
to	I-P
-	I-P
moderate	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
.	O

METHODS	O
:	O
23	B-P
participants	I-P
with	I-P
a	I-P
diagnosis	I-P
of	I-P
mild	I-P
-	I-P
to	I-P
-	I-P
moderate	I-P
probable	I-P
AD	I-P
according	I-P
to	I-P
National	I-P
Institute	I-P
of	I-P
Neurologic	I-P
and	I-P
Communicative	I-P
Disorder	I-P
and	I-P
Stroke	I-P
-	I-P
Alzheimer	I-P
'	I-P
s	I-P
Disease	I-P
and	I-P
Related	I-P
Disorders	I-P
criteria	I-P
were	O
randomized	O
into	O
the	O
experimental	O
(	O
modafinil	B-I
200	O
mg	O
daily	O
)	O
or	O
control	O
(	O
placebo	B-C
)	O
groups	O
.	O

All	O
participants	O
were	O
also	O
receiving	O
stable	O
doses	O
of	O
a	O
cholinesterase	O
inhibitor	O
medication	O
.	O

Participants	O
completed	O
assessments	O
at	O
baseline	O
and	O
after	O
8	O
weeks	O
of	O
treatment	O
.	O

Outcome	O
measures	O
included	O
family	O
report	O
measures	O
of	O
apathy	B-O
,	O
ADL	B-O
performance	I-O
,	O
and	O
caregiver	B-O
burden	I-O
,	O
as	O
well	O
as	O
direct	O
assessment	O
of	O
ADL	B-O
performance	I-O
.	O

The	O
study	O
was	O
conducted	O
at	O
a	O
private	O
psychiatric	O
hospital	O
in	O
Rhode	O
Island	O
from	O
September	O
2005	O
until	O
September	O
2007	O
.	O

-DOCSTART-	O

Title	O
:	O
Heat	B-I
-	I-I
processed	I-I
ginseng	I-I
enhances	O
the	O
cognitive	O
function	O
in	O
patients	B-P
with	I-P
moderately	I-P
severe	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
.	O

METHODS	O
:	O
Forty	B-P
patients	I-P
with	I-P
AD	I-P
were	O
randomized	O
into	O
one	O
of	O
three	O
different	O
dose	O
groups	O
or	O
the	O
control	O
group	O
as	O
follows	O
:	O
1	O
.	O
5	O
g	O
/	O
day	O
(	O
n	O
=	O
10	O
)	O
,	O
3	O
g	O
/	O
day	O
(	O
n	O
=	O
10	O
)	O
,	O
and	O
4	O
.	O
5	O
g	O
/	O
day	O
(	O
n	O
=	O
10	O
)	O
groups	O
,	O
or	O
control	O
(	O
n	O
=	O
10	O
)	O
.	O

The	B-O
Alzheimer	I-O
'	I-O
s	I-O
Disease	I-O
Assessment	I-O
Scale	I-O
(	I-O
ADAS	I-O
)	I-O
and	O
Mini	B-O
-	I-O
Mental	I-O
State	I-O
Examination	I-O
(	I-O
MMSE	I-O
)	I-O
were	O
used	O
to	O
assess	O
cognitive	O
function	O
for	O
24	O
weeks	O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
Chinese	B-I
herbal	I-I
medicine	I-I
for	O
patients	B-P
with	I-P
mild	I-P
to	I-P
moderate	I-P
Alzheimer	I-P
disease	I-P
based	I-P
on	I-P
syndrome	I-P
differentiation	I-P
:	O
a	O
randomized	O
controlled	O
trial	O
]	O
.	O

METHODS	O
:	O
Adopting	O
the	O
internationally	O
recognized	O
criteria	O
developed	O
by	O
National	O
Institute	O
of	O
Neurological	O
and	O
Communicative	O
Diseases	O
and	O
Stroke	O
/	O
Alzheimer	O
'	O
s	O
Disease	O
and	O
Related	O
Disorders	O
Association	O
,	O
the	O
clinical	O
trial	O
was	O
conducted	O
on	O
131	B-P
patients	I-P
with	I-P
mild	I-P
to	I-P
moderate	I-P
AD	I-P
from	I-P
5	I-P
communities	I-P
and	I-P
7	I-P
social	I-P
welfare	I-P
institutions	I-P
.	O

Participants	O
were	O
accepted	O
after	O
informed	O
consent	O
was	O
received	O
,	O
and	O
laboratory	O
tests	O
and	O
a	O
head	O
imaging	O
study	O
were	O
conducted	O
.	O

The	O
patients	O
were	O
randomly	O
divided	O
into	O
Chinese	B-I
medicine	I-I
group	O
(	O
CMG	O
)	O
(	O
66	O
cases	O
)	O
or	O
Western	B-I
medicine	I-I
group	O
(	O
WMG	O
)	O
(	O
65	O
cases	O
)	O
.	O

Patients	O
in	O
the	O
CMG	O
were	O
treated	O
monthly	O
with	O
Chinese	B-I
medicine	I-I
according	O
to	O
syndrome	O
differentiation	O
.	O

Patients	O
in	O
the	O
WMG	O
were	O
treated	O
with	O
donepezil	B-I
at	O
a	O
dose	O
of	O
5	O
mg	O
once	O
daily	O
.	O

The	O
therapeutic	O
course	O
lasted	O
48	O
weeks	O
.	O

The	B-O
scores	I-O
of	I-O
Mini	I-O
-	I-O
Mental	I-O
State	I-O
Examination	I-O
(	I-O
MMSE	I-O
)	I-O
,	O
Fuld	B-O
Object	I-O
-	I-O
Memory	I-O
Evaluation	I-O
(	I-O
FOM	I-O
)	I-O
,	O
Block	B-O
Design	I-O
(	I-O
BD	I-O
)	I-O
and	O
Digit	B-O
Span	I-O
(	I-O
DS	I-O
)	I-O
were	O
used	O
to	O
evaluate	O
the	B-O
cognitive	I-O
function	I-O
;	O
resting	B-O
-	I-O
state	I-O
fMRI	I-O
was	O
used	O
for	O
observing	O
brain	B-O
function	I-O
.	O

The	B-O
questionnaires	I-O
and	O
fMRI	B-O
were	O
performed	O
before	O
and	O
after	O
treatments	O
.	O

-DOCSTART-	O

Title	O
:	O
Efficacy	O
of	O
psychosocial	O
intervention	O
in	O
patients	B-P
with	I-P
mild	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
:	O
the	O
multicentre	O
,	O
rater	O
blinded	O
,	O
randomised	O
Danish	O
Alzheimer	O
Intervention	O
Study	O
(	O
DAISY	O
)	O
.	O

METHODS	O
:	O
Multicentre	O
,	O
randomised	O
,	O
controlled	O
,	O
rater	O
blinded	O
trial	O
.	O

Primary	O
care	O
and	O
memory	O
clinics	O
in	O
five	O
Danish	O
districts	O
.	O

330	B-P
outpatients	I-P
with	I-P
mild	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
and	I-P
their	I-P
330	I-P
primary	I-P
care	I-P
givers	I-P
.	O

Participating	O
dyads	O
(	O
patient	O
and	O
primary	O
care	O
giver	O
)	O
were	O
randomised	O
to	O
control	B-C
support	I-C
during	O
follow	O
-	O
up	O
or	O
to	O
control	B-C
support	I-C
plus	O
DAISY	B-I
intervention	I-I
(	O
multifaceted	B-I
and	I-I
semi	I-I
-	I-I
tailored	I-I
counselling	I-I
,	O
education	B-I
,	O
and	O
support	B-I
)	O
.	O

Primary	O
outcomes	O
at	O
12	O
months	O
for	O
patients	O
were	O
change	O
from	O
baseline	O
in	O
mini	B-O
mental	I-O
state	I-O
examination	I-O
(	I-O
MMSE	I-O
)	I-O
score	I-O
,	O
Cornell	B-O
depression	I-O
scale	I-O
score	I-O
,	O
and	O
proxy	B-O
rated	I-O
European	I-O
quality	I-O
of	I-O
life	I-O
visual	I-O
analogue	I-O
scale	I-O
(	I-O
EQ	I-O
-	I-O
VAS	I-O
)	I-O
score	I-O
.	O

For	O
care	O
givers	O
,	O
outcomes	O
were	O
change	O
from	O
baseline	O
in	O
geriatric	B-O
depression	I-O
scale	I-O
(	I-O
GDS	I-O
30	I-O
items	I-O
)	I-O
score	I-O
and	O
EQ	B-O
-	I-O
VAS	I-O
score	I-O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
Psychosocial	B-I
care	I-I
assistants	I-I
caring	I-I
for	O
residents	B-P
with	I-P
dementia	I-P
according	I-P
to	I-P
section	I-P
87	I-P
b	I-P
SGB	I-P
XI	I-P
.	O

Emotional	O
and	O
cognitive	O
effects	O
]	O
.	O

METHODS	O
:	O
Using	O
a	O
longitudinal	O
control	O
group	O
design	O
the	O
effects	O
of	O
additional	B-I
low	I-I
threshold	I-I
psychosocial	I-I
assistance	I-I
were	O
recorded	O
and	O
analysed	O
for	O
ten	O
months	O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
ASCOMALVA	O
trial	O
:	O
association	O
between	O
the	B-I
cholinesterase	I-I
inhibitor	I-I
donepezil	I-I
and	O
the	B-I
cholinergic	I-I
precursor	I-I
choline	I-I
alphoscerate	I-I
in	O
Alzheimer	O
'	O
s	O
disease	O
with	O
cerebrovascular	O
injury	O
:	O
interim	O
results	O
.	O

METHODS	O
:	O
ASCOMALVA	O
is	O
a	O
double	O
-	O
blind	O
multicentre	O
trial	O
that	O
has	O
completed	O
the	O
first	O
12	O
months	O
of	O
observation	O
of	O
91	B-P
patients	I-P
of	I-P
the	I-P
210	I-P
planned	I-P
.	O

Patients	O
were	O
aged	O
between	O
56	O
and	O
91	O
years	O
(	O
mean	O
75	O
	O
10	O
years	O
)	O
and	O
were	O
included	O
in	O
the	O
protocol	O
with	O
a	O
MMSE	O
score	O
between	O
15	O
and	O
24	O
.	O

Patients	B-P
with	I-P
AD	I-P
diagnosed	I-P
according	I-P
to	I-P
the	I-P
DSM	I-P
IV	I-P
criteria	I-P
suffer	I-P
from	I-P
ischemic	I-P
brain	I-P
damage	I-P
documented	I-P
by	I-P
neuroimaging	I-P
(	I-P
MRI	I-P
and	I-P
CT	I-P
scan	I-P
)	I-P
,	I-P
with	I-P
a	I-P
score?2	I-P
in	I-P
at	I-P
least	I-P
one	I-P
subfield	I-P
of	I-P
the	I-P
New	I-P
Rating	I-P
Scale	I-P
for	I-P
Age	I-P
-	I-P
Related	I-P
White	I-P
Matter	I-P
Changes	I-P
(	I-P
ARWMC	I-P
)	I-P
.	O

Patients	O
were	O
randomly	O
allotted	O
to	O
an	O
active	O
treatment	O
group	O
(	O
donepezil	B-I
+	O
choline	B-I
alphoscerate	I-I
)	O
or	O
to	O
a	O
reference	O
treatment	O
group	O
(	O
donepezil	B-C
+	O
placebo	B-C
)	O
and	O
were	O
examined	O
after	O
3	O
,	O
6	O
,	O
9	O
and	O
12	O
months	O
of	O
treatment	O
.	O

-DOCSTART-	O

Title	O
:	O
Cognitive	O
outcomes	O
after	O
sertaline	B-I
treatment	I-I
in	O
patients	B-P
with	I-P
depression	I-P
of	I-P
Alzheimer	I-P
disease	I-P
.	O

METHODS	O
:	O
Placebo	O
-	O
controlled	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
trial	O
.	O

Outpatient	O
memory	O
clinics	O
at	O
five	O
academic	O
medical	O
centers	O
in	O
the	O
United	O
States	O
.	O

A	B-P
total	I-P
of	I-P
131	I-P
patients	I-P
with	I-P
dAD	I-P
(	I-P
60	I-P
men	I-P
)	I-P
and	I-P
Mini	I-P
-	I-P
Mental	I-P
State	I-P
Examination	I-P
scores	I-P
of	I-P
10	I-P
-	I-P
26	I-P
.	O

Sertraline	B-I
(	O
n	O
=	O
67	O
)	O
,	O
target	O
dose	O
of	O
100	O
mg	O
daily	O
or	O
matching	B-C
placebo	I-C
(	O
n	O
=	O
64	O
)	O
.	O

Caregivers	O
received	O
standardized	O
psychosocial	O
intervention	O
throughout	O
the	O
trial	O
.	O

Mini	B-O
-	I-O
Mental	I-O
State	I-O
Examination	I-O
,	O
cognitive	B-O
subscale	I-O
of	I-O
the	I-O
Alzheimer	I-O
'	I-O
s	I-O
Disease	I-O
Assessment	I-O
Scale	I-O
,	O
letter	B-O
fluency	I-O
,	O
backward	B-O
digit	I-O
span	I-O
,	O
Symbol	B-O
Digit	I-O
Modalities	I-O
Test	I-O
,	O
and	O
Finger	B-O
Tapping	I-O
Test	I-O
,	O
administered	O
at	O
baseline	O
,	O
and	O
8	O
,	O
16	O
,	O
and	O
24	O
weeks	O
following	O
baseline	O
.	O

-DOCSTART-	O

Title	O
:	O
Effects	O
of	O
the	B-I
apolipoprotein	I-I
E	I-I
?4	I-I
allele	I-I
on	O
functional	O
MRI	O
during	O
n	O
-	O
back	O
working	O
memory	O
tasks	O
in	O
healthy	B-P
middle	I-P
-	I-P
aged	I-P
adults	I-P
.	O

METHODS	O
:	O
From	O
110	B-P
participants	I-P
,	I-P
81	I-P
individuals	I-P
without	I-P
objective	I-P
or	I-P
subjective	I-P
cognitive	I-P
impairment	I-P
underwent	O
APOE	O
genotyping	O
.	O

Nine	B-P
APOE4	I-P
carriers	I-P
and	I-P
9	I-P
age	I-P
-	I-P
and	I-P
sex	I-P
-	I-P
matched	I-P
non	I-P
-	I-P
APOE4	I-P
controls	I-P
were	O
recruited	O
for	O
fMRI	O
examinations	O
during	O
WM	O
tasks	O
.	O

-DOCSTART-	O

Title	O
:	O
Safety	O
and	O
pharmacology	O
of	O
ponezumab	B-I
(	I-I
PF	I-I
-	I-I
04360365	I-I
)	I-I
after	O
a	O
single	O
10	O
-	O
minute	O
intravenous	O
infusion	O
in	O
subjects	B-P
with	I-P
mild	I-P
to	I-P
moderate	I-P
Alzheimer	I-P
disease	I-P
.	O

METHODS	O
:	O
Subjects	B-P
with	I-P
mild	I-P
to	I-P
moderate	I-P
AD	I-P
received	O
ponezumab	B-I
1	O
mg	O
/	O
kg	O
(	O
n	O
=	O
3	O
)	O
,	O
3	O
mg	O
/	O
kg	O
(	O
n	O
=	O
3	O
)	O
,	O
5	O
mg	O
/	O
kg	O
(	O
n	O
=	O
4	O
)	O
,	O
or	O
10	O
mg	O
/	O
kg	O
(	O
n	O
=	O
5	O
)	O
.	O

They	O
were	O
followed	O
up	O
as	O
outpatients	O
for	O
6	O
months	O
.	O

-DOCSTART-	O

Title	O
:	O
Intravenous	B-I
immunoglobulin	I-I
for	O
treatment	O
of	O
mild	O
-	O
to	O
-	O
moderate	O
Alzheimer	O
'	O
s	O
disease	O
:	O
a	O
phase	O
2	O
,	O
randomised	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
dose	O
-	O
finding	O
trial	O
.	O

METHODS	O
:	O
We	O
did	O
a	O
multicentre	O
,	O
placebo	O
-	O
controlled	O
phase	O
2	O
trial	O
at	O
seven	O
sites	O
in	O
the	O
USA	O
and	O
five	O
in	O
Germany	O
.	O

Participants	B-P
with	I-P
probable	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
aged	I-P
50	I-P
-	I-P
85	I-P
years	I-P
were	O
randomly	O
assigned	O
(	O
by	O
a	O
computer	O
-	O
generated	O
randomisation	O
sequence	O
,	O
with	O
block	O
sizes	O
of	O
eight	O
)	O
to	O
infusions	O
every	O
4	O
weeks	O
(	O
02	B-I
,	O
05	B-I
,	O
or	O
08	B-I
g	I-I
intravenous	I-I
immunoglobulin	I-I
per	O
kg	O
bodyweight	O
,	O
or	O
placebo	B-C
)	O
or	O
infusions	O
every	O
2	O
weeks	O
(	O
01	B-I
,	O
025	B-I
,	O
or	O
04	B-I
g	I-I
/	I-I
kg	I-I
,	O
or	O
placebo	B-C
)	O
.	O

Patients	O
,	O
caregivers	O
,	O
investigators	O
assessing	O
outcomes	O
,	O
and	O
staff	O
at	O
imaging	O
facilities	O
and	O
the	O
clinical	O
research	O
organisation	O
were	O
masked	O
to	O
treatment	O
allocation	O
,	O
but	O
dispensing	O
pharmacists	O
,	O
the	O
statistician	O
,	O
and	O
the	O
person	O
responsible	O
for	O
final	O
PET	O
analyses	O
were	O
not	O
.	O

Treatment	O
was	O
masked	O
with	O
opaque	O
pouches	O
and	O
infusion	O
lines	O
.	O

The	O
primary	O
endpoint	O
was	O
median	O
area	O
under	O
the	O
curve	O
(	O
AUC	O
)	O
of	O
plasma	B-O
amyloid	I-O
?	I-O
(	I-O
A?	I-O
)	I-O
(	I-O
1	I-O
-	I-O
40	I-O
)	I-O
between	O
the	O
last	O
infusion	O
and	O
the	O
final	O
visit	O
(	O
2	O
weeks	O
or	O
4	O
weeks	O
depending	O
on	O
infusion	O
interval	O
)	O
in	O
the	O
intention	O
-	O
to	O
-	O
treat	O
population	O
.	O

The	O
trial	O
is	O
registered	O
at	O
ClinicalTrials	O
.	O
gov	O
(	O
NCT00812565	O
)	O
and	O
controlled	O
-	O
trials	O
.	O
com	O
(	O
ISRCTN64846759	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Effects	O
of	O
SolCos	B-I
model	I-I
-	I-I
based	I-I
individual	I-I
reminiscence	I-I
on	O
older	B-P
adults	I-P
with	I-P
mild	I-P
to	I-P
moderate	I-P
dementia	I-P
due	I-P
to	I-P
Alzheimer	I-P
disease	I-P
:	O
a	O
pilot	O
study	O
.	O

METHODS	O
:	O
In	O
this	O
study	O
,	O
82	B-P
older	I-P
adults	I-P
with	I-P
probable	I-P
AD	I-P
were	O
recruited	O
from	O
psychiatric	O
day	O
care	O
,	O
inpatient	O
,	O
and	O
long	O
term	O
care	O
facilities	O
.	O

Of	O
the	O
study	O
group	O
,	O
41	O
participants	O
were	O
randomly	O
selected	O
for	O
individual	B-I
reminiscence	I-I
sessions	I-I
during	O
4	O
weeks	O
performed	O
by	O
1	O
facilitator	O
.	O

A	O
control	O
group	O
of	O
41	O
older	O
adults	O
were	O
randomly	O
involved	O
and	O
had	O
no	B-C
planned	I-C
reminiscence	I-C
treatment	I-C
of	O
any	O
kind	O
in	O
the	O
study	O
period	O
.	O

All	O
study	O
participants	O
were	O
tested	O
pre	O
-	O
and	O
postintervention	O
period	O
with	O
validated	O
assessment	O
scales	O
to	O
evaluate	O
cognition	B-O
and	O
behavior	B-O
.	O

Analyses	O
were	O
based	O
on	O
delta	O
scores	O
,	O
the	O
differences	O
between	O
assessment	O
scales	O
pre	O
-	O
and	O
postintervention	O
scores	O
,	O
compared	O
between	O
the	O
intervention	O
and	O
the	O
control	O
group	O
.	O

-DOCSTART-	O

Title	O
:	O
Phase	O
I	O
study	O
on	O
the	O
pharmacokinetics	O
and	O
tolerance	O
of	O
ZT	B-I
-	I-I
1	I-I
,	O
a	B-I
prodrug	I-I
of	I-I
huperzine	I-I
A	I-I
,	O
for	O
the	O
treatment	O
of	O
Alzheimer	O
'	O
s	O
disease	O
.	O

METHODS	O
:	O
This	O
was	O
a	O
double	O
-	O
blinded	O
,	O
placebo	O
-	O
controlled	O
,	O
randomized	O
,	O
single	O
-	O
and	O
multiple	O
-	O
dose	O
study	O
.	O

For	O
the	O
single	O
-	O
dose	O
study	O
,	O
9	B-P
subjects	I-P
were	O
randomly	O
divided	O
into	O
3	O
groups	O
receiving	O
ZT	B-I
-	I-I
1	I-I
(	O
0	O
.	O
5	O
,	O
0	O
.	O
75	O
or	O
1	O
mg	O
,	O
po	O
)	O
according	O
to	O
a	O
Three	O
-	O
way	O
Latin	O
Square	O
Design	O
.	O

For	O
the	O
multiple	O
-	O
dose	O
study	O
,	O
9	B-P
subjects	I-P
receiving	O
ZT	B-I
-	I-I
1	I-I
(	O
0	O
.	O
75	O
mg	O
/	O
d	O
,	O
po	O
)	O
for	O
8	O
consecutive	O
days	O
.	O

In	O
the	O
tolerance	O
study	O
,	O
40	B-P
subjects	I-P
were	O
randomly	O
divided	O
into	O
5	O
groups	O
receiving	O
a	B-I
single	I-I
dose	I-I
of	I-I
ZT	I-I
-	I-I
1	I-I
(	O
0	O
.	O
5	O
,	O
0	O
.	O
75	O
,	O
1	O
,	O
1	O
.	O
25	O
or	O
1	O
.	O
5	O
mg	O
,	O
po	O
)	O
.	O

Plasma	B-O
and	O
urine	B-O
concentrations	I-O
of	I-O
ZT	I-O
-	I-O
1	I-O
and	O
Hup	B-O
A	I-O
were	O
determined	O
using	O
LC	B-O
-	I-O
MS	I-O
/	I-O
MS	I-O
.	O

Pharmacokinetic	B-O
parameters	I-O
,	O
including	O
Cmax	B-O
,	O
AUC0	B-O
-	I-O
72	I-O
h	I-O
and	O
AUC0	B-O
-	I-O
?	I-O
were	O
calculated	O
.	O

Tolerance	B-O
assessments	I-O
were	O
conducted	O
throughout	O
the	O
study	O
.	O

-DOCSTART-	O

Title	O
:	O
Efficacy	O
of	O
rivastigmine	B-I
in	O
comparison	O
to	O
ginkgo	B-C
for	O
treating	O
Alzheimer	O
'	O
s	O
dementia	O
.	O

METHODS	O
:	O
Total	B-P
56	I-P
patients	I-P
aged	I-P
50	I-P
-	I-P
75	I-P
years	I-P
,	I-P
suffering	I-P
from	I-P
dementia	I-P
,	O
were	O
allocated	O
into	O
one	O
of	O
the	O
two	O
treatments	O
:	O
group	O
1	O
)	O
Ginkgo	B-C
biloba	I-C
(	O
120	O
mg	O
daily	O
dose	O
)	O
;	O
group	O
2	O
)	O
rivastigmine	B-I
(	O
4	O
.	O
5	O
mg	O
daily	O
dose	O
)	O
in	O
a	O
24	O
-	O
week	O
randomized	O
double	O
blind	O
study	O
.	O

The	B-O
degree	I-O
of	I-O
severity	I-O
of	I-O
dementia	I-O
was	O
assessed	O
by	O
the	B-O
Seven	I-O
Minute	I-O
test	I-O
and	O
the	B-O
Mini	I-O
-	I-O
Mental	I-O
State	I-O
Examination	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Safety	O
and	O
efficacy	O
of	O
methylphenidate	B-I
for	O
apathy	O
in	O
Alzheimer	O
'	O
s	O
disease	O
:	O
a	O
randomized	O
,	O
placebo	O
-	O
controlled	O
trial	O
.	O

METHODS	O
:	O
Six	O
-	O
week	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
multicenter	O
trial	O
enrolling	O
Alzheimer	B-P
'	I-P
s	I-P
disease	I-P
participants	I-P
(	I-P
NINCDS	I-P
-	I-P
ADRDA	I-P
criteria	I-P
)	I-P
with	I-P
apathy	I-P
assigned	O
to	O
methylphenidate	B-I
20	O
mg	O
daily	O
or	O
placebo	B-C
,	O
conducted	O
from	O
June	O
2010	O
to	O
December	O
2011	O
.	O

Primary	O
outcomes	O
were	O
change	O
in	O
Apathy	B-O
Evaluation	I-O
Scale	I-O
(	I-O
AES	I-O
)	I-O
score	I-O
and	O
modified	B-O
Alzheimer	I-O
'	I-O
s	I-O
Disease	I-O
Cooperative	I-O
Study	I-O
-	I-O
Clinical	I-O
Global	I-O
Impression	I-O
of	I-O
Change	I-O
(	I-O
ADCS	I-O
-	I-O
CGI	I-O
-	I-O
C	I-O
)	I-O
.	O

Secondary	O
outcomes	O
included	O
change	O
in	O
Neuropsychiatric	B-O
Inventory	I-O
(	I-O
NPI	I-O
)	I-O
apathy	I-O
score	I-O
,	O
Mini	B-O
-	I-O
Mental	I-O
State	I-O
Examination	I-O
(	I-O
MMSE	I-O
)	I-O
score	I-O
,	O
and	O
safety	B-O
.	O

-DOCSTART-	O

Title	O
:	O
Effects	O
of	O
a	B-I
non	I-I
-	I-I
focal	I-I
plasticity	I-I
protocol	I-I
on	O
apathy	O
in	O
moderate	O
Alzheimer	O
'	O
s	O
disease	O
:	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
sham	O
-	O
controlled	O
trial	O
.	O

METHODS	O
:	O
Forty	B-P
patients	I-P
were	O
randomized	O
to	O
receive	O
either	O
active	B-I
or	O
sham	B-C
-	I-C
tDCS	I-C
over	O
the	O
left	O
dorsolateral	O
prefrontal	O
cortex	O
(	O
DLPFC	O
)	O
.	O

Patients	O
received	O
six	O
sessions	O
of	O
intervention	O
during	O
2	O
weeks	O
and	O
were	O
evaluated	O
at	O
baseline	O
,	O
at	O
week	O
1	O
and	O
2	O
,	O
and	O
after	O
1	O
week	O
without	O
intervention	O
.	O

Clinical	O
raters	O
,	O
patients	O
,	O
and	O
caregivers	O
were	O
blinded	O
.	O

The	O
primary	O
outcome	O
was	O
apathy	B-O
.	O

Global	B-O
cognition	I-O
and	O
neuropsychiatric	B-O
symptoms	I-O
were	O
examined	O
as	O
secondary	O
outcomes	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
16	O
-	O
week	O
study	O
of	O
the	B-I
H3	I-I
receptor	I-I
antagonist	I-I
,	O
GSK239512	B-I
as	O
a	O
monotherapy	O
in	O
subjects	B-P
with	I-P
mild	I-P
-	I-P
to	I-P
-	I-P
moderate	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
.	O

METHODS	O
:	O
In	O
this	O
16	O
-	O
week	O
,	O
double	O
-	O
blind	O
,	O
randomized	O
,	O
parallel	O
group	O
study	O
,	O
196	B-P
currently	I-P
untreated	I-P
subjects	I-P
with	I-P
mild	I-P
-	I-P
tomoderate	I-P
AD	I-P
(	I-P
Mini	I-P
Mental	I-P
State	I-P
Examination	I-P
[	I-P
MMSE	I-P
]	I-P
16	I-P
-	I-P
24	I-P
)	I-P
received	O
GSK239512	B-I
(	O
n=97	O
)	O
;	O
or	O
placebo	B-C
(	O
n=99	O
)	O
administered	O
orally	O
each	O
morning	O
.	O

After	O
a	O
two	O
-	O
week	O
placebo	O
run	O
-	O
in	O
period	O
GSK239512	O
was	O
up	O
-	O
titrated	O
over	O
4	O
weeks	O
in	O
a	O
flexible	O
manner	O
(	O
10-20-40	O
-	O
80	O
microgram	O
[	O
g	O
]	O
)	O
followed	O
by	O
a	O
12	O
-	O
week	O
Maintenance	O
Phase	O
.	O

Co	O
-	O
primary	O
efficacy	O
endpoints	O
were	O
change	O
from	O
baseline	O
in	O
Episodic	B-O
Memory	I-O
and	O
Executive	B-O
Function	I-O
/	O
Working	B-O
Memory	I-O
composite	I-O
scores	I-O
from	O
the	B-O
CogState	I-O
neuropsychological	I-O
test	I-O
battery	I-O
(	I-O
NTB	I-O
)	I-O
at	O
Week	O
16	O
.	O

-DOCSTART-	O

Title	O
:	O
Taste	B-I
-	I-I
masked	I-I
and	I-I
affordable	I-I
donepezil	I-I
hydrochloride	I-I
orally	O
disintegrating	O
tablet	O
as	O
promising	O
solution	O
for	O
non	O
-	O
compliance	O
in	O
Alzheimer	B-P
'	I-P
s	I-P
disease	I-P
patients	I-P
.	O

METHODS	O
:	O
The	B-I
ODT	I-I
was	O
manufactured	O
using	O
simple	O
wet	O
-	O
granulation	O
method	O
.	O

Crospovidone	O
XL	O
-	O
10	O
was	O
used	O
as	O
superdisintegrant	O
and	O
optimization	O
was	O
done	O
by	O
comparing	O
the	O
effect	O
of	O
three	B-I
grades	I-I
of	I-I
lactose	I-I
monohydrate	I-I
compound	I-I
as	O
filler	O
:	O
Starlac	B-I
,	O
Flowlac	B-I
and	O
Tablettose	B-I
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
citalopram	B-I
on	O
agitation	O
in	O
Alzheimer	O
disease	O
:	O
the	O
CitAD	O
randomized	O
clinical	O
trial	O
.	O

METHODS	O
:	O
The	B-I
Citalopram	I-I
for	O
Agitation	O
in	O
Alzheimer	O
Disease	O
Study	O
(	O
CitAD	O
)	O
was	O
a	O
randomized	O
,	O
placebo	O
-	O
controlled	O
,	O
double	O
-	O
blind	O
,	O
parallel	O
group	O
trial	O
that	O
enrolled	O
186	B-P
patients	I-P
with	I-P
probable	I-P
Alzheimer	I-P
disease	I-P
and	I-P
clinically	I-P
significant	I-P
agitation	I-P
from	I-P
8	I-P
academic	I-P
centers	I-P
in	I-P
the	I-P
United	I-P
States	I-P
and	I-P
Canada	I-P
from	I-P
August	I-P
2009	I-P
to	I-P
January	I-P
2013	I-P
.	O

Participants	B-P
(	I-P
n	I-P
=	I-P
186	I-P
)	I-P
were	O
randomized	O
to	O
receive	O
a	B-I
psychosocial	I-I
intervention	I-I
plus	O
either	O
citalopram	B-I
(	O
n	O
=	O
94	O
)	O
or	O
placebo	B-C
(	O
n	O
=	O
92	O
)	O
for	O
9	O
weeks	O
.	O

Dosage	O
began	O
at	O
10	O
mg	O
per	O
day	O
with	O
planned	O
titration	O
to	O
30	O
mg	O
per	O
day	O
over	O
3	O
weeks	O
based	O
on	O
response	O
and	O
tolerability	O
.	O

Primary	O
outcome	O
measures	O
were	O
based	O
on	O
scores	O
from	O
the	B-O
18	I-O
-	I-O
point	I-O
Neurobehavioral	I-O
Rating	I-O
Scale	I-O
agitation	I-O
subscale	I-O
(	I-O
NBRS	I-O
-	I-O
A	I-O
)	I-O
and	O
the	B-O
modified	I-O
Alzheimer	I-O
Disease	I-O
Cooperative	I-O
Study	I-O
-	I-O
Clinical	I-O
Global	I-O
Impression	I-O
of	I-O
Change	I-O
(	I-O
mADCS	I-O
-	I-O
CGIC	I-O
)	I-O
.	O

Other	O
outcomes	O
were	O
based	O
on	O
scores	O
from	O
the	B-O
Cohen	I-O
-	I-O
Mansfield	I-O
Agitation	I-O
Inventory	I-O
(	I-O
CMAI	I-O
)	I-O
and	O
the	B-O
Neuropsychiatric	I-O
Inventory	I-O
(	I-O
NPI	I-O
)	I-O
,	O
ability	B-O
to	I-O
complete	I-O
activities	I-O
of	I-O
daily	I-O
living	I-O
(	I-O
ADLs	I-O
)	I-O
,	O
caregiver	B-O
distress	I-O
,	O
cognitive	B-O
safety	I-O
(	O
based	O
on	O
scores	O
from	O
the	B-O
30	I-O
-	I-O
point	I-O
Mini	I-O
Mental	I-O
State	I-O
Examination	I-O
[	I-O
MMSE	I-O
]	I-O
)	O
,	O
and	O
adverse	B-O
events	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Rivastigmine	B-I
transdermal	I-I
patch	I-I
and	O
physical	B-I
exercises	I-I
for	O
Alzheimer	O
'	O
s	O
disease	O
:	O
a	O
randomized	O
clinical	O
trial	O
.	O

METHODS	O
:	O
A	O
randomized	O
,	O
controlled	O
,	O
single	O
-	O
blinded	O
trial	O
was	O
conducted	O
in	O
40	B-P
patients	I-P
with	I-P
mild	I-P
to	I-P
moderate	I-P
stages	I-P
of	I-P
AD	I-P
.	O

All	O
patients	O
were	O
daily	O
treated	O
with	O
rivastigmine	B-I
transdermal	I-I
patch	I-I
at	O
a	O
stable	O
dose	O
of	O
4	O
.	O
6	O
mg	O
and	O
randomized	O
into	O
two	O
groups	O
:	O
physical	B-I
exercises	I-I
or	O
control	O
.	O

The	B-I
exercise	I-I
program	I-I
consisted	O
of	O
aerobic	B-I
,	O
flexibility	B-I
,	O
strength	B-I
and	O
balance	B-I
movements	I-I
,	O
twice	O
a	O
week	O
for	O
6	O
months	O
.	O

Main	O
outcomes	O
were	O
Quality	B-O
of	I-O
Life	I-O
in	I-O
Alzheimer	I-O
'	I-O
s	I-O
disease	I-O
scale	I-O
(	I-O
QOL	I-O
)	I-O
,	O
Activities	B-O
of	I-O
Daily	I-O
Living	I-O
Questionnaire	I-O
(	I-O
ADL	I-O
)	I-O
,	O
Mini	B-O
-	I-O
Mental	I-O
State	I-O
Examination	I-O
(	I-O
MMSE	I-O
)	I-O
and	O
"	B-O
Time	I-O
Up	I-O
and	I-O
Go	I-O
Test	I-O
"	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Add	B-I
-	I-I
on	I-I
prolonged	I-I
-	I-I
release	I-I
melatonin	I-I
for	O
cognitive	O
function	O
and	O
sleep	O
in	O
mild	O
to	O
moderate	O
Alzheimer	O
'	O
s	O
disease	O
:	O
a	O
6	O
-	O
month	O
,	O
randomized	O
,	O
placebo	O
-	O
controlled	O
,	O
multicenter	O
trial	O
.	O

METHODS	O
:	O
The	O
effects	O
of	O
add	B-I
-	I-I
on	I-I
prolonged	I-I
-	I-I
release	I-I
melatonin	I-I
(	I-I
PRM	I-I
)	I-I
(	O
2	O
mg	O
)	O
to	O
standard	B-C
therapy	I-C
on	O
cognitive	O
functioning	O
and	O
sleep	O
were	O
investigated	O
in	O
80	B-P
patients	I-P
(	I-P
men	I-P
[	I-P
50	I-P
.	I-P
7	I-P
%	I-P
]	I-P
,	I-P
women	I-P
[	I-P
49	I-P
.	I-P
3	I-P
%	I-P
]	I-P
,	I-P
average	I-P
age	I-P
75	I-P
.	I-P
3	I-P
years	I-P
[	I-P
range	I-P
,	I-P
52	I-P
-	I-P
85	I-P
years	I-P
]	I-P
)	I-P
diagnosed	I-P
with	I-P
mild	I-P
to	I-P
moderate	I-P
AD	I-P
,	I-P
with	I-P
and	I-P
without	I-P
insomnia	I-P
comorbidity	I-P
,	I-P
and	I-P
receiving	I-P
standard	I-P
therapy	I-P
(	I-P
acetylcholinesterase	I-P
inhibitors	I-P
with	I-P
or	I-P
without	I-P
memantine	I-P
)	I-P
.	O

In	O
this	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
parallel	O
-	O
group	O
study	O
,	O
patients	O
were	O
treated	O
for	O
2	O
weeks	O
with	O
placebo	B-C
and	O
then	O
randomized	O
(	O
1	O
:	O
1	O
)	O
to	O
receive	O
2	B-I
mg	I-I
of	I-I
PRM	I-I
or	O
placebo	B-C
nightly	O
for	O
24	O
weeks	O
,	O
followed	O
by	O
2	B-C
weeks	I-C
placebo	I-C
.	O

The	B-O
AD	I-O
Assessment	I-O
Scale	I-O
-	I-O
Cognition	I-O
(	I-O
ADAS	I-O
-	I-O
Cog	I-O
)	I-O
,	O
Instrumental	B-O
Activities	I-O
of	I-O
Daily	I-O
Living	I-O
(	I-O
IADL	I-O
)	I-O
,	O
Mini	B-O
-	I-O
Mental	I-O
State	I-O
Examination	I-O
(	I-O
MMSE	I-O
)	I-O
,	O
sleep	B-O
,	O
as	O
assessed	O
by	O
the	B-O
Pittsburgh	I-O
Sleep	I-O
Quality	I-O
Index	I-O
(	I-O
PSQI	I-O
)	I-O
and	O
a	B-O
daily	I-O
sleep	I-O
diary	I-O
,	O
and	O
safety	B-O
parameters	I-O
were	O
measured	O
.	O

-DOCSTART-	O

Title	O
:	O
Safety	O
and	O
tolerability	O
of	O
immune	B-I
globulin	I-I
intravenous	I-I
(	I-I
human	I-I
)	I-I
,	O
10	O
%	O
solution	O
in	O
Japanese	B-P
subjects	I-P
with	I-P
mild	I-P
to	I-P
moderate	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
.	O

METHODS	O
:	O
Among	O
the	B-P
16	I-P
subjects	I-P
,	O
12	O
subjects	O
were	O
assigned	O
to	O
the	B-I
IGIV	I-I
group	O
and	O
4	O
subjects	O
to	O
the	B-C
placebo	I-C
group	O
.	O

Subjects	O
received	O
a	O
total	O
of	O
six	O
infusions	O
of	O
either	O
IGIV	B-I
at	O
a	O
dose	O
of	O
0	O
.	O
2	O
or	O
0	O
.	O
4	O
g	O
/	O
kg	O
,	O
or	O
placebo	B-C
every	O
2	O
weeks	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
single	O
-	O
dose	O
pilot	O
trial	O
of	O
intranasal	B-I
rapid	I-I
-	I-I
acting	I-I
insulin	I-I
in	O
apolipoprotein	B-P
E4	I-P
carriers	I-P
with	I-P
mild	I-P
-	I-P
moderate	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
.	O

METHODS	O
:	O
We	O
performed	O
a	O
double	O
-	O
blinded	O
,	O
randomized	O
,	O
cross	O
-	O
over	O
study	O
of	O
RA	B-I
insulin	I-I
glulisine	I-I
in	O
nine	B-P
mild	I-P
-	I-P
moderate	I-P
AD	I-P
subjects	I-P
to	O
better	O
understand	O
the	O
relationship	O
between	O
RA	B-O
insulin	I-O
,	O
ApoE4	B-O
carrier	I-O
status	I-O
and	O
memory	B-O
performance	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Donepezil	B-I
decreases	O
annual	O
rate	O
of	O
hippocampal	O
atrophy	O
in	O
suspected	O
prodromal	O
Alzheimer	O
'	O
s	O
disease	O
.	O

METHODS	O
:	O
A	O
double	O
-	O
blind	O
,	O
randomized	O
,	O
placebo	O
-	O
controlled	O
parallel	O
group	O
design	O
using	O
donepezil	B-I
(	O
10	O
mg	O
/	O
day	O
)	O
in	O
subjects	B-P
with	I-P
suspected	I-P
prodromal	I-P
AD	I-P
.	O

Subjects	O
underwent	O
two	O
brain	O
magnetic	O
resonance	O
imaging	O
scans	O
(	O
baseline	O
and	O
final	O
visit	O
)	O
.	O

The	O
primary	O
efficacy	O
outcome	O
was	O
the	O
annualized	O
percentage	O
change	O
(	O
APC	O
)	O
of	O
total	B-O
hippocampal	I-O
volume	I-O
(	I-O
left	I-O
+	I-O
right	I-O
)	I-O
measured	O
by	O
an	B-O
automated	I-O
segmentation	I-O
method	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Characterization	O
of	O
hepatic	O
enzyme	O
activity	O
in	O
older	B-P
adults	I-P
with	I-P
dementia	I-P
:	O
potential	O
impact	O
on	O
personalizing	O
pharmacotherapy	O
.	O

METHODS	O
:	O
A	O
multisite	O
cross	O
-	O
sectional	O
study	O
was	O
carried	O
out	O
across	O
four	O
memory	O
care	O
practices	O
in	O
the	O
greater	O
Indianapolis	O
area	O
.	O

Participants	O
were	O
adults	B-P
aged	I-P
65	I-P
years	I-P
and	I-P
older	I-P
with	I-P
a	I-P
diagnosis	I-P
of	I-P
probable	I-P
or	I-P
possible	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
(	I-P
AD	I-P
)	I-P
(	I-P
n=105	I-P
)	I-P
.	O

Blood	O
samples	O
and	O
self	O
-	O
reported	O
medication	O
data	O
were	O
collected	O
.	O

Since	O
two	O
of	O
the	O
three	O
AChEIs	O
are	O
metabolized	O
by	O
cytochrome	O
P450	O
(	O
CYP	O
)	O
-	O
2D6	O
,	O
we	O
determined	O
the	B-O
frequency	I-O
of	I-O
functional	I-O
genetic	I-O
variants	I-O
in	I-O
the	I-O
CYP2D6	I-O
gene	I-O
and	O
calculated	O
their	B-O
predicted	I-O
CYP2D6	I-O
-	I-O
activity	I-O
scores	I-O
.	O

Concurrent	O
medication	O
data	O
were	O
collected	O
from	O
self	O
-	O
reported	O
medication	O
surveys	O
,	O
and	O
their	O
predicted	O
effect	O
on	O
the	B-O
pharmacokinetics	I-O
of	I-O
AChEIs	I-O
was	O
determined	O
based	O
on	O
their	O
known	O
effects	O
on	O
CYP2D6	B-O
and	O
CYP3A4	B-O
/	I-O
5	I-O
enzyme	I-O
activities	I-O
.	O

-DOCSTART-	O

Title	O
:	O
First	O
administration	O
of	O
the	B-I
Fc	I-I
-	I-I
attenuated	I-I
anti	I-I
-	I-I
?	I-I
amyloid	I-I
antibody	I-I
GSK933776	I-I
to	O
patients	B-P
with	I-P
mild	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
:	O
a	O
randomized	O
,	O
placebo	O
-	O
controlled	O
study	O
.	O

METHODS	O
:	O
This	O
was	O
a	O
two	O
-	O
part	O
,	O
single	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
first	O
-	O
time	O
-	O
in	O
-	O
human	O
(	O
FTIH	O
)	O
study	O
of	O
single	B-I
(	O
n	O
=	O
18	O
)	O
and	O
repeat	B-I
dose	I-I
(	I-I
n	I-I
=	I-I
32	I-I
)	I-I
intravenous	I-I
GSK933776	I-I
0	O
.	O
001	O
-	O
6	O
mg	O
/	O
kg	O
(	O
ClinicalTrials	O
.	O
gov	O
:	O
NCT00459550	O
)	O
.	O

Additional	O
safety	O
data	O
from	O
an	O
open	O
-	O
label	O
,	O
uncontrolled	O
,	O
single	B-I
dose	I-I
study	I-I
of	I-I
intravenous	I-I
GSK933776	I-I
1	O
-	O
6	O
mg	O
/	O
kg	O
(	O
n	O
=	O
18	O
)	O
are	O
included	O
(	O
ClinicalTrials	O
.	O
gov	O
:	O
NCT01424436	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Tailored	B-I
nutritional	I-I
guidance	I-I
for	O
home	B-P
-	I-P
dwelling	I-P
AD	I-P
families	I-P
:	O
the	O
Feasibility	O
of	O
and	O
Elements	O
Promoting	O
Positive	O
Changes	O
in	O
Diet	O
(	O
NuAD	O
-	O
Trial	O
)	O
.	O

METHODS	O
:	O
This	O
qualitative	O
study	O
comprised	O
40	B-P
persons	I-P
with	I-P
AD	I-P
and	I-P
spousal	I-P
caregivers	I-P
of	I-P
our	I-P
trial	I-P
.	O

Our	O
intervention	O
during	O
one	O
year	O
involved	O
tailored	B-I
nutritional	I-I
guidance	I-I
for	O
these	O
couples	O
.	O

The	B-I
nutritionist	I-I
'	I-I
s	I-I
field	I-I
notes	I-I
(	O
about	O
100	O
pages	O
)	O
and	O
the	B-I
participant	I-I
feedback	I-I
questionnaires	I-I
(	O
N	O
=	O
28	O
)	O
served	O
to	O
analyse	O
the	O
feasibility	B-O
of	I-O
intervention	I-O
,	O
factors	B-O
promoting	I-O
the	I-O
application	I-O
of	I-O
intervention	I-O
and	O
challenges	B-O
hindering	I-O
it	I-O
.	O

Thematic	O
content	O
analysis	O
served	O
to	O
analyse	O
our	O
data	O
with	O
the	O
grounded	O
theory	O
approach	O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
Clinical	O
observation	O
of	O
Alzheimer	O
'	O
s	O
disease	O
treated	O
with	O
acupuncture	B-I
]	O
.	O

METHODS	O
:	O
One	B-P
hundred	I-P
and	I-P
forty	I-P
-	I-P
one	I-P
patients	I-P
were	O
randomized	O
into	O
an	B-I
acupuncture	I-I
group	O
(	O
72	O
cases	O
)	O
and	O
a	B-I
medicine	I-I
group	O
(	O
69	O
cases	O
)	O
.	O

In	O
the	B-I
acupuncture	I-I
group	O
,	O
the	O
needling	O
technique	O
for	O
benefiting	O
qi	O
,	O
promoting	O
blood	O
circulation	O
,	O
regulating	O
mind	O
and	O
improving	O
intelligence	O
was	O
used	O
at	O
Shenting	O
(	O
GV	O
24	O
)	O
,	O
Baihui	O
(	O
GV	O
20	O
)	O
,	O
Fengchi	O
(	O
GB	O
20	O
)	O
,	O
Wangu	O
(	O
GB	O
12	O
)	O
,	O
Danzhong	O
(	O
CV	O
17	O
)	O
,	O
Zhangwan	O
(	O
CV	O
12	O
)	O
,	O
Qihai	O
(	O
CV	O
6	O
)	O
,	O
Xuehai	O
(	O
SP	O
10	O
)	O
and	O
Zusanli	O
(	O
ST	O
36	O
)	O
.	O

The	O
supplementary	O
acupoints	O
were	O
selected	O
according	O
to	O
the	O
symptoms	O
and	O
physical	O
signs	O
.	O

Acupuncture	O
was	O
given	O
once	O
a	O
day	O
and	O
6	O
treatments	O
were	O
required	O
for	O
a	O
week	O
.	O

In	O
the	B-I
medicine	I-I
group	O
,	O
the	B-I
choline	I-I
sterase	I-I
inhibitor	I-I
,	O
donepezil	B-I
(	I-I
aricept	I-I
)	I-I
was	O
prescribed	O
for	O
oral	O
administration	O
,	O
1	O
tablet	O
(	O
5	O
mg	O
)	O
each	O
time	O
,	O
once	O
every	O
night	O
.	O

Four	O
weeks	O
later	O
,	O
the	O
dose	O
was	O
increased	O
to	O
2	O
tablets	O
(	O
10	O
mg	O
)	O
each	O
time	O
.	O

In	O
the	O
two	O
groups	O
,	O
the	O
treatment	O
of	O
4	O
weeks	O
made	O
one	O
session	O
and	O
4	O
sessions	O
were	O
required	O
.	O

The	O
changes	O
of	O
scores	O
before	O
and	O
after	O
treatment	O
in	O
the	B-O
minimum	I-O
mental	I-O
state	I-O
examination	I-O
(	I-O
MMSE	I-O
)	I-O
,	O
the	B-O
activity	I-O
of	I-O
daily	I-O
living	I-O
scale	I-O
(	I-O
ADL	I-O
)	I-O
,	O
Alzheimer	B-O
'	I-O
s	I-O
disease	I-O
assessment	I-O
scale	I-O
-	I-O
cognition	I-O
(	I-O
ADAS	I-O
-	I-O
cog	I-O
)	I-O
and	O
the	B-O
digit	I-O
span	I-O
(	I-O
DS	I-O
)	I-O
were	O
observed	O
.	O

-DOCSTART-	O

Title	O
:	O
A	B-I
web	I-I
-	I-I
based	I-I
psychoeducational	I-I
program	I-I
for	O
informal	B-P
caregivers	I-P
of	I-P
patients	I-P
with	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
:	O
a	O
pilot	O
randomized	O
controlled	O
trial	O
.	O

METHODS	O
:	O
We	O
recruited	O
and	O
randomized	O
offline	O
49	B-P
informal	I-P
caregivers	I-P
of	I-P
a	I-P
PWAD	I-P
in	I-P
a	I-P
day	I-P
care	I-P
center	I-P
in	I-P
Paris	I-P
,	I-P
France	I-P
.	O

They	O
either	O
received	O
the	B-I
Web	I-I
-	I-I
based	I-I
intervention	I-I
and	O
usual	B-C
care	I-C
for	O
3	O
months	O
(	O
experimental	O
group	O
,	O
n=25	O
)	O
or	O
only	B-C
usual	I-C
care	I-C
(	O
control	O
group	O
,	O
n=24	O
)	O
.	O

Caregivers	B-O
'	I-O
perceived	I-O
stress	I-O
(	O
PSS	B-O
-	I-O
14	I-O
,	O
primary	O
outcome	O
)	O
,	O
self	B-O
-	I-O
efficacy	I-O
,	O
burden	B-O
,	O
perceived	B-O
health	I-O
status	I-O
,	O
and	O
depression	B-O
(	O
secondary	O
outcomes	O
)	O
were	O
measured	O
during	O
3	O
face	O
-	O
to	O
-	O
face	O
on	O
-	O
site	O
visits	O
:	O
at	O
baseline	O
,	O
at	O
the	O
end	O
of	O
the	O
program	O
(	O
month	O
3	O
)	O
,	O
and	O
after	O
follow	O
-	O
up	O
(	O
month	O
6	O
)	O
.	O

Additionally	O
,	O
semistructured	O
interviews	O
were	O
conducted	O
with	O
experimental	O
group	O
caregivers	O
at	O
month	O
6	O
and	O
examined	O
with	O
thematic	O
analysis	O
.	O

-DOCSTART-	O

Title	O
:	O
Cognitive	O
Improvement	O
during	O
Treatment	O
for	O
Mild	O
Alzheimer	O
'	O
s	O
Disease	O
with	O
a	B-I
Chinese	I-I
Herbal	I-I
Formula	I-I
:	O
A	O
Randomized	O
Controlled	O
Trial	O
.	O

METHODS	O
:	O
Patients	B-P
with	I-P
mild	I-P
AD	I-P
meeting	I-P
the	I-P
criteria	I-P
were	O
randomized	O
into	O
Chinese	B-I
herbal	I-I
formula	I-I
Yishen	I-I
Huazhuo	I-I
decoction	I-I
(	I-I
YHD	I-I
)	I-I
group	O
and	O
donepezil	B-I
hydrochloride	I-I
(	I-I
DH	I-I
)	I-I
group	O
during	O
the	O
24	O
-	O
week	O
trial	O
.	O

The	O
outcomes	O
were	O
measured	O
by	O
ADAS	B-O
-	I-O
cog	I-O
,	O
MMSE	B-O
,	O
ADL	B-O
,	O
and	O
NPI	B-O
with	O
linear	O
mixed	O
-	O
effect	O
models	O
.	O

-DOCSTART-	O

Title	O
:	O
Early	B-I
psychosocial	I-I
intervention	I-I
does	O
not	O
delay	O
institutionalization	O
in	O
persons	B-P
with	I-P
mild	I-P
Alzheimer	I-P
disease	I-P
and	O
has	O
impact	O
on	O
neither	O
disease	O
progression	O
nor	O
caregivers	O
'	O
well	O
-	O
being	O
:	O
ALSOVA	O
3	O
-	O
year	O
follow	O
-	O
up	O
.	O

METHODS	O
:	O
Kuopio	O
ALSOVA	O
study	O
,	O
a	O
prospective	O
,	O
randomized	O
intervention	O
study	O
with	O
a	O
3	O
-	O
year	O
follow	O
-	O
up	O
,	O
was	O
carried	O
out	O
at	O
memory	O
clinics	O
.	O

Home	B-P
-	I-P
dwelling	I-P
persons	I-P
with	I-P
very	I-P
mild	I-P
or	I-P
mild	I-P
AD	I-P
(	I-P
n	I-P
=	I-P
236	I-P
)	I-P
and	I-P
AD	I-P
-	I-P
targeted	I-P
therapy	I-P
and	I-P
their	I-P
family	I-P
caregivers	I-P
(	I-P
n	I-P
=	I-P
236	I-P
)	I-P
were	O
randomized	O
to	O
the	O
intervention	O
or	O
control	O
group	O
(	O
1	O
:	O
2	O
)	O
.	O

Psychosocial	B-I
intervention	I-I
including	O
education	B-I
,	O
counseling	B-I
,	O
and	O
social	B-I
support	I-I
was	O
given	O
during	O
the	O
first	O
2	O
years	O
(	O
16	O
days	O
)	O
.	O

The	O
primary	O
outcome	O
was	O
the	B-O
cumulative	I-O
risk	I-O
(	I-O
controlled	I-O
for	I-O
death	I-O
)	I-O
of	O
institutionalization	O
over	O
36	O
months	O
.	O

Secondary	O
outcomes	O
were	O
adjusted	O
mean	O
changes	O
from	O
baseline	O
in	O
disease	B-O
severity	I-O
,	O
cognition	B-O
,	O
daily	B-O
activities	I-O
,	O
behavior	B-O
,	O
and	O
HRQoL	B-O
for	O
persons	B-P
with	I-P
AD	I-P
;	O
and	O
change	O
in	O
psychological	B-O
distress	I-O
,	O
depression	B-O
,	O
and	O
HRQoL	B-O
for	O
caregivers	B-P
.	O

-DOCSTART-	O

Title	O
:	O
Effects	O
of	O
Souvenaid	B-I
on	O
plasma	O
micronutrient	O
levels	O
and	O
fatty	O
acid	O
profiles	O
in	O
mild	O
and	O
mild	O
-	O
to	O
-	O
moderate	O
Alzheimer	O
'	O
s	O
disease	O
.	O

METHODS	O
:	O
Subjects	B-P
with	I-P
mild	I-P
(	I-P
RCT1	I-P
,	I-P
RCT2	I-P
)	I-P
or	I-P
mild	I-P
-	I-P
to	I-P
-	I-P
moderate	I-P
AD	I-P
(	I-P
RCT3	I-P
)	I-P
received	O
active	O
or	O
control	O
product	O
once	O
daily	O
for	O
12	O
-	O
24	O
weeks	O
or	O
active	O
product	O
during	O
the	O
24	O
-	O
week	O
OLE	O
following	O
RCT2	O
(	O
n	O
=	O
212	O
-	O
527	O
)	O
.	O

Measurements	O
included	O
plasma	B-O
levels	I-O
of	I-O
B	I-O
vitamins	I-O
,	O
choline	B-O
,	O
vitamin	B-O
E	I-O
,	O
selenium	B-O
,	O
uridine	B-O
and	O
homocysteine	B-O
and	O
proportions	B-O
of	I-O
DHA	I-O
,	O
EPA	B-O
and	O
total	B-O
n	I-O
-	I-O
3	I-O
long	I-O
-	I-O
chain	I-O
polyunsaturated	I-O
fatty	I-O
acids	I-O
in	I-O
plasma	I-O
and	O
erythrocytes	B-O
.	O

Between	O
-	O
group	O
comparisons	O
were	O
made	O
using	O
t	O
tests	O
or	O
non	O
-	O
parametric	O
alternatives	O
.	O

-DOCSTART-	O

Title	O
:	O
Citalopram	B-I
for	O
the	O
Treatment	O
of	O
Agitation	O
in	O
Alzheimer	O
Dementia	O
:	O
Genetic	O
Influences	O
.	O

METHODS	O
:	O
We	O
utilized	O
data	O
from	O
the	B-I
Citalopram	I-I
for	O
Agitation	O
in	O
Alzheimer	O
'	O
s	O
Disease	O
(	O
CitAD	O
)	O
database	O
.	O

CitAD	O
was	O
a	O
9	O
-	O
week	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
multicenter	O
clinical	O
trial	O
showing	O
significant	O
improvement	O
in	O
agitation	O
and	O
caregiver	O
distress	O
in	O
patients	O
treated	O
with	O
citalopram	B-I
.	O

Proportional	O
odds	O
logistic	O
regression	O
and	O
mixed	O
effects	O
models	O
were	O
used	O
to	O
examine	O
the	O
above	O
-	O
mentioned	O
outcome	O
measures	O
.	O

-DOCSTART-	O

Title	O
:	O
Effects	O
of	O
the	B-I
Acetylcholine	I-I
Release	I-I
Agent	I-I
ST101	I-I
with	O
Donepezil	B-I
in	O
Alzheimer	O
'	O
s	O
Disease	O
:	O
A	O
Randomized	O
Phase	O
2	O
Study	O
.	O

METHODS	O
:	O
A	O
phase	O
2	O
double	O
blind	O
,	O
placebo	O
-	O
controlled	O
study	O
enrolled	O
210	B-P
AD	I-P
patients	I-P
(	I-P
MMSE	I-P
10	I-P
-	I-P
20	I-P
)	I-P
on	O
10	B-I
mg	I-I
donepezil	I-I
QD	I-I
.	O

Patients	O
received	O
ST101	B-I
(	O
10	O
,	O
60	O
,	O
or	O
120	O
mg	O
QD	O
)	O
or	O
placebo	B-C
for	O
12	O
weeks	O
.	O

The	O
primary	O
endpoint	O
was	O
change	O
in	O
cognitive	B-O
function	I-O
measured	O
by	O
ADAS	B-O
-	I-O
cog	I-O
in	O
the	O
modified	O
Intent	O
To	O
Treat	O
(	O
MITT	O
)	O
population	O
and	O
the	O
Per	O
Protocol	O
(	O
PP	O
)	O
population	O
.	O

-DOCSTART-	O

Title	O
:	O
Nutritional	B-I
Guidance	I-I
Improves	O
Nutrient	O
Intake	O
and	O
Quality	O
of	O
Life	O
,	O
and	O
May	O
Prevent	O
Falls	O
in	O
Aged	B-P
Persons	I-P
with	I-P
Alzheimer	I-P
Disease	I-P
Living	I-P
with	I-P
a	I-P
Spouse	I-P
(	O
NuAD	O
Trial	O
)	O
.	O

METHODS	O
:	O
Randomised	O
controlled	O
trial	O
.	O

Persons	B-P
with	I-P
AD	I-P
living	I-P
with	I-P
a	I-P
spouse	I-P
.	O

Tailored	B-I
nutritional	I-I
guidance	I-I
with	O
home	O
visits	O
during	O
one	O
year	O
.	O

The	O
control	O
group	O
received	O
a	B-C
written	I-C
guide	I-C
about	O
nutrition	O
in	O
older	B-P
adults	I-P
and	I-P
all	I-P
community	I-P
-	I-P
provided	I-P
normal	I-P
care	I-P
.	O

The	O
primary	O
outcome	O
measure	O
was	O
weight	B-O
change	I-O
,	O
and	O
secondary	O
outcomes	O
included	O
changes	O
in	O
protein	B-O
and	O
micronutrient	B-O
intakes	I-O
from	I-O
three	I-O
-	I-O
day	I-O
food	I-O
records	I-O
,	O
HRQoL	B-O
(	I-O
15	I-O
D	I-O
)	I-O
and	O
rate	B-O
of	I-O
falls	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Changes	O
in	O
Brain	O
Volume	O
with	O
Bapineuzumab	B-I
in	O
Mild	O
to	O
Moderate	O
Alzheimer	O
'	O
s	O
Disease	O
.	O

METHODS	O
:	O
Bapineuzumab	B-I
dosages	O
included	O
0	O
.	O
5	O
mg	O
/	O
kg	O
in	O
carriers	O
and	O
0	O
.	O
5	O
or	O
1	O
.	O
0	O
mg	O
/	O
kg	O
in	O
noncarriers	O
,	O
every	O
13	O
weeks	O
for	O
78	O
weeks	O
.	O

Volumetric	O
outcomes	O
included	O
annualized	B-O
brain	I-O
,	O
ventricular	B-O
,	O
and	O
mean	B-O
hippocampal	I-O
boundary	I-O
shift	I-O
integrals	I-O
(	O
BBSI	B-O
;	O
VBSI	B-O
;	O
HBSI	B-O
)	O
up	O
to	O
Week	O
71	O
.	O

Treatment	O
differences	O
were	O
estimated	O
using	O
mixed	O
models	O
for	O
repeated	O
measures	O
.	O

-DOCSTART-	O

Title	O
:	O
Transcranial	B-I
direct	I-I
current	I-I
stimulation	I-I
as	O
a	O
memory	O
enhancer	O
in	O
patients	B-P
with	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
:	O
a	O
randomized	O
,	O
placebo	O
-	O
controlled	O
trial	O
.	O

METHODS	O
:	O
We	O
conducted	O
a	O
randomized	O
,	O
placebo	O
-	O
controlled	O
clinical	O
trial	O
in	O
which	O
tDCS	B-I
was	O
applied	O
in	O
six	O
30	O
-	O
minute	O
sessions	O
for	O
10	O
days	O
.	O

tDCS	B-I
was	O
delivered	O
to	O
the	O
left	O
temporal	O
cortex	O
with	O
2	O
-	O
mA	O
intensity	O
.	O

A	B-P
total	I-P
of	I-P
25	I-P
patients	I-P
with	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
were	O
enrolled	O
in	O
the	O
study	O
.	O

All	O
of	O
the	O
patients	O
were	O
diagnosed	O
according	O
to	O
National	O
Institute	O
of	O
Neurological	O
and	O
Communicative	O
Disorders	O
and	O
Stroke	O
and	O
Alzheimer	O
'	O
s	O
Disease	O
and	O
Related	O
Disorders	O
Association	O
criteria	O
.	O

Twelve	O
patients	O
received	O
active	B-I
stimulation	I-I
,	O
and	O
thirteen	O
patients	O
received	O
placebo	B-C
stimulation	I-C
.	O

The	O
primary	O
outcome	O
measure	O
was	O
the	O
change	O
in	O
two	B-O
parallel	I-O
versions	I-O
of	I-O
the	I-O
California	I-O
Verbal	I-O
Learning	I-O
Test	I-O
-	I-O
Second	I-O
Edition	I-O
,	O
a	B-O
standardized	I-O
neuropsychological	I-O
memory	I-O
test	I-O
normalized	I-O
by	I-O
age	I-O
and	I-O
gender	I-O
.	O

The	O
secondary	O
outcome	O
measures	O
were	O
the	B-O
Mini	I-O
Mental	I-O
State	I-O
Examination	I-O
,	O
clock	B-O
-	I-O
drawing	I-O
test	I-O
,	O
and	O
Trail	B-O
Making	I-O
Test	I-O
A	I-O
and	O
B	B-O
.	O

-DOCSTART-	O

Title	O
:	O
Safety	O
and	O
tolerability	O
of	O
BAN2401	B-I
-	O
-	O
a	O
clinical	O
study	O
in	O
Alzheimer	O
'	O
s	O
disease	O
with	O
a	B-I
protofibril	I-I
selective	I-I
A?	I-I
antibody	I-I
.	O

METHODS	O
:	O
Here	O
we	O
describe	O
the	O
first	O
clinical	O
study	O
with	O
BAN2401	B-I
.	O

Safety	B-O
and	O
tolerability	B-O
were	O
investigated	O
in	O
mild	O
to	O
moderate	O
AD	O
.	O

A	O
study	O
design	O
was	O
used	O
with	O
staggered	O
parallel	O
single	O
and	O
multiple	O
ascending	O
doses	O
,	O
from	O
0	O
.	O
1	O
mg	O
/	O
kg	O
as	O
a	O
single	O
dose	O
to	O
10	O
mg	O
/	O
kg	O
biweekly	O
for	O
four	O
months	O
.	O

The	B-O
presence	I-O
of	I-O
amyloid	I-O
related	I-O
imaging	I-O
abnormalities	I-O
(	O
ARIA	B-O
,	O
E	B-O
for	I-O
edema	I-O
,	O
H	B-O
for	I-O
hemorrhage	I-O
)	O
was	O
assessed	O
with	O
magnetic	B-O
resonance	I-O
imaging	I-O
(	I-O
MRI	I-O
)	I-O
.	O

Cerebrospinal	B-O
fluid	I-O
(	I-O
CSF	I-O
)	I-O
and	O
plasma	B-O
samples	I-O
were	O
analyzed	O
to	O
investigate	O
pharmacokinetics	B-O
(	I-O
PK	I-O
)	I-O
and	O
effects	B-O
on	I-O
biomarkers	I-O
.	O

-DOCSTART-	O

Title	O
:	O
R	B-I
-	I-I
and	O
S	B-I
-	I-I
citalopram	I-I
concentrations	O
have	O
differential	O
effects	O
on	O
neuropsychiatric	O
scores	O
in	O
elders	B-P
with	I-P
dementia	I-P
and	I-P
agitation	I-P
.	O

METHODS	O
:	O
Citalopram	B-I
enantiomer	O
exposures	O
(	O
AUC	O
(	O
0	O
,	O
24	O
h	O
)	O
)	O
derived	O
from	O
an	O
established	O
population	O
pharmacokinetic	O
analysis	O
were	O
utilized	O
to	O
explore	O
the	O
relationship	O
between	O
(	B-I
R	I-I
)	I-I
-	I-I
and	O
(	B-I
S	I-I
)	I-I
-	I-I
citalopram	I-I
area	O
under	O
the	O
curve	O
(	O
AUC	O
(	O
0	O
,	O
24	O
)	O
)	O
and	O
Mini	B-O
-	I-O
Mental	I-O
State	I-O
Examination	I-O
(	I-O
MMSE	I-O
)	I-O
,	O
Neurobehavioural	B-O
Rating	I-O
Scale	I-O
-	I-O
Agitation	I-O
Subscale	I-O
(	I-O
NBRS	I-O
-	I-O
A	I-O
)	I-O
,	O
modified	B-O
Alzheimer	I-O
'	I-O
s	I-O
Disease	I-O
Cooperative	I-O
Study	I-O
-	I-O
Clinical	I-O
Global	I-O
Impression	I-O
of	I-O
Change	I-O
(	I-O
mADCS	I-O
-	I-O
CGIC	I-O
)	I-O
and	O
Neuropsychiatric	B-O
Inventory	I-O
Agitation	I-O
subscale	I-O
(	I-O
NPIA	I-O
)	I-O
scores	I-O
.	O

Time	O
dependent	O
changes	O
in	O
these	O
scores	O
(	O
disease	O
progression	O
)	O
were	O
accounted	O
for	O
prior	O
to	O
exploring	O
the	O
exposure	O
effect	O
relationship	O
for	O
each	O
enantiomer	O
.	O

These	O
relationships	O
were	O
evaluated	O
using	O
a	O
non	O
-	O
linear	O
-	O
mixed	O
effects	O
modelling	O
approach	O
as	O
implemented	O
in	O
nonmem	O
v7	O
.	O
3	O
.	O

-DOCSTART-	O

Title	O
:	O
Alzheimer	O
'	O
s	O
Disease	O
Severity	O
is	O
Not	O
Significantly	O
Associated	O
with	O
Short	B-I
Sleep	I-I
:	O
Survey	O
by	O
Actigraphy	O
on	O
208	B-P
Mild	I-P
and	I-P
Moderate	I-P
Alzheimer	I-P
'	I-P
s	I-P
Disease	I-P
Patients	I-P
.	O

METHODS	O
:	O
During	O
an	O
observational	O
first	O
step	O
of	O
a	O
clinical	O
trial	O
,	O
sleep	O
was	O
assessed	O
in	O
institutionalized	B-P
patients	I-P
with	I-P
mild	I-P
or	I-P
moderate	I-P
AD	I-P
using	O
actigraphy	B-O
(	O
MW8	B-O
,	O
Camtech	O
,	O
Cambridge	O
,	O
UK	O
)	O
for	O
14	O
consecutive	O
24	O
-	O
hour	O
periods	O
.	O

Sleep	O
parameters	O
analyzed	O
were	O
:	O
TST	B-O
,	O
time	B-O
in	I-O
bed	I-O
(	I-O
TIB	I-O
)	I-O
,	O
wake	B-O
after	I-O
sleep	I-O
onset	I-O
(	I-O
WASO	I-O
)	I-O
,	O
sleep	B-O
efficiency	I-O
(	I-O
SE	I-O
)	I-O
defined	O
by	O
the	B-O
ratio	I-O
TST	I-O
/	I-O
TIB	I-O
,	O
in	O
percentage	O
)	O
,	O
the	B-O
number	I-O
and	I-O
length	I-O
of	I-O
awakenings	I-O
,	O
the	B-O
night	I-O
fragmentation	I-O
index	I-O
,	O
the	B-O
interdaily	I-O
stability	I-O
,	O
and	O
intradaily	B-O
variability	I-O
indexes	I-O
.	O

Statistical	O
association	O
analyses	O
were	O
tested	O
between	O
these	O
values	O
and	O
AD	O
apathy	O
and	O
severity	O
scores	O
.	O

-DOCSTART-	O

Title	O
:	O
Cost	O
-	O
effectiveness	O
of	O
donepezil	B-I
and	O
memantine	B-I
in	O
moderate	O
to	O
severe	O
Alzheimer	O
'	O
s	O
disease	O
(	O
the	O
DOMINO	O
-	O
AD	O
trial	O
)	O
.	O

METHODS	O
:	O
Cost	O
-	O
effectiveness	O
analysis	O
was	O
based	O
on	O
a	O
52	O
-	O
week	O
,	O
multicentre	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
factorial	O
clinical	O
trial	O
.	O

A	B-P
total	I-P
of	I-P
295	I-P
community	I-P
-	I-P
dwelling	I-P
patients	I-P
with	I-P
moderate	I-P
/	I-P
severe	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
,	O
already	O
treated	O
with	O
donepezil	B-I
,	O
were	O
randomised	O
to	O
:	O
(	O
i	O
)	O
continue	O
donepezil	B-I
;	O
(	O
ii	O
)	O
discontinue	O
donepezil	B-I
;	O
(	O
iii	O
)	O
discontinue	O
donepezil	B-I
and	O
start	O
memantine	B-I
;	O
or	O
(	O
iv	O
)	O
continue	O
donepezil	B-I
and	O
start	O
memantine	B-I
.	O

-DOCSTART-	O

Title	O
:	O
Poor	O
Safety	O
and	O
Tolerability	O
Hamper	O
Reaching	O
a	O
Potentially	O
Therapeutic	O
Dose	O
in	O
the	O
Use	O
of	O
Thalidomide	B-I
for	O
Alzheimer	O
'	O
s	O
Disease	O
:	O
Results	O
from	O
a	O
Double	O
-	O
Blind	O
,	O
Placebo	O
-	O
Controlled	O
Trial	O
.	O

METHODS	O
:	O
This	O
was	O
a	O
24	O
-	O
week	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
parallel	O
group	O
study	O
with	O
escalating	O
dose	O
regimen	O
of	O
thalidomide	B-I
with	O
a	O
target	O
dose	O
of	O
400	O
mg	O
daily	O
in	O
patients	B-P
with	I-P
mild	I-P
to	I-P
moderate	I-P
AD	I-P
.	O

The	O
primary	O
outcome	O
measures	O
were	O
tolerability	B-O
and	O
cognitive	B-O
performance	I-O
assessed	O
by	O
a	O
battery	O
of	O
tests	O
.	O

-DOCSTART-	O

Title	O
:	O
Long	O
-	O
Term	O
Extensions	O
of	O
Randomized	O
Vaccination	O
Trials	O
of	O
ACC	B-I
-	I-I
001	I-I
and	O
QS	B-I
-	I-I
21	I-I
in	O
Mild	O
to	O
Moderate	O
Alzheimer	O
'	O
s	O
Disease	O
.	O

METHODS	O
:	O
Phase	O
2	O
a	O
extension	O
studies	O
of	O
randomized	O
parent	O
trials	O
were	O
conducted	O
in	O
the	O
United	O
States	O
,	O
European	O
Union	O
,	O
and	O
Japan	O
.	O

Four	O
immunizations	O
of	O
ACC	B-I
-	I-I
001	I-I
were	O
administered	O
at	O
the	O
same	O
3	O
dose	O
levels	O
(	O
3	O
,	O
10	O
,	O
and	O
30	O
?g	O
)	O
to	O
subjects	B-P
randomized	I-P
in	I-P
the	I-P
parent	I-P
studies	I-P
;	O
ACC	B-I
-	I-I
001	I-I
was	O
administered	O
with	O
QS	B-I
-	I-I
21	I-I
adjuvant	O
.	O

Safety	B-O
,	O
tolerability	B-O
,	O
and	O
immunogenicity	B-O
were	O
assessed	O
during	O
active	O
treatment	O
and	O
6	O
-	O
month	O
follow	O
-	O
up	O
.	O

-DOCSTART-	O

Title	O
:	O
Efficacy	O
of	O
Hearing	B-I
Aids	I-I
on	O
the	O
Cognitive	O
Status	O
of	O
Patients	B-P
with	I-P
Alzheimer	I-P
'	I-P
s	I-P
Disease	I-P
and	I-P
Hearing	I-P
Loss	I-P
:	O
A	O
Multicenter	O
Controlled	O
Randomized	O
Trial	O
.	O

METHODS	O
:	O
A	O
multicenter	O
double	O
-	O
blind	O
randomized	O
placebo	O
-	O
controlled	O
trial	O
was	O
conducted	O
in	O
patients	B-P
aged	I-P
more	I-P
than	I-P
65	I-P
years	I-P
.	O

A	O
group	O
was	O
equipped	O
with	O
active	B-I
HA	I-I
for	O
6	O
months	O
(	O
active	O
group	O
)	O
and	O
a	O
second	O
group	O
had	O
placebo	B-C
HA	I-C
for	O
6	O
months	O
(	O
placebo	O
group	O
)	O
followed	O
by	O
a	O
secondary	O
activation	O
phase	O
for	O
a	O
further	O
6	O
months	O
(	O
semi	O
crossover	O
procedure	O
)	O
.	O

Both	O
groups	O
were	O
retested	O
after	O
a	O
12	O
-	O
month	O
period	O
.	O

The	O
primary	O
endpoint	O
was	O
the	O
change	O
from	O
baseline	O
of	O
the	B-O
Alzheimer	I-O
'	I-O
s	I-O
Disease	I-O
Assessment	I-O
Scale	I-O
-	I-O
Cognitive	I-O
subscale	I-O
(	I-O
ADAS	I-O
Cog	I-O
)	I-O
after	O
a	O
6	O
-	O
month	O
period	O
in	O
both	O
groups	O
and	O
after	O
6	O
months	O
of	O
secondary	O
HA	O
activation	O
in	O
the	O
placebo	O
group	O
.	O

A	O
smaller	O
cognitive	O
decline	O
should	O
be	O
obtained	O
with	O
HA	B-I
use	O
;	O
an	O
increase	O
in	O
ADAS	B-O
Cog	I-O
score	I-O
of	O
less	O
than	O
6	O
points	O
was	O
defined	O
a	O
success	O
.	O

-DOCSTART-	O

Title	O
:	O
Home	B-I
-	I-I
Based	I-I
Exercise	I-I
Program	I-I
Improves	O
Balance	O
and	O
Fear	O
of	O
Falling	O
in	O
Community	B-P
-	I-P
Dwelling	I-P
Older	I-P
Adults	I-P
with	I-P
Mild	I-P
Alzheimer	I-P
'	I-P
s	I-P
Disease	I-P
:	O
A	O
Pilot	O
Study	O
.	O

METHODS	O
:	O
A	O
prospective	O
randomized	O
controlled	O
parallel	O
-	O
group	O
trial	O
(	O
Wii	B-I
-	I-I
Fit	I-I
versus	O
walking	B-I
)	O
was	O
conducted	O
in	O
thirty	B-P
community	I-P
-	I-P
dwelling	I-P
older	I-P
adults	I-P
(	I-P
736	I-P
.	I-P
2	I-P
years	I-P
)	I-P
with	I-P
mild	I-P
AD	I-P
.	O

Home	B-I
-	I-I
based	I-I
exercises	I-I
were	O
performed	O
under	O
caregiver	O
supervision	O
for	O
8	O
weeks	O
.	O

Primary	O
(	O
Berg	B-O
Balance	I-O
Scale	I-O
,	I-O
BBS	I-O
)	O
and	O
secondary	O
outcomes	O
(	O
fear	B-O
of	I-O
falls	I-O
and	O
quality	B-O
of	I-O
life	I-O
)	O
were	O
measured	O
at	O
baseline	O
,	O
8	O
weeks	O
(	O
end	O
of	O
intervention	O
)	O
,	O
and	O
16	O
weeks	O
(	O
8	O
-	O
weeks	O
post	O
-	O
intervention	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Efficacy	O
and	O
Safety	O
of	O
Citalopram	B-I
Compared	O
to	O
Atypical	B-C
Antipsychotics	I-C
on	O
Agitation	O
in	O
Nursing	B-P
Home	I-P
Residents	I-P
With	I-P
Alzheimer	I-P
Dementia	I-P
.	O

METHODS	O
:	O
Longitudinal	O
,	O
6	O
-	O
month	O
study	O
.	O

Nursing	O
home	O
(	O
NH	O
)	O
.	O

75	B-P
NH	I-P
residents	I-P
with	I-P
AD	I-P
and	I-P
agitation	I-P
,	O
randomized	O
to	O
citalopram	B-I
(	O
n	O
=	O
25	O
)	O
,	O
quetiapine	B-I
(	O
n	O
=	O
25	O
)	O
,	O
or	O
olanzapine	B-I
(	O
n	O
=	O
25	O
)	O
.	O

Changes	O
in	O
Neuropsychiatric	B-O
Inventory	I-O
(	I-O
NPI	I-O
)	I-O
agitation	I-O
subscale	I-O
score	I-O
and	O
the	B-O
modified	I-O
Alzheimer	I-O
Disease	I-O
Cooperative	I-O
Study	I-O
-	I-O
Clinical	I-O
Global	I-O
Impression	I-O
of	I-O
Change	I-O
(	I-O
mADCS	I-O
-	I-O
CGIC	I-O
)	I-O
were	O
used	O
to	O
assess	O
treatment	O
efficacy	O
.	O

Participants	O
were	O
surveilled	O
for	O
adverse	B-O
health	I-O
outcomes	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Psychosocial	B-I
behaviour	I-I
management	I-I
programme	I-I
for	O
home	B-P
-	I-P
dwelling	I-P
people	I-P
with	I-P
dementia	I-P
:	O
A	O
cluster	O
-	O
randomized	O
controlled	O
trial	O
.	O

Little	O
is	O
known	O
about	O
the	O
effectiveness	O
of	O
a	O
psychosocial	O
behaviour	O
management	O
programme	O
on	O
home	O
-	O
dwelling	O
people	O
with	O
dementia	O
.	O

We	O
developed	O
a	O
Behaviour	O
Analytics	O
&	O
Support	O
Enhancement	O
(	O
BASE	O
)	O
programme	O
for	O
care	O
managers	O
and	O
professional	O
caregivers	O
of	O
home	O
care	O
services	O
in	O
Japan	O
.	O

We	O
investigated	O
the	O
effects	O
of	O
BASE	O
on	O
challenging	O
behaviour	O
of	O
home	O
-	O
dwelling	O
people	O
with	O
dementia	O
.	O

METHODS	O
:	O
A	O
cluster	O
-	O
randomized	O
controlled	O
trial	O
was	O
conducted	O
with	O
home	O
care	O
providers	O
from	O
3	O
different	O
districts	O
in	O
Tokyo	O
.	O

Each	O
provider	O
recruited	O
persons	B-P
with	I-P
dementia	I-P
aged	I-P
65	I-P
years	I-P
or	I-P
older	I-P
to	I-P
receive	I-P
home	I-P
care	I-P
in	I-P
the	I-P
BASE	I-P
programme	I-P
in	I-P
August	I-P
2016	I-P
.	O

An	B-O
online	I-O
monitoring	I-O
and	O
assessment	B-O
system	I-O
was	O
introduced	O
to	O
the	O
intervention	O
group	O
for	O
repeated	O
measures	O
of	O
challenging	B-O
behaviour	I-O
with	O
a	B-O
total	I-O
score	I-O
of	I-O
the	I-O
Neuropsychiatric	I-O
Inventory	I-O
.	O

Care	O
professionals	O
in	O
both	O
the	O
intervention	O
and	O
control	O
groups	O
evaluated	O
challenging	O
behaviour	O
of	O
persons	O
with	O
dementia	O
at	O
baseline	O
(	O
September	O
2016	O
)	O
and	O
follow	O
-	O
up	O
(	O
February	O
2017	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
value	O
of	O
subtraction	B-I
MRI	I-I
in	O
detection	O
of	O
amyloid	O
-	O
related	O
imaging	O
abnormalities	O
with	O
oedema	O
or	O
effusion	O
in	O
Alzheimer	O
'	O
s	O
patients	O
:	O
An	O
interobserver	O
study	O
.	O

METHODS	O
:	O
We	O
included	O
75	B-P
AD	I-P
patients	I-P
receiving	I-P
bapineuzumab	I-P
treatment	I-P
,	I-P
including	I-P
29	I-P
ARIA	I-P
-	I-P
E	I-P
cases	I-P
.	O

Five	O
neuroradiologists	O
rated	O
their	O
brain	O
MRI	O
-	O
scans	O
with	B-I
and	O
without	B-I
subtraction	I-I
images	I-I
.	O

The	B-O
accuracy	I-O
of	I-O
evaluating	I-O
the	I-O
presence	I-O
of	I-O
ARIA	I-O
-	I-O
E	I-O
,	O
intraclass	B-O
correlation	I-O
coefficient	I-O
(	I-O
ICC	I-O
)	I-O
and	O
specific	B-O
agreement	I-O
was	O
calculated	O
.	O

-DOCSTART-	O

Title	O
:	O
Cross	O
-	O
Sectional	O
Associations	O
of	O
Total	B-I
Plasma	I-I
Homocysteine	I-I
with	O
Cortical	B-I
?	I-I
-	I-I
Amyloid	I-I
Independently	O
and	O
as	O
a	O
Function	O
of	O
Omega	O
3	O
Polyunsaturated	O
Fatty	O
Acid	O
Status	O
in	O
Older	B-P
Adults	I-P
at	I-P
Risk	I-P
of	I-P
Dementia	I-P
.	O

METHODS	O
:	O
This	O
is	O
a	O
cross	O
-	O
sectional	O
study	O
using	O
data	O
from	O
the	O
Multidomain	O
Alzheimer	O
Preventive	O
Trial	O
(	O
MAPT	O
)	O
;	O
a	O
randomised	O
controlled	O
trial	O
.	O

French	B-P
community	I-P
dwellers	I-P
aged	I-P
70	I-P
or	I-P
over	I-P
reporting	I-P
subjective	I-P
memory	I-P
complaints	I-P
,	I-P
but	I-P
free	I-P
from	I-P
a	I-P
diagnosis	I-P
of	I-P
clinical	I-P
dementia	I-P
.	O

Individuals	O
were	O
from	O
the	O
MAPT	O
trial	O
(	O
n	O
=	O
177	O
)	O
with	O
data	O
on	O
total	O
plasma	O
homocysteine	O
at	O
baseline	O
and	O
cortical	O
A?	O
load	O
.	O

Cortical	B-O
-	I-O
to	I-O
-	I-O
cerebellar	I-O
standard	I-O
uptake	I-O
value	I-O
ratios	I-O
were	O
assessed	O
using	O
[	B-O
18	I-O
F	I-O
]	I-O
florbetapir	I-O
positron	I-O
emission	I-O
tomography	I-O
(	I-O
PET	I-O
)	I-O
.	O

Total	B-O
baseline	I-O
plasma	I-O
homocysteine	I-O
was	O
measured	O
using	O
an	B-O
enzymatic	I-O
cycling	I-O
assay	I-O
.	O

Baseline	B-O
omega	I-O
3	I-O
index	I-O
was	O
measured	O
using	O
gas	B-O
chromatography	I-O
.	O

Cross	O
-	O
sectional	O
associations	O
were	O
explored	O
using	O
adjusted	O
multiple	O
linear	O
regression	O
models	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
phase	O
III	O
randomized	O
trial	O
of	O
gantenerumab	B-I
in	O
prodromal	O
Alzheimer	O
'	O
s	O
disease	O
.	O

METHODS	O
:	O
In	O
this	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
phase	O
III	O
study	O
,	O
we	O
investigated	O
gantenerumab	B-I
over	O
2	O
years	O
.	O

Patients	O
were	O
randomized	O
to	O
gantenerumab	B-I
105	O
mg	O
or	O
225	O
mg	O
or	O
placebo	B-C
every	O
4	O
weeks	O
by	O
subcutaneous	O
injection	O
.	O

The	O
primary	O
endpoint	O
was	O
the	O
change	O
from	O
baseline	O
to	O
week	O
104	O
in	O
Clinical	B-O
Dementia	I-O
Rating	I-O
Sum	I-O
of	I-O
Boxes	I-O
(	I-O
CDR	I-O
-	I-O
SB	I-O
)	I-O
score	I-O
.	O

We	O
evaluated	O
treatment	O
effects	O
on	O
cerebrospinal	B-O
fluid	I-O
biomarkers	I-O
(	O
all	O
patients	O
)	O
and	O
amyloid	B-O
positron	I-O
emission	I-O
tomography	I-O
(	O
substudy	O
)	O
.	O

A	O
futility	O
analysis	O
was	O
performed	O
once	O
50	O
%	O
of	O
patients	O
completed	O
2	O
years	O
of	O
treatment	O
.	O

Safety	O
was	O
assessed	O
in	O
patients	O
who	O
received	O
at	O
least	O
one	O
dose	O
.	O

-DOCSTART-	O

Title	O
:	O
Long	O
-	O
Lasting	O
Neuropsychological	O
Effects	O
of	O
a	B-I
Computerized	I-I
Cognitive	I-I
Training	I-I
in	O
Patients	B-P
Affected	I-P
by	I-P
Early	I-P
Stage	I-P
Alzheimer	I-P
'	I-P
s	I-P
Disease	I-P
:	O
Are	O
They	O
Stable	O
Over	O
Time	O
?	O
.	O

METHODS	O
:	O
Eighty	B-P
AD	I-P
patients	I-P
were	O
randomized	O
in	O
two	O
groups	O
and	O
underwent	O
a	B-I
computerized	I-I
cognitive	I-I
training	I-I
,	O
or	O
a	O
control	O
intervention	O
.	O

-DOCSTART-	O

Title	O
:	O
Delayed	O
-	O
Start	O
Analyses	O
in	O
the	O
Phase	O
3	O
Solanezumab	B-I
EXPEDITION3	O
Study	O
in	O
Mild	O
Alzheimer	O
'	O
s	O
Disease	O
.	O

METHODS	O
:	O
EXPEDITION3	O
was	O
a	O
Phase	O
3	O
,	O
double	O
-	O
blind	O
study	O
with	O
participants	O
randomized	O
to	O
solanezumab	B-I
(	O
400	O
mg	O
)	O
or	O
placebo	B-C
every	O
4	O
weeks	O
for	O
80	O
weeks	O
,	O
with	O
an	O
optional	O
extension	O
of	O
active	O
treatment	O
.	O

The	O
delayed	O
-	O
start	O
analysis	O
was	O
designed	O
to	O
determine	O
if	O
a	O
statistically	O
significant	O
treatment	O
difference	O
established	O
during	O
the	O
placebo	O
-	O
controlled	O
period	O
is	O
maintained	O
(	O
at	O
predefined	O
level	O
)	O
during	O
the	O
delayed	O
-	O
start	O
period	O
,	O
which	O
would	O
suggest	O
the	O
active	O
drug	O
has	O
a	O
disease	O
-	O
modifying	O
effect	O
.	O

The	O
delayed	O
-	O
start	O
analysis	O
was	O
assessed	O
across	O
multiple	O
efficacy	O
measures	O
,	O
and	O
includes	O
data	O
from	O
baseline	O
in	O
the	O
placebo	O
-	O
controlled	O
period	O
and	O
up	O
to	O
9	O
months	O
in	O
the	O
delayed	O
-	O
start	O
period	O
.	O

-DOCSTART-	O

Title	O
:	O
Effectiveness	O
of	O
Anti	B-I
-	I-I
Dementia	I-I
Drugs	I-I
in	O
Extremely	O
Severe	O
Alzheimer	O
'	O
s	O
Disease	O
:	O
A	O
12	O
-	O
Week	O
,	O
Multicenter	O
,	O
Randomized	O
,	O
Single	O
-	O
Blind	O
Study	O
.	O

METHODS	O
:	O
In	O
this	O
randomized	O
and	O
rater	O
-	O
blinded	O
trial	O
,	O
65	B-P
AD	I-P
patients	I-P
with	I-P
a	I-P
Mini	I-P
-	I-P
Mental	I-P
State	I-P
Examination	I-P
score	I-P
from	I-P
0	I-P
to	I-P
5	I-P
and	I-P
a	I-P
score	I-P
of	I-P
6	I-P
c	I-P
or	I-P
worse	I-P
on	I-P
Functional	I-P
Assessment	I-P
Staging	I-P
were	O
randomly	O
assigned	O
to	O
an	B-I
ADD	I-I
-	I-I
continuation	I-I
group	O
(	O
N	O
=	O
30	O
)	O
or	O
an	B-I
ADD	I-I
-	I-I
discontinuation	I-I
group	O
(	O
N	O
=	O
35	O
)	O
.	O

The	O
current	O
use	O
of	O
donepezil	O
or	O
memantine	O
was	O
maintained	O
for	O
12	O
weeks	O
in	O
the	B-I
ADD	I-I
-	I-I
continuation	I-I
group	O
and	O
was	O
discontinued	O
after	O
baseline	O
in	O
the	B-I
ADD	I-I
-	I-I
discontinuation	I-I
group	O
.	O

Efficacy	O
measures	O
were	O
obtained	O
at	O
baseline	O
and	O
12	O
weeks	O
.	O

The	O
primary	O
efficacy	O
variable	O
was	O
the	O
change	O
from	O
baseline	O
to	O
the	O
end	O
of	O
the	O
study	O
in	O
Baylor	B-O
Profound	I-O
Mental	I-O
State	I-O
Examination	I-O
(	I-O
BPMSE	I-O
)	I-O
scores	I-O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
Applicability	O
of	O
a	B-I
High	I-I
-	I-I
Intensity	I-I
Functional	I-I
Exercise	I-I
Program	I-I
Among	O
Older	B-P
People	I-P
With	I-P
Dementia	I-P
Living	I-P
in	I-P
Nursing	I-P
Homes	I-P
.	O

METHODS	O
:	O
The	O
Ume	O
Dementia	O
and	O
Exercise	O
study	O
,	O
a	O
cluster	O
-	O
randomized	O
controlled	O
trial	O
set	O
in	O
16	O
nursing	O
homes	O
in	O
Ume	O
,	O
Sweden	O
.	O

Ninety	B-P
-	I-P
three	I-P
people	I-P
with	I-P
dementia	I-P
(	I-P
mean	I-P
[	I-P
SD	I-P
]	I-P
Mini	I-P
-	I-P
Mental	I-P
State	I-P
Examination	I-P
score	I-P
of	I-P
15	I-P
.	I-P
4	I-P
[	I-P
3	I-P
.	I-P
4	I-P
]	I-P
)	I-P
were	O
randomized	O
to	O
the	B-I
exercise	I-I
intervention	I-I
.	O

Thirty	O
-	O
four	O
participants	O
had	O
Alzheimer	O
'	O
s	O
disease	O
(	O
AD	O
)	O
and	O
59	O
non	O
-	O
Alzheimer	O
'	O
s	O
dementia	O
(	O
non	O
-	O
AD	O
)	O
.	O

High	B-I
-	I-I
Intensity	I-I
Functional	I-I
Exercise	I-I
(	I-I
HIFE	I-I
)	I-I
program	I-I
was	O
conducted	O
in	O
groups	O
of	O
3	O
to	O
8	O
participants	O
.	O

Two	O
physiotherapists	O
led	O
5	O
sessions	O
(	O
45	O
minutes	O
each	O
)	O
per	O
fortnight	O
for	O
4	O
months	O
(	O
total	O
40	O
sessions	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Effects	O
of	O
Physical	B-I
Activity	I-I
in	O
Nursing	B-P
Home	I-P
Residents	I-P
with	I-P
Dementia	I-P
:	O
A	O
Randomized	O
Controlled	O
Trial	O
.	O

METHODS	O
:	O
Eighty	B-P
-	I-P
seven	I-P
nursing	I-P
home	I-P
residents	I-P
with	I-P
dementia	I-P
were	O
randomly	O
assigned	O
to	O
3	B-I
physical	I-I
activity	I-I
interventions	I-I
:	O
activities	B-I
of	I-I
daily	I-I
living	I-I
(	I-I
ADL	I-I
)	I-I
training	I-I
,	O
multicomponent	B-I
exercise	I-I
training	I-I
,	O
or	O
combined	B-I
multicomponent	I-I
exercise	I-I
and	O
ADL	B-I
training	I-I
.	O

Outcomes	O
were	O
measured	O
at	O
baseline	O
,	O
and	O
after	O
3	O
and	O
6	O
months	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
Precision	O
Medicine	O
Model	O
for	O
Targeted	B-I
NSAID	I-I
Therapy	I-I
in	O
Alzheimer	O
'	O
s	O
Disease	O
.	O

METHODS	O
:	O
Proteomic	B-O
assays	I-O
of	I-O
plasma	I-O
from	O
a	O
multicenter	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
parallel	O
group	O
trial	O
,	O
with	O
1	O
-	O
year	O
exposure	O
to	O
rofecoxib	B-I
(	O
25	O
mg	O
once	O
daily	O
)	O
,	O
naproxen	B-I
(	O
220	O
mg	O
twice	O
-	O
daily	O
)	O
or	O
placebo	B-C
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
Exercise	B-I
on	O
Drug	O
-	O
Related	O
Falls	O
Among	O
Persons	B-P
with	I-P
Alzheimer	I-P
'	I-P
s	I-P
Disease	I-P
:	O
A	O
Secondary	O
Analysis	O
of	O
the	O
FINALEX	O
Study	O
.	O

METHODS	O
:	O
In	O
the	O
FINALEX	O
trial	O
,	O
community	B-P
-	I-P
dwelling	I-P
persons	I-P
with	I-P
AD	I-P
received	O
either	O
home	B-I
-	I-I
based	I-I
or	O
group	B-I
-	I-I
based	I-I
exercise	I-I
twice	O
weekly	O
for	O
1	O
year	O
(	O
n	O
=129	O
)	O
;	O
the	O
control	O
group	O
received	O
normal	B-C
care	I-C
(	O
n	O
=65	O
)	O
.	O

The	O
number	O
of	O
falls	O
was	O
based	O
on	O
spouses	O
'	O
fall	O
diaries	O
.	O

We	O
examined	O
the	B-O
incidence	I-O
rate	I-O
ratios	I-O
(	I-O
IRRs	I-O
)	I-O
for	I-O
falls	I-O
among	O
both	O
non	O
-	O
users	O
and	O
users	O
of	O
various	O
FRDs	O
(	O
antihypertensives	O
,	O
psychotropics	O
,	O
drugs	O
with	O
anticholinergic	O
properties	O
[	O
DAPs	O
]	O
)	O
in	O
both	O
control	O
and	O
combined	O
intervention	O
groups	O
.	O

-DOCSTART-	O

Title	O
:	O
Probiotic	B-I
and	O
selenium	B-I
co	I-I
-	I-I
supplementation	I-I
,	O
and	O
the	O
effects	O
on	O
clinical	O
,	O
metabolic	O
and	O
genetic	O
status	O
in	O
Alzheimer	O
'	O
s	O
disease	O
:	O
A	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
controlled	O
trial	O
.	O

METHODS	O
:	O
This	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
controlled	O
clinical	O
trial	O
was	O
conducted	O
among	O
79	B-P
patients	I-P
with	I-P
AD	I-P
.	O

Patients	O
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
selenium	B-I
(	O
200	O
?g	O
/	O
day	O
)	O
plus	O
probiotic	B-I
containing	O
Lactobacillus	B-I
acidophilus	I-I
,	O
Bifidobacterium	B-I
bifidum	I-I
,	O
and	O
Bifidobacterium	B-I
longum	I-I
(	O
2	O
	O
109	O
CFU	O
/	O
day	O
each	O
)	O
(	O
n	O
=	O
27	O
)	O
,	O
selenium	B-I
(	O
200	O
?g	O
/	O
day	O
)	O
(	O
n	O
=	O
26	O
)	O
or	O
placebo	B-C
(	O
n	O
=	O
26	O
)	O
for	O
12	O
weeks	O
.	O

-DOCSTART-	O

Title	O
:	O
Effects	O
of	O
a	B-I
Tailored	I-I
Lighting	I-I
Intervention	I-I
on	O
Sleep	O
Quality	O
,	O
Rest	O
-	O
Activity	O
,	O
Mood	O
,	O
and	O
Behavior	O
in	O
Older	B-P
Adults	I-P
With	I-P
Alzheimer	I-P
Disease	I-P
and	I-P
Related	I-P
Dementias	I-P
:	O
A	O
Randomized	O
Clinical	O
Trial	O
.	O

METHODS	O
:	O
This	O
14	O
-	O
week	O
randomized	O
,	O
placebo	O
-	O
controlled	O
,	O
crossover	O
design	O
clinical	O
trial	O
administered	O
an	B-I
all	I-I
-	I-I
day	I-I
active	I-I
or	O
control	B-C
lighting	I-C
intervention	I-C
to	O
46	B-P
patients	I-P
with	I-P
ADRD	I-P
in	I-P
8	I-P
long	I-P
-	I-P
term	I-P
care	I-P
facilities	I-P
for	I-P
two	I-P
4	I-P
-	I-P
week	I-P
periods	I-P
(	I-P
separated	I-P
by	I-P
a	I-P
4	I-P
-	I-P
week	I-P
washout	I-P
)	I-P
.	O

The	O
study	O
employed	O
wrist	B-O
-	I-O
worn	I-O
actigraphy	I-O
measures	I-O
and	O
standardized	B-O
measures	I-O
of	I-O
sleep	I-O
quality	I-O
,	O
mood	B-O
,	O
and	O
behavior	B-O
.	O

-DOCSTART-	O

Title	O
:	O
Long	O
-	O
term	O
safety	O
and	O
tolerability	O
of	O
atabecestat	B-I
(	I-I
JNJ	I-I
-	I-I
54861911	I-I
)	I-I
,	O
an	B-I
oral	I-I
BACE1	I-I
inhibitor	I-I
,	O
in	O
early	B-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
spectrum	I-P
patients	I-P
:	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
study	O
and	O
a	O
two	O
-	O
period	O
extension	O
study	O
.	O

METHODS	O
:	O
In	O
the	O
placebo	O
-	O
controlled	O
double	O
-	O
blind	O
parent	O
ALZ2002	O
study	O
,	O
participants	B-P
aged	I-P
50	I-P
to	I-P
85	I-P
years	I-P
were	O
randomized	O
(	O
1:1:1	O
)	O
to	O
placebo	B-C
or	O
atabecestat	B-I
10	O
or	O
50	O
mg	O
once	O
daily	O
(	O
later	O
reduced	O
to	O
5	O
and	O
25	O
mg	O
)	O
for	O
6	O
months	O
.	O

Participants	O
entered	O
ALZ2004	O
,	O
a	O
12	O
-	O
month	O
treatment	O
extension	O
with	O
placebo	B-C
or	O
atabecestat	B-I
10	O
or	O
25	O
mg	O
,	O
followed	O
by	O
an	O
open	O
-	O
label	O
phase	O
.	O

Safety	B-O
,	O
changes	O
in	O
CSF	B-O
biomarker	I-O
levels	I-O
,	O
brain	B-O
volume	I-O
,	O
and	O
effects	O
on	O
cognitive	B-O
performance	I-O
were	O
assessed	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
randomized	O
,	O
controlled	O
clinical	O
trial	O
of	O
plasma	B-I
exchange	I-I
with	O
albumin	B-I
replacement	I-I
for	O
Alzheimer	O
'	O
s	O
disease	O
:	O
Primary	O
results	O
of	O
the	O
AMBAR	O
Study	O
.	O

METHODS	O
:	O
Three	B-P
hundred	I-P
forty	I-P
-	I-P
seven	I-P
patients	I-P
(	I-P
496	I-P
screened	I-P
)	I-P
were	O
randomized	O
(	O
1:1:1	O
:	O
1	O
)	O
into	O
three	B-I
PE	I-I
treatment	I-I
arms	O
with	O
different	B-I
doses	I-I
of	I-I
albumin	I-I
and	O
intravenous	B-I
immunoglobulin	I-I
replacement	I-I
(	O
6	O
-	O
week	O
period	O
of	O
weekly	O
conventional	O
PE	O
followed	O
by	O
a	O
12	O
-	O
month	O
period	O
of	O
monthly	O
low	O
-	O
volume	O
PE	O
)	O
,	O
and	O
placebo	B-C
(	O
sham	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Introduction	O
of	O
a	B-I
Management	I-I
Toolkit	I-I
for	O
Lewy	O
Body	O
Dementia	O
:	O
A	O
Pilot	O
Cluster	O
-	O
Randomized	O
Trial	O
.	O

METHODS	O
:	O
We	O
randomized	O
23	O
memory	O
/	O
dementia	O
,	O
movement	O
disorder	O
,	O
or	O
nonspecialist	O
secondary	O
care	O
services	O
to	O
the	B-I
management	I-I
toolkit	I-I
or	O
usual	B-C
care	I-C
.	O

People	B-P
with	I-P
dementia	I-P
with	I-P
Lewy	I-P
bodies	I-P
or	I-P
Parkinson	I-P
'	I-P
s	I-P
disease	I-P
dementia	I-P
underwent	I-P
assessments	I-P
of	I-P
cognition	I-P
,	I-P
motor	I-P
and	I-P
neuropsychiatric	I-P
symptoms	I-P
,	I-P
and	I-P
global	I-P
outcome	I-P
at	I-P
baseline	I-P
and	I-P
3	I-P
and	I-P
6	I-P
months	I-P
.	O

Healthcare	B-O
,	O
personal	B-O
and	O
social	B-O
care	I-O
costs	I-O
,	O
and	O
carer	B-O
-	I-O
related	I-O
outcomes	I-O
of	I-O
carer	I-O
stress	I-O
,	O
depression	B-O
,	O
and	O
anxiety	B-O
were	O
also	O
examined	O
.	O

-DOCSTART-	O

Title	O
:	O
One	O
call	O
makes	O
a	O
difference	O
:	O
An	O
evaluation	O
of	O
the	B-I
Alzheimer	I-I
'	I-I
s	I-I
Association	I-I
National	I-I
Helpline	I-I
on	O
dementia	B-P
caregiver	I-P
outcomes	O
.	O

METHODS	O
:	O
Four	B-P
hundred	I-P
and	I-P
forty	I-P
-	I-P
five	I-P
non	I-P
-	I-P
crisis	I-P
callers	I-P
were	O
randomly	O
assigned	O
to	O
the	B-C
traditional	I-C
Helpline	I-C
"	I-C
Care	I-C
Consultation	I-C
"	I-C
or	O
a	B-I
"	I-I
Care	I-I
Consultation	I-I
Plus	I-I
"	I-I
condition	I-I
that	O
included	O
one	O
additional	O
booster	O
call	O
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
long	B-I
-	I-I
term	I-I
omega	I-I
-	I-I
3	I-I
supplementation	I-I
and	O
a	B-I
lifestyle	I-I
multidomain	I-I
intervention	I-I
on	O
intrinsic	O
capacity	O
among	O
community	B-P
-	I-P
dwelling	I-P
older	I-P
adults	I-P
:	O
Secondary	O
analysis	O
of	O
a	O
randomized	O
,	O
placebo	O
-	O
controlled	O
trial	O
(	O
MAPT	O
study	O
)	O
.	O

METHODS	O
:	O
Secondary	O
analysis	O
from	O
the	O
factorial	O
-	O
design	O
3	O
-	O
year	O
Multidomain	O
Alzheimer	O
Preventive	O
Trial	O
(	O
MAPT	O
)	O
with	O
1445	B-P
subjects	I-P
(	I-P
64	I-P
.	I-P
2	I-P
%	I-P
female	I-P
,	I-P
mean	I-P
age	I-P
75	I-P
.	I-P
3	I-P
years	I-P
,	I-P
SD	I-P
=	I-P
4	I-P
.	I-P
4	I-P
)	I-P
randomized	O
to	O
one	O
group	O
of	O
MI	B-I
plus	O
?	B-I
-	I-I
3	I-I
(	O
800	B-I
mg	I-I
docosahexaenoic	I-I
acid	I-I
and	O
225	B-I
mg	I-I
eicosapentaenoic	I-I
acid	I-I
/	O
day	O
)	O
;	O
MI	B-I
plus	O
placebo	B-C
;	O
?	B-I
-	I-I
3	I-I
supplementation	I-I
alone	O
;	O
or	O
placebo	B-C
alone	I-C
.	O

Data	O
collection	O
was	O
held	O
between	O
2008	O
and	O
2014	O
.	O

IC	B-O
domains	I-O
were	O
examined	O
with	O
the	B-O
Geriatric	I-O
Depression	I-O
Scale	I-O
(	O
psychological	B-O
)	O
;	O
Short	B-O
Physical	I-O
Performance	I-O
Battery	I-O
(	O
mobility	B-O
)	O
;	O
Z	B-O
-	I-O
score	I-O
combining	I-O
four	I-O
tests	I-O
(	O
cognitive	B-O
function	I-O
)	O
;	O
and	O
handgrip	B-O
strength	I-O
(	O
vitality	B-O
)	O
.	O

All	O
domains	O
were	O
combined	O
into	O
a	O
composite	O
IC	O
Z	O
-	O
score	O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
Cognition	O
and	O
Flow	O
Study	O
:	O
A	O
Feasibility	O
Randomized	O
Controlled	O
Trial	O
of	O
the	O
Effects	O
of	O
Cognitive	B-I
Training	I-I
on	O
Cerebral	O
Blood	O
Flow	O
.	O

METHODS	O
:	O
Twenty	B-P
HG	I-P
,	I-P
24	I-P
with	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
(	I-P
AD	I-P
)	I-P
,	I-P
and	I-P
12	I-P
with	I-P
MCI	I-P
were	O
randomized	O
to	O
12	O
weeks	O
of	O
multi	B-I
-	I-I
domain	I-I
CT	I-I
or	O
control	O
.	O

Outcomes	O
included	O
:	O
cognition	B-O
(	O
Addenbrooke	B-O
'	I-O
s	I-O
Cognitive	I-O
Examination	I-O
III	I-O
)	O
,	O
mood	B-O
,	O
quality	B-O
of	I-O
life	I-O
(	I-O
QoL	I-O
)	I-O
,	O
physical	B-O
,	O
and	O
neurovascular	B-O
function	I-O
(	O
transcranial	B-O
Doppler	I-O
ultrasonography	I-O
measured	I-O
task	I-O
activation	I-O
of	I-O
CBFv	I-O
responses	I-O
)	O
.	O

Data	O
are	O
presented	O
as	O
mean	O
difference	O
(	O
MD	O
)	O
and	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Safety	O
,	O
pharmacokinetics	O
and	O
exploratory	O
pro	O
-	O
cognitive	O
effects	O
of	O
HTL0018318	B-I
,	O
a	B-I
selective	I-I
M	I-I
1	I-I
receptor	I-I
agonist	I-I
,	O
in	O
healthy	B-P
younger	I-P
adult	I-P
and	I-P
elderly	I-P
subjects	I-P
:	O
a	O
multiple	O
ascending	O
dose	O
study	O
.	O

METHODS	O
:	O
This	O
randomised	O
,	O
double	O
blind	O
,	O
placebo	O
-	O
controlled	O
study	O
was	O
performed	O
,	O
investigating	O
oral	B-I
doses	I-I
of	I-I
15	I-I
-	I-I
35	I-I
mg	I-I
/	I-I
day	I-I
HTL0018318	I-I
or	O
placebo	B-C
in	O
7	B-P
cohorts	I-P
of	I-P
healthy	I-P
younger	I-P
adult	I-P
(	I-P
n	I-P
=	I-P
36	I-P
;	I-P
3	I-P
cohorts	I-P
)	I-P
and	I-P
elderly	I-P
(	I-P
n	I-P
=	I-P
50	I-P
;	I-P
4	I-P
cohorts	I-P
)	I-P
subjects	I-P
.	O

Safety	B-O
,	O
tolerability	B-O
and	O
pharmacokinetic	B-O
measurements	I-O
were	O
performed	O
.	O

Pharmacodynamics	O
were	O
assessed	O
using	O
a	B-O
battery	I-O
of	I-O
neurocognitive	I-O
tasks	I-O
and	O
electrophysiological	B-O
biomarkers	I-O
of	I-O
synaptic	I-O
and	O
cognitive	B-O
functions	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Interventional	O
Study	O
to	O
Evaluate	O
the	O
Clinical	O
Effects	O
and	O
Safety	O
of	O
the	B-I
Nutraceutical	I-I
Compound	I-I
BrainUp	I-I
-	I-I
10	I-I
in	O
a	B-P
Cohort	I-P
of	I-P
Patients	I-P
with	I-P
Alzheimer	I-P
'	I-P
s	I-P
Disease	I-P
:	O
A	O
Multicenter	O
,	O
Randomized	O
,	O
Double	O
-	O
Blind	O
,	O
and	O
Placebo	O
-	O
Controlled	O
Trial	O
.	O

METHODS	O
:	O
The	O
was	O
a	O
multicenter	O
,	O
randomized	O
,	O
double	O
blind	O
,	O
placebo	O
-	O
controlled	O
phase	O
II	O
clinical	O
study	O
in	O
mild	B-P
to	I-P
moderate	I-P
AD	I-P
patients	I-P
treated	O
with	O
BrainUp	B-I
-	I-I
10	I-I
daily	O
,	O
while	O
controls	O
received	O
a	B-C
placebo	I-C
.	O

Primary	O
endpoint	O
was	O
Apathy	B-O
(	O
AES	B-O
scale	I-O
)	O
,	O
while	O
secondary	O
endpoints	O
included	O
Mini	B-O
-	I-O
Mental	I-O
State	I-O
Examination	I-O
(	I-O
MMSE	I-O
)	I-O
,	O
Trail	B-O
Making	I-O
Test	I-O
(	O
TMT	B-O
A	I-O
and	O
TMT	B-O
B	I-O
)	O
,	O
and	O
Neuropsychiatry	B-O
Index	I-O
(	I-O
NPI	I-O
)	I-O
.	O

AD	O
blood	O
biomarkers	O
were	O
analyzed	O
.	O

Laboratory	O
tests	O
were	O
applied	O
to	O
all	O
subjects	O
.	O

-DOCSTART-	O

Title	O
:	O
Learning	B-I
to	I-I
play	I-I
golf	I-I
for	O
elderly	B-P
people	I-P
with	I-P
subjective	I-P
memory	I-P
complaints	I-P
:	O
feasibility	O
of	O
a	O
single	O
-	O
blinded	O
randomized	O
pilot	O
trial	O
.	O

METHODS	O
:	O
In	O
a	O
22	O
-	O
week	O
single	O
-	O
blinded	O
randomized	O
controlled	O
trial	O
,	O
elderly	B-P
people	I-P
with	I-P
SMC	I-P
were	O
allocated	O
to	O
the	B-I
golf	I-I
(	O
n	O
=	O
25	O
,	O
180	O
min	O
training	O
/	O
week	O
)	O
or	O
control	O
group	O
(	O
n	O
=	O
21	O
)	O
.	O

Primary	O
outcomes	O
were	O
feasibility	B-O
(	O
golf	B-O
exam	I-O
,	O
adherence	B-O
,	O
adverse	B-O
events	I-O
)	O
and	O
general	B-O
cognitive	I-O
function	I-O
(	O
Alzheimer	B-O
'	I-O
s	I-O
Disease	I-O
Assessment	I-O
Scale	I-O
)	O
.	O

Secondary	O
outcomes	O
include	O
specific	B-O
cognitive	I-O
functions	I-O
(	O
Response	B-O
Inhibition	I-O
,	O
Corsi	B-O
Block	I-O
Tapping	I-O
Test	I-O
,	O
Trail	B-O
Making	I-O
Test	I-O
)	O
,	O
KP	B-O
metabolites	I-O
and	O
physical	B-O
performance	I-O
(	O
6	B-O
-	I-O
Minute	I-O
-	I-O
Walk	I-O
-	I-O
Test	I-O
)	O
.	O

Baseline	O
-	O
adjusted	O
Analysis	O
-	O
of	O
-	O
Covariance	O
was	O
conducted	O
for	O
each	O
outcome	O
.	O

-DOCSTART-	O

Title	O
:	O
Effects	O
of	O
Folic	B-I
Acid	I-I
and	O
Vitamin	B-I
B12	I-I
Supplementation	I-I
on	O
Cognitive	O
Impairment	O
and	O
Inflammation	O
in	O
Patients	B-P
with	I-P
Alzheimer	I-P
'	I-P
s	I-P
Disease	I-P
:	O
A	O
Randomized	O
,	O
Single	O
-	O
Blinded	O
,	O
Placebo	O
-	O
Controlled	O
Trial	O
.	O

METHODS	O
:	O
This	O
was	O
a	O
randomized	O
,	O
single	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
trial	O
.	O

Patients	B-P
(	I-P
n=120	I-P
)	I-P
diagnosed	I-P
clinically	I-P
as	I-P
probable	I-P
AD	I-P
and	I-P
in	I-P
stable	I-P
condition	I-P
from	I-P
Tianjin	I-P
Key	I-P
Laboratory	I-P
of	I-P
Cerebrovascular	I-P
and	I-P
Neurodegenerative	I-P
Diseases	I-P
.	O

Individuals	O
were	O
randomly	O
divided	O
into	O
the	O
intervention	O
group	O
(	O
n=60	O
,	O
folic	B-I
acid	I-I
1	O
.	O
2	O
mg	O
/	O
d	O
+	O
vitamin	B-I
B12	I-I
50	O
?g	O
/	O
d	O
)	O
and	O
the	B-C
placebo	I-C
group	O
(	O
n=60	O
)	O
.	O

Cognitive	B-O
performance	I-O
,	O
blood	B-O
folate	I-O
,	O
vitamin	B-O
B12	I-O
,	O
one	B-O
carbon	I-O
cycle	I-O
metabolite	I-O
,	O
and	O
inflammatory	B-O
cytokine	I-O
levels	I-O
were	O
measured	O
at	O
baseline	O
and	O
after	O
6	O
months	O
.	O

The	O
data	O
were	O
analyzed	O
using	O
linear	O
mixed	O
models	O
for	O
repeated	O
measures	O
.	O

-DOCSTART-	O

Title	O
:	O
Efficacy	O
of	O
tablet	B-I
huperzine	I-I
-	I-I
A	I-I
on	O
memory	O
,	O
cognition	O
,	O
and	O
behavior	O
in	O
Alzheimer	O
'	O
s	O
disease	O
.	O

METHODS	O
:	O
Using	O
multicenter	O
,	O
prospective	O
,	O
double	O
-	O
blind	O
,	O
parallel	O
,	O
placebo	O
controlled	O
and	O
randomized	O
method	O
,	O
50	B-P
patients	I-P
were	O
administered	O
orally	O
0	B-I
.	I-I
2	I-I
mg	I-I
(	I-I
4	I-I
tablets	I-I
)	I-I
Hup	I-I
and	O
53	O
patients	O
were	O
given	O
po	B-C
4	I-C
tablets	I-C
of	I-C
placebo	I-C
bid	O
for	O
8	O
wk	O
.	O

All	O
patients	O
were	O
evaluated	O
with	O
Wechsler	B-O
memory	I-O
scale	I-O
,	O
Hasegawa	B-O
dementia	I-O
scale	I-O
,	O
mini	B-O
-	I-O
mental	I-O
state	I-O
examination	I-O
scale	I-O
,	O
activity	B-O
of	I-O
daily	I-O
living	I-O
scale	I-O
,	O
treatment	B-O
emergency	I-O
symptom	I-O
scale	I-O
,	O
and	O
measured	O
with	O
BP	B-O
,	O
HR	B-O
,	O
ECG	B-O
,	O
EEG	B-O
,	O
ALT	B-O
,	O
AKP	B-O
,	O
BUN	B-O
,	O
Cr	B-O
,	O
Hb	B-O
,	O
WBC	B-O
,	O
and	O
urine	B-O
routine	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Relationship	O
between	O
pharmacodynamic	O
activity	O
and	O
cognitive	O
effects	O
of	O
eptastigmine	B-I
in	O
patients	B-P
with	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
.	O

Eptastigmine	O
Study	O
Group	O
.	O

METHODS	O
:	O
This	O
was	O
a	O
double	O
-	O
blind	O
,	O
randomized	O
,	O
placebo	O
-	O
controlled	O
,	O
unbalanced	O
parallel	O
-	O
group	O
study	O
.	O

One	B-P
-	I-P
hundred	I-P
and	I-P
three	I-P
patients	I-P
(	O
83	O
in	O
the	B-I
eptastigmine	I-I
group	O
and	O
20	O
in	O
the	B-C
placebo	I-C
group	O
)	O
were	O
recruited	O
by	O
10	O
centers	O
.	O

Patients	O
received	O
20	B-I
mg	I-I
eptastigmine	I-I
or	O
placebo	B-C
for	O
4	O
weeks	O
with	O
twice	O
-	O
a	O
-	O
day	O
or	O
three	O
-	O
times	O
-	O
a	O
-	O
day	O
regimens	O
,	O
depending	O
on	O
body	O
weight	O
(	O
<	O
or	O
=	O
65	O
kg	O
or	O
>	O
65	O
kg	O
,	O
respectively	O
)	O
.	O

Patient	O
performance	O
on	O
the	B-O
Logical	I-O
Memory	I-O
Test	I-O
,	O
Semantic	B-O
Word	I-O
Fluency	I-O
Test	I-O
,	O
Trail	B-O
Making	I-O
Test	I-O
,	O
Index	B-O
of	I-O
Independence	I-O
in	I-O
Activities	I-O
of	I-O
Daily	I-O
Living	I-O
,	O
Instrumental	B-O
Activities	I-O
of	I-O
Daily	I-O
Living	I-O
Scales	I-O
(	I-O
IADL	I-O
)	I-O
,	O
and	O
the	B-O
Physician	I-O
and	I-O
Caregiver	I-O
Clinical	I-O
Global	I-O
Impression	I-O
of	I-O
Change	I-O
(	I-O
CGIC	I-O
)	I-O
was	O
assessed	O
at	O
baseline	O
and	O
at	O
the	O
end	O
of	O
treatment	O
.	O

-DOCSTART-	O

Title	O
:	O
A	B-I
family	I-I
intervention	I-I
to	O
delay	O
nursing	O
home	O
placement	O
of	O
patients	B-P
with	I-P
Alzheimer	I-P
disease	I-P
.	O

A	O
randomized	O
controlled	O
trial	O
.	O

METHODS	O
:	O
Randomized	O
controlled	O
intervention	O
study	O
.	O

Outpatient	O
research	O
clinic	O
in	O
the	O
New	O
York	O
City	O
metropolitan	O
area	O
.	O

Referred	B-P
,	I-P
volunteer	I-P
sample	I-P
of	I-P
206	I-P
spouse	I-P
-	I-P
caregivers	I-P
of	I-P
AD	I-P
patients	I-P
who	I-P
enrolled	I-P
in	I-P
the	I-P
study	I-P
during	I-P
a	I-P
3	I-P
1	I-P
/	I-P
2	I-P
-	I-P
year	I-P
period	I-P
.	O

All	O
patients	O
were	O
living	O
at	O
home	O
at	O
baseline	O
and	O
had	O
at	O
least	O
1	O
relative	O
living	O
in	O
the	O
area	O
.	O

Caregivers	O
in	O
the	O
treatment	O
group	O
were	O
provided	O
with	O
6	B-I
sessions	I-I
of	I-I
individual	I-I
and	I-I
family	I-I
counseling	I-I
within	O
4	O
months	O
of	O
enrollment	O
in	O
the	O
study	O
and	O
were	O
required	O
to	O
join	O
support	O
groups	O
.	O

In	O
addition	O
,	O
counselors	O
were	O
available	O
for	O
further	O
counseling	O
at	O
any	O
time	O
.	O

Time	B-O
from	I-O
enrollment	I-O
of	I-O
caregivers	I-O
in	I-O
the	I-O
study	I-O
to	I-O
placement	I-O
of	I-O
the	I-O
AD	I-O
patients	I-O
in	I-O
a	I-O
nursing	I-O
home	I-O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
multicenter	O
double	O
-	O
blind	O
study	O
of	O
controlled	B-I
-	I-I
release	I-I
physostigmine	I-I
for	O
the	O
treatment	O
of	O
symptoms	O
secondary	O
to	O
Alzheimer	O
'	O
s	O
disease	O
.	O

Physostigmine	O
Study	O
Group	O
.	O

METHODS	O
:	O
During	O
dose	O
titration	O
,	O
subjects	O
received	O
18	B-I
,	O
24	B-I
,	O
or	O
30	B-I
mg	I-I
of	I-I
physostigmine	I-I
or	O
placebo	B-C
daily	O
.	O

After	O
a	O
2	O
-	O
week	O
washout	O
period	O
,	O
366	B-P
subjects	I-P
with	I-P
putative	I-P
improvement	I-P
were	O
randomized	O
to	O
receive	O
either	O
placebo	B-C
or	O
their	B-I
best	I-I
dose	I-I
of	I-I
physostigmine	I-I
in	O
a	O
6	O
-	O
week	O
double	O
-	O
blind	O
trial	O
.	O

Nonresponding	O
patients	O
(	O
439	O
)	O
were	O
randomized	O
to	O
receive	O
in	O
a	O
separate	O
double	O
-	O
blind	O
trial	O
either	O
placebo	B-C
or	O
their	B-I
highest	I-I
tolerated	I-I
dose	I-I
of	I-I
physostigmine	I-I
.	O

The	O
primary	O
efficacy	O
measures	O
included	O
the	B-O
cognitive	I-O
subscale	I-O
of	I-O
the	I-O
Alzheimer	I-O
Disease	I-O
Assessment	I-O
Scale	I-O
(	I-O
ADAS	I-O
)	I-O
and	O
a	B-O
Clinical	I-O
Global	I-O
Impression	I-O
of	I-O
Change	I-O
(	I-O
CGIC	I-O
)	I-O
.	O

Secondary	O
measures	O
included	O
the	B-O
Mini	I-O
-	I-O
Mental	I-O
State	I-O
Examination	I-O
and	O
two	B-O
activities	I-O
-	I-O
of	I-O
-	I-O
daily	I-O
-	I-O
living	I-O
scales	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
tacrine	B-I
on	O
language	O
,	O
praxis	O
,	O
and	O
noncognitive	O
behavioral	O
problems	O
in	O
Alzheimer	O
disease	O
.	O

METHODS	O
:	O
An	O
exploratory	O
analysis	O
using	O
last	O
observation	O
carried	O
forward	O
.	O

The	O
study	O
population	O
included	O
a	B-C
placebo	I-C
group	O
(	O
n	O
=	O
181	O
)	O
and	O
all	O
patients	O
randomized	O
to	O
treatment	O
within	O
160	B-I
mg	I-I
/	I-I
d	I-I
of	I-I
tacrine	I-I
hydrochloride	I-I
(	O
n	O
=	O
234	O
)	O
,	O
regardless	O
of	O
highest	O
dose	O
achieved	O
or	O
duration	O
of	O
tacrine	B-I
therapy	I-I
.	O

Male	B-P
and	I-P
female	I-P
subjects	I-P
,	I-P
at	I-P
least	I-P
50	I-P
years	I-P
of	I-P
age	I-P
,	I-P
with	I-P
mild	I-P
to	I-P
moderate	I-P
AD	I-P
and	I-P
detectable	I-P
baseline	I-P
deficits	I-P
in	I-P
discrete	I-P
cognitive	I-P
and	I-P
noncognitive	I-P
parameters	I-P
.	O

Change	O
from	O
baseline	O
to	O
last	O
observation	O
carried	O
forward	O
in	O
discrete	B-O
subscale	I-O
scores	I-O
of	I-O
the	I-O
Alzheimer	I-O
'	I-O
s	I-O
Disease	I-O
Assessment	I-O
Scale	I-O
(	I-O
ADAS	I-O
)	I-O
:	O
cognitive	B-O
(	O
memory	B-O
,	O
language	B-O
,	O
praxis	B-O
)	O
and	O
noncognitive	B-O
(	O
mood	B-O
,	O
behavior	B-O
)	O
.	O

Improvement	O
was	O
defined	O
as	O
a	O
decrease	O
of	O
at	O
least	O
1	O
point	O
from	O
baseline	O
;	O
stabilization	O
was	O
defined	O
as	O
no	O
change	O
or	O
a	O
decrease	O
from	O
baseline	O
.	O

-DOCSTART-	O

Title	O
:	O
Metrifonate	B-I
benefits	O
cognitive	O
,	O
behavioral	O
,	O
and	O
global	O
function	O
in	O
patients	B-P
with	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
.	O

METHODS	O
:	O
A	O
prospective	O
,	O
36	O
-	O
week	O
,	O
multicenter	O
,	O
double	O
-	O
blind	O
,	O
randomized	O
,	O
parallel	O
group	O
study	O
of	O
metrifonate	B-I
in	O
probable	B-P
AD	I-P
patients	I-P
,	O
including	O
a	O
2	O
-	O
week	O
screening	O
period	O
,	O
a	O
26	O
-	O
week	O
double	O
-	O
blind	O
treatment	O
period	O
,	O
and	O
a	O
follow	O
-	O
up	O
visit	O
at	O
8	O
weeks	O
post	O
-	O
treatment	O
.	O

A	O
total	O
of	O
24	O
ambulatory	O
clinics	O
in	O
the	O
United	O
States	O
in	O
a	O
variety	O
of	O
settings	O
,	O
including	O
contract	O
research	O
organizations	O
,	O
public	O
health	O
facilities	O
,	O
and	O
universities	O
.	O

Patients	O
met	O
diagnostic	O
criteria	O
for	O
probable	O
AD	O
as	O
defined	O
by	O
the	O
work	O
group	O
of	O
the	O
National	O
Institute	O
for	O
Neurological	O
and	O
Communicative	O
Diseases	O
and	O
Stroke	O
and	O
the	O
Alzheimer	O
'	O
s	O
Disease	O
and	O
Related	O
Disorders	O
Association	O
.	O

Patients	O
had	O
Mini	O
-	O
Mental	O
State	O
Examination	O
(	O
MMSE	O
)	O
scores	O
of	O
10	O
to	O
26	O
and	O
Ischemic	O
Scores	O
(	O
Rosen	O
Modification	O
)	O
of	O
<	O
4	O
.	O

A	B-P
total	I-P
of	I-P
408	I-P
patients	I-P
were	O
enrolled	O
.	O

Percentages	O
of	O
patients	O
completing	O
double	O
-	O
blind	O
treatment	O
were	O
88	O
%	O
and	O
79	O
%	O
in	O
the	B-C
placebo	I-C
and	O
metrifonate	B-I
groups	O
,	O
respectively	O
.	O

Rates	O
of	O
discontinuation	O
due	O
to	O
adverse	O
events	O
were	O
4	O
%	O
in	O
the	B-C
placebo	I-C
group	O
and	O
12	O
%	O
in	O
the	B-I
metrifonate	I-I
group	O
.	O

Placebo	B-C
or	O
metrifonate	B-I
was	O
administered	O
once	O
daily	O
.	O

Metrifonate	B-I
-	O
treated	O
patients	O
received	O
a	O
loading	O
dose	O
of	O
100	O
to	O
180	O
mg	O
based	O
on	O
weight	O
(	O
2	O
.	O
0	O
mg	O
/	O
kg	O
)	O
for	O
2	O
weeks	O
,	O
followed	O
by	O
a	O
maintenance	O
dose	O
of	O
30	O
to	O
60	O
mg	O
based	O
on	O
weight	O
(	O
0	O
.	O
65	O
mg	O
/	O
kg	O
)	O
for	O
24	O
weeks	O
.	O

Primary	O
efficacy	O
variables	O
were	O
the	B-O
Alzheimer	I-O
'	I-O
s	I-O
Disease	I-O
Assessment	I-O
Scale	I-O
-	I-O
Cognitive	I-O
Subscale	I-O
(	I-O
ADAS	I-O
-	I-O
Cog	I-O
)	I-O
and	O
the	B-O
Clinician	I-O
'	I-O
s	I-O
Interview	I-O
-	I-O
Based	I-O
Impression	I-O
of	I-O
Change	I-O
with	I-O
Caregiver	I-O
Input	I-O
(	I-O
CIBIC	I-O
-	I-O
plus	I-O
)	I-O
.	O

Secondary	O
efficacy	O
variables	O
included	O
the	B-O
Neuropsychiatric	I-O
Inventory	I-O
(	I-O
NPI	I-O
)	I-O
,	O
the	B-O
Disability	I-O
Assessment	I-O
in	I-O
Dementia	I-O
,	O
the	B-O
Global	I-O
Deterioration	I-O
Scale	I-O
(	I-O
GDS	I-O
)	I-O
,	O
the	B-O
ADAS	I-O
-	I-O
Noncognitive	I-O
subscale	I-O
(	I-O
ADAS	I-O
-	I-O
Noncog	I-O
)	I-O
,	O
the	B-O
MMSE	I-O
,	O
and	O
the	B-O
Clinician	I-O
'	I-O
s	I-O
Interview	I-O
-	I-O
Based	I-O
Impression	I-O
of	I-O
Severity	I-O
with	I-O
Caregiver	I-O
Input	I-O
(	I-O
CIBIS	I-O
-	I-O
plus	I-O
)	I-O
.	O

Outcome	O
measures	O
reflected	O
changes	O
from	O
baseline	O
at	O
week	O
26	O
for	O
all	O
variables	O
.	O

Safety	O
was	O
assessed	O
with	O
incidences	B-O
of	I-O
premature	I-O
termination	I-O
,	O
treatment	B-O
-	I-O
emergent	I-O
events	I-O
and	O
mortality	B-O
,	O
and	O
routine	B-O
safety	I-O
evaluations	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Caffeine	O
based	O
measures	O
of	O
CYP1A2	O
activity	O
correlate	O
with	O
oral	O
clearance	O
of	O
tacrine	B-I
in	O
patients	B-P
with	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
.	O

METHODS	O
:	O
The	B-O
pharmokinetics	I-O
of	O
a	B-I
single	I-I
40	I-I
mg	I-I
oral	I-I
dose	I-I
of	I-I
tacrine	I-I
were	O
measured	O
in	O
19	B-P
patients	I-P
with	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
.	O

Each	O
patient	O
also	O
received	O
2	O
mg	O
kg	O
(	O
-	O
1	O
)	O
[	O
13	O
C	O
-	O
3	O
-	O
methyl	O
]	O
caffeine	O
orally	O
and	O
had	O
breath	O
and	O
urine	O
samples	O
collected	O
.	O

